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Abstract 
Targeted delivery of drugs to tumors is critical for optimal implementation of 
chemotherapy. Targeted drug delivery can be achieved by encapsulating drugs in 
nanometer-sized drug carriers. Consequently, a significant amount of preclinical 
research is focused on the development of nanoparticle-based 
chemotherapeutics. In spite of many key advances, these systems still have some 
major limitations. These stem from extensive distribution of nanoparticles to off-
target sites, and the presence of several resistance mechanisms within the tumor. 
The goal of this thesis was to investigate, and potentially improve, the various 
steps involved in the delivery of nanoparticles to solid tumors. 
Using a pharmacokinetic modeling approach, the effect of physicochemical 
properties of nanoparticles and vascular permeability of the tumor on the systemic 
distribution of nanoparticles was studied. Transport across compartments was 
calculated using equations for transvascular convection and diffusion of 
nanoparticles. The results of the modeling studies suggested that optimal drug 
targeting would be observed only in an intermediate particle size range. At a 
particle size below the vascular pore size of the toxicity compartment, 
nanoparticles extensively accumulated in that compartment. This reduced the 
fraction available for deposition into the tumor. At a particle size above the vascular 
pore size of the tumor, accumulation of nanoparticles in the tumor was not 
possible. Most of the drug was either eliminated in the form of nanoparticles or 
released in the central compartment. Hence, the lower and upper bounds of the 
optimal particle size range were determined by the vascular pore size of the toxicity 
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and target compartments, respectively. With a decrease in drug release rate, the 
average number of visits of the drug in the target compartment increased. Hence, 
decreasing the rate of drug release could favorably affect the drug targeting index. 
Maximal benefit with this strategy was also experienced in an intermediate particle 
size range, which was dictated by vascular pore sizes of the toxicity and target 
compartments.  
Due to leaky tumor blood vessels and prothrombogenic tumor 
microenvironment, fibrinogen gets deposited in the tumor and is converted to 
cross-linked fibrin. Using a series of immunohistochemistry analysis and in vitro 
diffusion studies, it was established that most human solid tumors are 
characterized by the deposition of a significant amount of fibrin and that the 
presence of fibrin retarded the mobility of nanoparticles. However, no previous 
studies have analyzed the influence of fibrin on the intratumoral distribution of 
nanoparticles. The central hypothesis of this chapter was that degrading fibrin 
using a fibrinolytic enzyme [tissue plasminogen activator (tPA)] will improve the 
intratumoral distribution of nanoparticles and their chemotherapeutic efficacy. In 
an A549 orthotopic lung cancer model, co-administration of tPA improved the anti-
cancer efficacy of paclitaxel nanoparticles (p<0.05, on Day 73 after 
commencement of treatment). In this chronic study, the average tumor 
bioluminescence in animals treated with the combination therapy was lower than 
the other groups for >2 months.  In a B16F10 mouse melanoma model the 
combination therapy reduced the rate of tumor growth by ~1.5 fold relative to that 
with just paclitaxel nanoparticles (p=0.08). Further, immunohistochemistry 
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revealed that administration of tPA resulted in the decompression of tumor blood 
vessels. Using Power Doppler ultrasound, we established that treatment with tPA 
led to a 3-4 fold improvement in tumor perfusion (p<0.05, after second dose). All 
these results suggest that fibrinolytic therapy may lead to an enhanced 
intratumoral distribution of nanoparticles.  
Tylocrebrine is a potent anti-cancer drug but has a narrow therapeutic index. 
Extensive distribution to the central nervous system and reduced cell uptake in the 
acidic tumor microenvironment limited the clinical translation of the drug. To 
address both issues, tylocrebrine was encapsulated in polymeric nanoparticles 
targeted to the epidermal growth factor receptor (EGFR). In vitro studies in human 
cancer cell lines showed that decrease in the extracellular pH led to a 3-fold 
decrease in drug uptake (p<0.05) and ~2-10 fold reduction in drug potency. 
However, when encapsulated in targeted nanoparticles, its potency was less 
affected by extracellular pH. Pharmacokinetic studies in mice revealed that the 
drug rapidly accumulated in the brain, and brain accumulation could be reduced 
by encapsulation in nanoparticles (~2-fold; p<0.05, compared to free drug at 0.5 h 
post dose). When delivered in targeted nanoparticles, the tumor accumulation and 
retention of the drug was also improved (p<0.05, compared to free drug at 4h post 
dose). In a xenograft mouse model of human epidermoid cancer, treatment with 
tylocrebrine solution retarded tumor growth. However, tumor inhibition was found 
to be more significant with EGFR targeted nanoparticles (p<0.05, compared to 
saline and non-targeted nanoparticle treated animals). This effect was likely due 
to the improved tumor accumulation and higher potency of targeted nanoparticles.  
viii 
 
In conclusion, this thesis presents an analysis of the three steps of nanoparticle 
transport from the site of administration to the site of action. These steps include 
systemic distribution, intratumoral distribution and cell uptake. Improving the 
efficiency of each of these steps can improve the overall efficacy of chemotherapy.  
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Chapter 1 Exploiting Nanotechnology to Overcome 
Tumor Drug Resistance: Challenges and 
Opportunities1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                           
1 Parts of this chapter are published elsewhere [460]. Reproduced with permission.  
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1.1  Summary 
Tumor cells develop resistance to chemotherapeutic drugs through multiple 
mechanisms. Overexpression of efflux transporters is an important source of drug 
resistance. Efflux transporters such as P-glycoprotein reduce intracellular drug 
accumulation and compromise drug efficacy. Various nanoparticle-based 
approaches have been investigated to overcome efflux-mediated resistance. 
These include the use of formulation excipients that inhibit transporter activity and 
co-delivery of the anticancer drug with a specific inhibitor of transporter function or 
expression. The effectiveness of nanoparticles and other colloidal drug carriers 
can be diminished by poor transport in the tumor tissue. Hence, adjunct therapies 
that improve the intratumoral distribution of nanoparticles may be vital to the 
successful application of nanotechnology to overcome tumor drug resistance. This 
review discusses the mechanisms of tumor drug resistance and highlights the 
opportunities and challenges in the use of nanoparticles to improve the efficacy of 
anticancer drugs against resistant tumors. 
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1.2 Introduction 
Despite major advances in cancer diagnosis and therapy, development of 
drug resistance and tumor relapse are frequent occurrences [2, 3]. While tumor 
cells evade death through multiple mechanisms [4], overexpression of efflux 
transporters is an important source of drug resistance. Tumor cells either 
inherently express efflux transporters or upregulate their expression in response 
to chemotherapy. Efflux transporters are capable of actively clearing a wide variety 
of substrates out of the cells. This results in sub-optimal intracellular drug 
concentrations and lack of efficacy [5]. Several efforts have been directed at 
inhibiting efflux transporters in tumors. Many small molecule efflux inhibitors have 
been tested in combination with chemotherapeutics in the clinic. However, 
unfavorable pharmacokinetics and significant dose-limiting toxicities have 
hampered their progress [6-8]. Co-administration of the chemotherapeutic and 
efflux inhibitor in nanoparticles (NPs) may allow temporal co-localization of these 
molecules, limit their non-specific distribution, and hence their toxicities [9]. In 
addition, several studies have shown that some of the excipients used in the 
construction of NPs are capable of inhibiting efflux transporters [10]. Taken 
together, nanotechnology offers a promising approach for overcoming efflux 
pump-based drug resistance (Figure 1-1). 
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Figure 1-1. Opportunities and challenges in utilizing nanotechnology to 
overcome drug resistance.  
Nanoparticles can inhibit drug efflux through (i) altered cellular distribution of the 
encapsulated drug (ii) use of specific excipients and (iii) co-delivery of agents that 
can inhibit efflux transporters. The drug resistant cells are often located farther 
away from blood vessels. High transport resistance within tumors limits NPs to 
regions adjacent to the blood vessels. It is critical that NPs reach areas distant 
from the blood vessels in order to effectively overcome drug resistance. Key: Blue 
cells—drug sensitive cells; yellow cells—resistant cells; grey area—tumor ECM; 
light blue circles—nanoparticle excipients; red dots—chemotherapeutic drug; blue 
triangles—efflux pump inhibitor. 
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In order for NP-based therapies to be successful, however, it is essential 
that NPs are transported efficiently to the tumor cells. Tumors are characterized 
by inadequate blood supply and elevated interstitial fluid pressure (IFP) [11]. As a 
result, transport in the tumor is highly hindered. Several approaches have been 
proposed for improving intratumoral transport of macromolecules and drug carriers 
[11]. These include the use of anti-angiogenics [12] and modification of the tumor 
stroma [13].   
In this review, we will focus on these two important issues: (1) the use of 
nanotechnology to overcome efflux activity in tumor cells and (2) inefficient 
transport of drugs and drug carriers within the tumor tissue. We will provide a 
mechanistic perspective of why nanotechnology has the potential to overcome 
drug resistance and why the use of adjunct therapies to improve transport may be 
critical to the success of nanotechnology-based anticancer therapies. 
1.3  Mechanisms of tumor drug resistance 
1.3.1 Efflux transporters 
A majority of chemotherapeutics have intracellular targets. Thus, to kill the 
tumor cell, many anticancer drugs have to accumulate inside the cell at sufficient 
concentrations. A major hurdle to achieving adequate intracellular drug 
concentrations is the presence of efflux proteins on the tumor cell membrane [14, 
15]. Drug efflux pumps belong to a family of transporters called the ATP-binding 
cassette (ABC) transporters. ABC transporters are one of the largest superfamily 
of proteins. The human genome encodes for 48 ABC proteins. These include 20 
6 
 
transporter proteins, further divided into 7 sub-families, ABC A-G [16]. Some of the 
important and well-studied transporters include ABCB 1 [P-glycoprotein (P-gp), 
multidrug resistance protein 1 (MDR1)], ABCC 1-3 [multidrug resistance 
associated protein (MRP) 1-3], and ABCG 2 [breast cancer resistance protein 
(BCRP)]. P-gp was the first discovered efflux transporter [17, 18]. In 1983, Kartner 
and coworkers first demonstrated the correlation between increased expression of 
P-gp in tumor cells with the development of drug resistance [19]. This was followed 
by Chen and others, who described the sequence of the MDR1 cDNA and its 
homology to two bacterial transporters, thereby defining the first member of the 
ABC transporter family [20]. Ueda and coworkers demonstrated that expression of 
a full length cDNA for the human MDR1 gene confers drug resistance in tumor 
cells, confirming the role of MDR1 gene in drug resistance [21]. It was later 
discovered that some tumor cells that did not have upregulated P-gp levels could 
also actively efflux drugs. This led to the discovery of MRP 1 [22]. Since then, 
additional transporters have been identified and their roles in drug transport have 
been investigated [16]. Of these, P-gp is one of the most consistently over-
expressed transporters in drug-resistant tumors [23]. 
Even under normal physiological conditions, efflux transporters are widely 
expressed in the body (reviewed in [24]). Some organs show a particularly high 
expression of these transporters. For example, P-gp, BCRP and MRP 2 are highly 
expressed on the apical sides of the lung, testis, placenta, and brain. On the other 
hand, MRP 1 is highly expressed on the basolateral side of these organs [4, 25-
30]. These transporters create a formidable barrier that protects important organs 
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from toxic xenobiotics. Consequently, these transporters play a key role in altering 
the absorption, distribution, metabolism, and excretion of drugs [31-33].  
1.3.1.1 Structure and mechanism of P-gp 
P-gp is a 170 kDa protein with broad substrate specificity [34]. Structurally, 
it comprises 2 transmembrane domains (TMDs) and 2 nucleotide binding domains 
(NBDs). The TMDs are hydrophobic domains consisting of 6 transmembrane 
segments, while NBDs are hydrophilic intracellular domains [35]. NBDs provide a 
docking site for the ATP molecules. While the exact mechanism by which P-gp 
interacts with its substrate is not fully understood, it is thought that binding of a 
substrate to the high-affinity binding site results in ATP hydrolysis, causing a 
conformational change that shifts the substrate to a lower affinity binding site and 
then into the extracellular space or outer leaflet of the membrane [36-38]. Whether 
P-gp extracts its substrate from the cytoplasm [39] or from within the membrane 
(‘vacuum cleaner’ hypothesis) is not clear, but evidence suggests that substrates 
diffuse from the lipid bilayer into the drug-binding pocket located in a hydrophobic 
environment [40, 41]. Studies from our laboratory suggest that drug released into 
the cytoplasm from NPs is susceptible to P-gp mediated efflux [42]. P-gp 
overexpression also confers resistance to drugs through mechanisms not directly 
related to transport. For example, overexpression of P-gp confers resistance to 
complement-mediated cytotoxicity due to delayed deposition of complement on 
the plasma membrane [43, 44]. Also, P-gp over-expressing cells are less sensitive 
to multiple forms of caspase-dependent cell death, including those mediated by 
Fas ligand [45] and serum withdrawal [46]. Some of the transport-independent 
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effects of P-gp may be explained by the fact that over-expressed P-gp can 
constitute an important part of the plasma membrane. In Chinese hamster ovary 
(CHO) cells, P-gp alone accounted for about 20% of the total plasma membrane 
proteins [47]. This degree of overexpression could affect the activity of other 
membrane proteins.  
1.3.1.2 Acquired and intrinsic resistance 
In vitro studies have shown that the expression of efflux pumps increases 
in response to chemotherapy. These changes arise from copy number alterations 
of the gene or increased expression of these genes [48-51]. This change in efflux 
transporters in response to chemotherapy is evident in clinical studies as well [52]. 
Abolhoda et al. tested the effect of doxorubicin treatment on five patients with lung 
metastasis [53]. The authors found that after a 20-minute chemoperfusion, there 
was a 6-7 fold increase in MDR1 gene expression in these tumors. This 
phenomenon of upregulation of efflux transporters in response to drug treatment 
is termed as acquired resistance. Interestingly, Levchenko et al. reported the 
intercellular transfer of functional P-gp protein from P-gp positive cells to P-gp 
negative cells both in vitro and in vivo [54]. The transfer occurred between different 
cell types, and allowed the recipient drug-sensitive cells to survive toxic drug 
concentrations, leading to increased tumor resistance. This mechanism could 
explain how some sensitive cells acquire drug resistance.  
Another striking feature of efflux transporters is the wide range of substrate 
specificity [34, 35]. Weakly basic and neutral compounds have been found to be 
the most vulnerable to these pumps [35, 55, 56]. However, some reports suggest 
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that even acidic compounds can be subject to efflux [57, 58]. A rare common 
feature is that most compounds transported by these pumps are amphiphilic in 
nature [35]. The broad substrate specificity and upregulation in response to 
chemotherapy have serious consequences. Resistance arising from one drug can 
lead to cross-resistance to other chemotherapeutics that are substrates of the 
same transporter. Such a resistance is termed as multidrug resistance (MDR). 
Because of this phenomenon, sequential chemotherapy or switching to a different 
drug class may not be useful once a patient develops resistance to one drug class.   
A fraction of tumor cells intrinsically have a higher expression of efflux 
transporters even before exposure to chemotherapy [5]. This phenotype may be a 
manifestation of tumor microenvironmental conditions, tissue of origin, and/or 
rampant genetic mutations characteristic of cancer cells [4]. This phenomenon is 
termed as intrinsic resistance.  
Acquired and intrinsic resistances may stem from mechanisms not involving 
efflux transporters as well. This is especially evident with drugs classified as 
‘targeted therapies’ [59]. These drugs target specific aberrant cellular pathways 
that are essential for the survival of cancer cells. For example, the epidermal 
growth factor receptor (EGFR) is upregulated in multiple cancers. Activation of 
EGFR results in the activation of multiple kinases that aid in tumor growth and 
survival. Hence, antagonists that block EGFR signaling are of considerable interest 
[60]. However, this enthusiasm has been dampened by the appearance of intrinsic 
and acquired resistances (reviewed in [61]). Upon continued exposure to EGFR 
antagonists, tumor cells resort to alternate pathways that enable survival and 
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proliferation independent of EGFR activation [62]. Thus, in spite of EGFR 
inhibition, there is no effect on the tumor cell viability.  On the other hand, some 
tumors do not rely on EGFR signaling at all. These tumors are intrinsically resistant 
to EGFR-targeted therapies. 
Intracellular detoxification is another mechanism of drug resistance. Such 
mechanisms enable faster elimination of the drug from within the cell and hence 
reduce their intracellular concentration [63]. Glutathione conjugation is an example 
of the detoxification strategy employed by tumor cells [64, 65]. Mellish et al. 
showed that this mechanism can be upregulated in response to sustained 
exposure to chemotherapeutics [66]. The authors isolated a human ovarian 
carcinoma cell line from untreated patients. This cell line was exposed to 
increasing concentrations of cisplatin for 18 months. The resultant cell line was 
less susceptible to cell death induced by cisplatin and other platinum containing 
drugs. The authors found that the resistant cell line had higher levels of glutathione 
and correspondingly lower intracellular drug concentration [66].  
Several anti-cancer agents induce DNA damage to bring about cell death. 
However, cancer cells can develop mechanisms to increase DNA repair and 
thereby develop resistance to these drugs. The mechanisms of DNA repair and 
drug resistance have been reviewed in detail elsewhere [67-69]. 
1.3.1.3 Efflux transporters and cancer stem cells 
According to the consensus definition, cancer stem cells (CSCs) are 
minority cells that are capable of potentially unlimited self-renewal owing to 
asymmetric cell division, and have the ability to produce multiple differentiated cell 
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types that constitute solid tumors [70]. Although not fully established, the origins of 
CSCs could theoretically arise from oncogene activation in normal adult tissue 
stem cells or through the acquisition of stem cell-like properties via 
microenvironmentally triggered phenotypic changes in cancer cells. CSCs 
possess a number of intrinsic properties that contribute to therapy resistance and 
ultimately disease recurrence [71]. Similar to normal stem cells, CSCs have 
protective mechanisms against external insults from cytotoxic chemotherapy, 
which include alterations in the intrinsic apoptotic pathway, DNA repair, and most 
notably, overexpression of efflux transporters [72].   
From the perspective of drug resistance, selective pressures within the 
tumor microenvironment can result in the generation of intrinsically resistant cells. 
In addition, standard therapeutic regimens, if ineffective in eradicating tumor cell 
burden, can result in a residual population of cells displaying acquired resistance. 
Both resistance mechanisms would ultimately result in the expansion of the CSC 
fraction within the tumor. These therapy-resistant cells, now considered the CSC 
population, are known to overexpress ABC transporters [73]. This principle is 
frequently exploited for their isolation. Rhodamine and Hoechst 33342 fluorescent 
dyes, substrates of both ABCG2 and ABCB1, are used in the analysis of the so-
called side population of cells displaying low dye retention, via flow cytometric 
techniques. These side population cells display the ability to actively efflux ABC 
transporter substrates, as well as additional properties ascribed to CSCs, including 
tumor seeding at limiting dilution, a heightened anti-apoptotic state, relative 
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proliferative quiescence, and resistance to conventional chemotherapy upon 
sorting these cells from the bulk population [74].  
To demonstrate the role of CSCs in acquired resistance, numerous reports 
document a selective enrichment of the CSC fraction following conventional 
chemotherapy treatment in vitro. The ovarian cancer cell lines OVCA 433 and 
HEY, when treated with cisplatin and paclitaxel in vitro, result in cells with 
increased sphere forming efficiency, CSC marker gene expression, and tumor 
seeding efficiency in vivo [75]. Immortalized mammary epithelial (HMLE) cells 
induced to passage through epithelial to mesenchymal transition (EMT) have been 
shown to display the properties of CSCs. When these cells are spiked into non-
CSC enriched HMLE cells and treated with paclitaxel in vitro, the CSCs selectively 
survive treatment, providing direct evidence for the role of CSCs in acquired drug 
resistance [76]. 
Another key reason for the therapeutic resistance of CSCs is their quiescent 
nature [77]. A number of chemotherapeutic agents are effective only against 
actively dividing cells. CSCs, like normal stem cells, divide infrequently and 
produce transient amplifying cells which populate the tumor. Hence, chemotherapy 
may be effective in eradicating the bulk of the tumor but may lack efficacy against 
the quiescent stem cell population [71].  
1.3.1.4 Elevated levels of efflux transporters and poor prognosis  
There is considerable evidence linking the presence of MDR cells with poor 
prognosis in cancer [78, 79]. Evidence for the role of P-gp in clinical tumor 
resistance was first provided by Trock and co-workers, who demonstrated P-gp 
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expression in about 40% of breast cancer samples and its correlation with 
decreased treatment response [80]. Additional studies [4, 81, 82] further confirm 
this observation, and suggest that pretreatment P-gp expression is a strong 
predictor for clinical response to drug therapy [83]. Karaszi et al. examined the 
response to therapy of 93 acute leukemia patients [84]. These patients were 
treated with various therapies depending on the disease subtype. Based on a 
calcein efflux assay, these patients were then classified into MDR+ or MDR- groups. 
It was found that 72% of the MDR- patients responded to therapy, while only 31% 
of MDR+ patients did. Consequently, there was a three-fold difference in median 
patient survival. Similar results were reported by Leith et al., who found that elderly 
leukemic patients responded poorly to treatment in comparison to younger patients 
because of elevated P-gp expression [85].  
1.3.2 Sequestration in acidic organelles 
In addition to efflux pumps, sequestration in acidic organelles can reduce 
the bioavailability of anticancer drugs at their intracellular site of action [86]. 
Anthracyclines such as doxorubicin and daunorubicin accumulate in the nucleus 
(its site of action) in sensitive cells. In drug resistant cells, these weakly basic drugs 
are primarily distributed into acidic organelles such as late endosomes and 
lysosomes  [87]. The elevated activity of the vacuolar H+-ATPase pump in drug 
resistant cells leads to highly acidified pH of these organelles [88, 89]. Basic drugs 
are expected to be highly ionized under these conditions. This results in their 
trapping within these organelles and loss of activity. The trapped drug is likely 
extruded out of the cell by exocytosis [90]. 
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1.3.3 Resistance to transport of macromolecules and drug carriers 
In addition to the tumor cells, the tumor extracellular matrix (ECM) is a 
source of resistance to chemotherapy. Transport of drug into and within the tumor 
is extremely inefficient [91, 92]. This leads to regions of high and low drug 
concentrations in the tumor [93]. The regions receiving lower drug concentrations 
often harbor the more aggressive and tumorigenic cells [94]. Thus, it is extremely 
important to achieve therapeutic drug concentrations in these under-supplied 
regions.  
In order to address the issue of inefficient drug distribution, it is essential to 
understand the processes governing drug transport in the tumor. In the following 
sections, we provide a brief description of the physiological factors governing 
intratumoral drug transport.  
1.3.3.1 Transport process in normal tissues 
Exchange of fluid and nutrients (as well as drugs) between blood vessels 
and tissue is governed by several parameters, and this relationship is defined 
quantitatively by Starling’s law (Figure 1-2) [95, 96]. There are two components 
that drive the outward flow of soluble drug molecules into the tissue: the hydrostatic 
pressure head (arising from convection in the capillaries) and osmotic pressure 
head (arising from a difference in concentration of solutes). In normal tissues, this 
net pressure is directed towards the tissue and allows a convenient exchange of 
nutrients with the vascular compartment. The excess fluid draining into the tissues 
is cleared by the lymphatic system. As a result, a net negative pressure is 
maintained [13, 97]. Additionally, each cell in the body is only a few cell-diameters 
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away from the nearest blood vessel. This restricts the distance a solute has to 
travel in the interstitium to encounter the farthest cell from the blood vessel [98]. 
Thus, the negative pressure difference and short interstitial distances allow 
efficient solute transport in normal tissues.  
 
Figure 1-2. Forces that regulate transcapillary transport in tissues.  
The figure shows the hydrostatic and colloid osmotic pressures in capillaries (PCAP 
and COPCAP, respectively) and the surrounding interstitium (PIF and COPIF, 
respectively) in normal tissues (a) and tumor tissues (b). It should be noted that 
values are approximate. (a) In normal human capillaries, the COPCAP is about 28 
mm Hg, which tends to keep fluid in the capillaries. The forces that tend to move 
fluid out from the capillaries are the PCAP (about 20 mm Hg), the COPIF (about 8 
mm Hg) and the PIF, which is normally negative (−1 to−3 mm Hg). So there is 
normally a net outward filtration pressure from the capillaries in tissues of 1–3 
mmHg. This outward pressure assures a flow of fluid out from the vessels and 
through the interstitium, and contributes to transport of molecules to and from cells. 
(b) In tumor tissues, the COPIF is increased to about 20 mm Hg and the PIF is 
increased to 10–30 mm Hg, resulting in some tumors in a net outward pressure of 
about 2 mm Hg (which is similar to that of normal tissues), but in other tumors in a 
net inward pressure of up to 18 mm Hg. Reprinted with permission from [13]. The 
equation describes Starling's law. Mass flux across the capillaries is governed by 
the hydraulic conductivity (Lp), blood vessel surface area (S), and pressure 
difference (ΔP). σ indicates the reflection co-efficient. 
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1.3.3.2 Transport process in the tumor 
Differences in tumor and normal tissue physiologies give rise to major 
obstacles to drug delivery to and within the tumor [99, 100]. The direction and 
magnitude of the driving force for drug transport is not constant throughout the 
tumor. This inconsistency in the driving force arises from the differences in the 
functionality of the lymphatic system. The advancing edge of the tumor exhibits 
normal lymphatic drainage. As a result, the fluid entering the tumor from the blood 
vessels is cleared normally [101]. This helps maintain a negative pressure gradient 
in this part of the tumor, similar to that in normal tissues [102]. However, the core 
of the tumor experiences no such driving force for drug transport. The lymphatic 
vessels are usually collapsed and show minimal hydraulic conductivity in the 
center of the tumor. As a result, excess fluid entering the tumor is not drained from 
this central core [101, 103]. Hence, the pressure differential in the core of the tumor 
is often in the opposite direction, i.e., from the tumor towards the blood vessels 
[13]. Additionally, the core of the tumor is characterized by poor vessel coverage 
[104-106]. Consequently, drug transport to the core of the tumor is reliant on the 
diffusion of the drug from well-perfused peripheral regions [107]. These disparities 
in normal and tumor physiologies arise from two major factors: angiogenesis and 
tumor microenvironment.  
1.3.3.3 Angiogenesis  
Tumor cells divide more rapidly than normal cells. As the tumor grows 
larger, it can no longer survive on the pre-existing blood vessels of the surrounding 
normal tissue. Tumors produce potent growth factors such as vascular endothelial 
growth factor (VEGF), which enable the sprouting of new blood vessels from 
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existing ones. This process is known as angiogenesis [108, 109]. In normal 
tissues, this process is tightly regulated and involves a balance between pro- and 
anti-angiogenic factors, leading to well-formed blood vessels with a hierarchical 
architecture. In contrast, tumors are characterized by a pro-angiogenic 
environment. This results in poorly developed vascular anatomy (lack of pericyte 
coverage and leakiness) and architecture (dead ends and irregular flow patterns) 
[110-112].  
The leakiness of tumor blood vessels leads to expulsion of vascular 
components including excess fluid into the tumor interstitium. The lack of lymphatic 
drainage restricts the removal of fluids and other vascular components from the 
tumor microenvironment. Presence of these vascular components in the limited 
ECM space results in elevated IFP [100, 102, 113-115] and prevents the entry of 
drugs into the tumor [116]. Elevated IFP has been shown to correlate with poor 
response to chemotherapy and immunotherapy [117]. A study by Curti and 
coworkers followed the response of 6 non-Hodgkin’s lymphoma patients to 
chemotherapy. The patients received a chemotherapy combination consisting of 
either ProMACE CytaBOM (cyclophosphamide, doxorubicin, etoposide cytozar, 
bleomycin, vincristine, methotrexate and prednisone) or EPOCH (etoposide, 
prednisolone, vincristine, doxorubicin and cyclophosphamide). Tumor IFPs were 
monitored before and after treatment. The authors found that the responders 
showed a lower pre-treatment IFP as compared to the non-responders. 
Additionally, the tumor IFPs of the responders decreased with treatment while that 
of the non-responders increased. This study also monitored the IFP of 10 
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melanoma patients treated with interleukin-1 and 2 based immunotherapy. The 
melanoma nodules that responded to immunotherapy showed a lower IFP than 
those that did not respond to immunotherapy. These results show that elevated 
IFP can significantly decrease therapeutic efficacy of multiple treatment modalities.  
1.3.3.4 Reactive tumor microenvironment 
Overexpression of cross-linking agents such as lysyl oxidase in tumors 
leads to a higher degree of polymerization of biopolymers like collagen and 
hyaluronic acid [118, 119]. Moreover, fibroblasts in the tumor microenvironment 
are in an activated state. Activated fibroblasts, or myofibroblasts, secrete copious 
amounts of ECM components. Additionally, myofibroblasts use specialized 
receptors on their cell surface to engage these biopolymers and increase the 
overall ECM rigidity [120, 121]. All these factors contribute to a reactive tumor 
microenvironment and an increased resistance to diffusional drug transport within 
the tumor ECM [122].  
It should be noted, however, the rigidity of tumor ECM is likely 
heterogeneous. Overexpression of matrix metalloproteinases is a hallmark of 
many tumors and is associated with increased tumor invasiveness [123]. The 
expression of this enzyme brings about proteolysis of the collagen fibrils in the 
tumor [123], and should thus reduce matrix stiffness. However, this reduction in 
matrix stiffness may be spatially and temporally limited. Tumor cells present on the 
periphery are more likely to migrate [124]. Hence the stiffness of the bulk of the 
tumor may not be affected by the expression of the protease.   
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1.3.3.4.1 Presence of fibrin in tumors 
An important feature distinguishing normal tissues from tumors is the presence 
of fibrin in the ECM. Fibrin is the key ingredient of the blood clot and is deposited 
at sites of pathological damage, inflammation and in tumors.  
1.3.3.4.1.1 Source of fibrin in tumors 
Fibrinogen, a soluble blood protein, exists as a dimer and consists of 3 peptide 
chains, viz. Aα, Bβ and γ. Upon thrombin-mediated cleavage of N-terminus 
peptides from the A and B chains, fibrinogen is converted to insoluble fibrin. 
Further action by Factor XIIIa leads to the covalent cross-linking of the α and γ 
chains [125]. This cross linked product resembles fibrin found in tumors. This 
product can be characterized by the presence of γ dimers and its insolubility in 
urea [126].  
Tumor blood vessels are hyperpermeable due to proangiogenic tumor 
microenvironment. As a result, fibrinogen gets deposited within the tumor [127]. 
Additionally, tumor cells express significant amount of thrombin and tissue factor 
[128]. This leads to the conversion of fibrinogen to cross-linked fibrin.  
Early studies utilized immunohistochemistry or immunofluorescence 
techniques to detect fibrin in tumors [129]. However, antibodies used for these 
purposes could not distinguish between fibrinogen and fibrin. Key evidence for 
accumulation of cross-linked fibrin in tumors was provided by Dvorak and 
colleagues. In these experiments, 125I-labeled fibrinogen was injected in guinea 
pigs bearing bile duct carcinomas [130]. A few minutes after injection, animals 
were sacrificed and tumors were collected. Radioactivity in urea-soluble and urea-
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insoluble fractions of the tumor were measured. The radioactivity in the urea 
soluble fraction (representing fibrinogen, fibrinogen-degradation products and 
insoluble but non-cross linked fibrin) of the tumor was found to be 5-6 fold higher 
than surrounding normal tissues. This supported previous studies suggesting 
extravasation of fibrinogen in tumors. More interestingly, the radioactivity in the 
urea-insoluble fraction of the tumor (denoting cross-linked fibrin) was ~10-20 fold 
higher than the surrounding normal tissues. This provided strong evidence 
supporting the presence of fibrin, and not just fibrinogen, in tumors. Half of the 
radioactive product present in these tumors was in the form of fibrin. Similar results 
were obtained in different mouse tumor models as well [131].  
The two factors responsible for fibrin deposition in tumors are 
hyperpermeability of blood vessels and high activity of coagulation factors. Studies 
in healthy eyes and muscles of guinea pigs have revealed that increasing the 
permeability of blood vessels by local administration of VEGF and histamine can 
cause accumulation of cross-linked fibrin in these tissues [132]. This suggests that 
most cells do possess a certain level of thrombogenic activity. However, normal 
tissues do not accumulate significant fibrin due to the poor extravasation of 
fibrinogen from the blood vessels. Some studies in renal cell carcinomas have 
shown that the level of VEGF secretion (and hence hyperpermeability) may predict 
fibrin deposition in tumors [133]. 
1.3.3.4.1.2 Function of fibrin in tumors 
Fibrin serves an important function in tumor growth [134, 135]. As one of the 
earliest events in tumor development [135], fibrin provides a scaffold for the tumor 
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cells to attach. As time progresses the fibrin scaffold is first replaced by an 
undifferentiated tissue, and finally by ECM components such as collagen [136]. 
Consequently, fibrin expression is often found to be most around the growing 
edges of the tumor.  
In addition to providing a scaffold for tumor cells, fibrin plays an important role 
in modulating the activity of fibroblasts and macrophages. It was shown that 
fibroblasts migrated efficiently in fibrin matrices prepared from cross-linked fibrin 
[137]. On the other hand, macrophage mobility was dramatically reduced in cross-
linked fibrin [138]. Presence of fibronectins or glycosamoniglycans in the fibrin 
matrix (as found in tumor matrices) further decreased the migration of 
macrophages. This opposite effect of cross-linked fibrin on the mobility of 
fibroblasts and macrophages is interesting. Fibroblasts play an important role in 
the synthesis, organization and maturation of the ECM in tumors [139], while, in 
certain conditions, macrophages can potentially inhibit tumor growth [140]. Hence, 
these studies provide some evidence to the protective and nurturing role of fibrin 
in tumor growth. It is interesting to note that tissue remodeling and inhibition of 
inflammation are physiological functions of fibrin during wound healing [141]. This 
mechanism is hijacked by tumors to support its growth.  
Finally, fibrin turnover is rapid in tumors [142]. This leads to generation of large 
amounts of fibrin degradation products. In their experiments with chick 
chorioallantoic membrane, Thompson et al. showed that fibrin degradation 
products led to angiogenesis [143]. This provides further evidence to the patho-
physiologic roles of fibrin in tumors.  
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1.3.3.4.1.3 Effect of fibrin on tumor drug delivery 
Due to the high expression of fibrin in tumors and a limited expression in normal 
tissues, it can be a good target for drug delivery. However, very few literature 
reports make use of this strategy.  
Bale et al. used an antibody targeted to fibrin for the tumor specific delivery of 
radioactive I131 [144]. In a variety of rat tumors, accumulation of fibrin-targeted 
antibody was found to be 5-6-fold higher than the control antibody. Treatment with 
the targeted antibody labeled with I131 resulted in complete regression of tumors 
with no relapse. While control animals treated with non-targeted radiation therapy 
responded to the treatment, almost all tumors relapsed within a week.  
In another report, Nishikawa et al. presented an elegant use of platelets for 
drug targeting [145]. The envelope of Sendai virus is known to generate an anti-
tumor immune response. Unfortunately, systemic administration of the viral 
envelope causes haemagglutination. Platelets are known to engulf several 
particulate matter in vivo. Moreover, they have the property to home to the site of 
fibrin accumulation. Hence, platelets can act as suitable carriers to minimize 
systemic toxicity and maximize tumor homing of the viral envelope. Encapsulation 
of the viral envelope in platelets decreased its systemic toxicities. Importantly, in a 
B16F10 melanoma model, platelets were found to co-localize with fibrin within the 
tumor. This led to a significant suppression of tumor growth as compared to the 
untreated controls [145].  
Fibrin accumulation in the tumor has also been used for an interesting 
‘amplification’ strategy. Simberg and colleagues reported the discovery of CREKA 
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peptide that binds fibrin [146]. Conjugation of the peptide to the surface of 
liposomes and iron oxide nanoparticles improved their delivery of B16F1 tumors. 
Microscopy studies showed the colocalization of nanoparticles with fibrin in tumors. 
Interestingly, the authors found that the peptide promoted clotting within tumors. 
Increase in fibrin levels led to an amplification in signal available for successive 
dose of nanoparticles. In another report, von Maltzahn et al. showed that gold 
nanoparticle-mediated hyperthermia or delivery of tumor specific tissue factor can 
also increase fibrin accumulation in tumors [147]. Increase in fibrin accumulation 
in tumors can further improve the tumor delivery of fibrin homing nanoparticles. It 
is interesting to note that the intravascular clotting caused by the CREKA peptide 
led to the arrest of nanoparticles inside tumor blood vessels. This provides initial 
evidence that fibrin may occlude drug delivery to tumors.  
These studies suggest that fibrin can act as a viable target for drug delivery. 
However, the role of fibrin in mediating solid stress or its effect on the intratumoral 
distribution of drugs has not been yet studied.  
1.3.4 Acidic and hypoxic microenvironment 
Limited solute distribution within the tumor ECM also means reduced 
transport of oxygen to the tumor cells. This leads to regions within the tumor that 
are hypoxic [148, 149]. Hypoxia can directly and indirectly affect the effectiveness 
of chemotherapy (reviewed in [150]). Many cytotoxics (eg.bleomycin) and 
photosensitizers (eg. porphyrin) rely on the production of free radicals for their 
activity [151, 152]. The activity of these drugs is compromised under hypoxia. 
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Additionally, hypoxia reduces cell proliferation [153]. Since a number of anti-cancer 
drugs selectively kill rapidly dividing cells, these drugs are relatively ineffective in 
these regions. 
Hypoxia leads to stabilization of an otherwise labile transcriptional factor 
called hypoxia inducible factor 1α (HIF1α) [154, 155]. This leads to the activation 
of several genes associated with the hypoxia responsive element (HRE). MDR1 
gene is one of those genes regulated by HRE [156]. As discussed before, 
upregulation of MDR1 gene leads to resistance to drug therapy. It is thus 
conceivable that the hypoxic regions are rich in cells expressing the efflux 
transporters.  
Tumor cells rely on glycolysis for energy production. This phenomenon is 
termed as the Warburg effect [157, 158]. Excess glycolysis, leads to the generation 
of lactic acid. Poor transport of nutrients in tumors is coupled with poor drainage 
of waste products as well. Thus, lactic acid is not cleared from the tumor efficiently, 
resulting in a drop in local pH. The acidic microenvironmental pH leads to ionization 
of weakly basic drugs such as doxorubicin in the tumor ECM. Since ionized drugs 
do not cross cell membranes efficiently, the acidic microenvironment limits 
intracellular drug accumulation and can, thus, lead to a loss in therapeutic efficacy 
[159].  
1.4 Approaches to overcome tumor drug resistance 
Upregulation of efflux transporters is correlated with poor prognosis in a 
number of cancers [78]. Consequently, a significant body of research has been 
directed towards overcoming drug resistance by inhibiting or circumventing these 
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transport processes. Many of these efforts have involved the use of NPs [160]. In 
the following sections, we provide the rationale for the use of NPs for drug delivery 
to tumors. We also outline the various mechanisms by which NPs can be used to 
overcome efflux transport mediated drug resistance.  
1.4.1 Enhanced permeability and retention (EPR) effect 
The task of delivering drugs selectively to tumors is extremely challenging. 
Several strategies have been developed to maximize drug delivery to solid tumors. 
These include conjugation of drugs to antibodies or antibody fragments that bind 
to tumor cells [161-163], conversion to non-toxic prodrugs that are activated in the 
tumor [164-166], conjugation to hydrophilic polymers [167-169] and encapsulation 
in nanocarriers [170-172]. The rationale driving the use of macromolecules and 
nanoparticles for tumor-targeted drug delivery is summarized as the EPR effect 
[173]. Proposed by Matsumura and Maeda almost three decades ago [174], the 
EPR effect states that colloidal carriers have a greater tendency to enter tumors 
than normal tissues. Additionally, their elimination from tumors is delayed. This can 
result in greater drug exposure in tumors than in normal tissues.  
Unfortunately, very few literature reports have analyzed the pharmacokinetics 
underlying the EPR effect from a mechanistic perspective [175, 176]. Additionally, 
expectations from the nanoparticle-based therapy are often unrealistic [177, 178], 
which can adversely affect the future development of these technologies. In the 
following sections, we summarize the fundamentals of drug transport across tumor 
blood vessels. We also discuss some features of nanoparticles and drug that 
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enable the existence of the EPR effect. We show here that several physiological 
features of the tumor and physicochemical properties of the drug as well as 
nanoparticles affect drug transport, making the EPR effect a specialized 
phenomenon. It will be clear that although only a small number of variables are 
considered in this discussion, drawing any general conclusions is challenging. This 
highlights the complexities of drug targeting to tumors.  
1.4.1.1 Factors affecting drug concentration in the tumor 
Upon IV administration, the rate of change of drug concentration in the tumor 
can be described using the following equation: 
 	 =   −   
Where  represents the concentration of drug in plasma,  
represents drug concentration in the tumor.  and represent 
distributional clearances for drug deposition into the tumor and drug elimination 
from the tumor, respectively.  
Higher drug concentration in the tumor can be achieved by altering any or all 
of the three parameters: increase in the deposition clearance , increase 
in drug concentration in the central compartment  or decrease in elimination 
clearance from the tumor . In the following sections, we analyze which 
of these parameters can be favorably affected by nanoencapsulation.  
1.4.1.2 Deposition clearance into the tumor 
Angiogenesis is a hallmark of most solid tumors [179]. Due to excessive 
secretion of pro-angiogenic factors, tumor blood vessels develop in a disorderly 
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manner. Consequently, they lack pericyte coverage and a well-developed 
basement membrane, and often have gaps between their endothelial cells. Hence, 
tumor blood vessels are considered porous in nature [110, 180].  
As described extensively by Jain and colleagues, drug transport across porous 
blood vessels occurs by two processes, convection and diffusion [99, 107, 181, 
182]. Convectional transport is driven by the pressure differential between the 
capillary and tumor interstitium, and is proportional to the reflection coefficient of 
nanoparticles. Diffusional transport arises from the concentration difference 
between the capillary and tumor tissue. Diffusional flux is directly proportional to 
the diffusion coefficient of nanoparticles. Due to the colloidal size of nanoparticles, 
diffusion is rather limited and convection is the major mode of transport [183] (at 
least in the peripheral regions of the tumor [102], where majority of drug exchange 
occurs [184]). On the other hand, transport of soluble drug molecules occurs 
predominantly by diffusion [183].  
Several studies have analyzed the transvascular flux of macromolecules [176, 
185, 186] and nanoparticles [1, 185, 186]. Generally, with an increase in particle 
size, transvascular flux (and hence deposition clearance) decreases [1]. Studies 
comparing the transvascular flux of nanoparticles to soluble drug molecules have 
not been conducted. Hence, providing experimental evidence to compare 
deposition clearance of nanoparticles and soluble drug molecules is not currently 
possible. However, some speculations can be made. For drugs with favorable 
tumor to plasma partition coefficients, distribution across tumor blood vessels is 
limited by blood flow. In this condition, molecular/particle size may be a good 
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predictor of transvascular flux, and the free drug should deposit within the tumor 
with much greater efficiency than nanoparticles. For drugs that have low tumor to 
plasma partition coefficients, drug transport is limited by their partition coefficient 
and size may not be a good predictor of transvascular flux. In such a case, 
deposition clearance of the soluble drug may or may not be higher than that of 
nanoparticles.  
1.4.1.3 Drug concentration in the central compartment 
Drug concentration in the central compartment is another important 
determinant of tumor concentration. The concentration-time profile of a drug in the 
central compartment after a single intravenous dose is determined by its systemic 
clearance and volume of distribution.  
Drawing generalizations comparing the pharmacokinetics of a soluble drug to 
its nanoparticle formulation is obviously not possible without experiments. 
However, there is extensive work comparing the pharmacokinetics of doxorubicin 
and paclitaxel in soluble form and in various nanoparticle formulations. Some 
common trends are observed. Encapsulating paclitaxel in nanoparticles results in 
a reduction in systemic clearance [187-192] (as observed by the reduced terminal 
slope of the concentration-time profile) and a reduced volume of distribution [188, 
190, 193] (as evidenced by the increase in the initial plasma concentration) of the 
drug. Similar results have also been reported for various formulations of 
doxorubicin [194-198]. Reduced drug clearance can be attributed to delayed 
release of the drug from the nanoparticles and resultant protection from hepatic 
enzymes and renal filtration. The altered distribution of the drug can be a result of 
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the limited ability of nanoparticles to extravasate across intact normal blood 
vessels. Regardless of the mechanism, an increase in plasma concentration of the 
drug increases the driving force for accumulation in the tumor. Not surprisingly, 
some reports show a near linear relationship between half-life of nanoparticles and 
tumor exposure [199, 200].  
The ‘enhanced permeability’ component of the EPR effect is a complex and 
conditional phenomenon. The name ‘enhanced permeability’ gives an impression 
that nanoparticles may have a greater deposition clearance into the tumor than the 
free drug. However, that is likely to occur only under special circumstances. The 
more likely explanation (that is currently supported by experimental evidence) for 
the increased tumor entry of nanoparticles is the increased plasma concentration. 
In any case, ‘enhanced permeability’ should be characterized and justified on a 
case-by-case basis.   
1.4.1.4 Elimination clearance of nanoparticles 
Under normal physiological conditions, fluid entering tissues returns back into 
systemic circulation via lymphatic drainage. Due to increased solid stress, 
lymphatics in the core of the tumor are compressed and non-functional [201, 202]. 
As a result, convective forces, driving the movement of fluid out, are absent or 
minimal in the core of the tumor. Fluid exchange can still occur in the peripheral 
regions of the tumor. Hence, the limited convection and diffusion in the tumor 
periphery are the major routes of elimination from the tumor [181]. Several factors 
such as partition coefficient, concentration difference and size play an important 
role in determining the rate of transport. Hence, it is not possible to draw any 
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generalizations. However, if size was the only determining factor, nanoparticles 
are significantly larger than the soluble drug molecule. Consequently, the 
elimination clearance of nanoparticles from tumors would be lower than that of the 
free drug. The impaired pathophysiology of tumors enables a delayed retention of 
nanoparticles and encapsulated drug within the tumor [174].  
Thus, the EPR effect is a highly specialized occurrence. The existence of this 
effect relies on several variables such as the type of tumor, type of drug, 
physicochemical properties of nanoparticles, pharmacokinetics of the drug and 
nanoparticles, and so on. Though a very limited number of variables were 
considered in the discussion above, making generalizations about the EPR effect 
is not possible.  
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Table 1-1. Tumor targets, ligands, and type of nanoparticles used for active 
targeting 
Target Type of ligand Type of nanoparticle Reference 
αvβ3 Peptide 
 
 
 
 
 
 
Antibody 
Perfluorocarbon 
Silica 
Polysaccharide 
Micelles 
Polymer 
Quantum dots 
Iron oxide 
Perfluorocarbon 
[203] 
[204] 
[205] 
[206-208] 
[209, 210] 
[211] 
[212, 213] 
[214] 
Biotin Small molecule Polymer [9, 215] 
CA125 Antibody Liposomes [216] 
CD13 Peptide Liposomes [217] 
CD133 Antibody Polymer [218] 
CD19 Antibody Liposomes [219] 
CD20 Antibody Polymer [220] 
CD3 Antibody Polymer [221] 
CD44 Glycosaminoglycan Polymer [222] 
Claudin 4 Antibody Silica [223] 
EGFR scFv 
 
Peptide 
 
Antibody 
 
Gold 
Quantum dots 
Polymer 
Iron oxide 
Gold 
Polymer 
Iron oxide 
[224] 
[225] 
[226, 227] 
[228] 
[229-231] 
[220] 
[232-234] 
Folate 
receptor 
Small molecule Polysaccharide 
Iron oxide 
Polymer 
Quantum dots 
Oligonucleotide 
Liposomes 
Micelles 
[235, 236] 
[237] 
[215, 238-241] 
[242] 
[243] 
[244] 
[245] 
Glucose 
transporter 
Small molecule 
Antibody 
Polymer 
Liposomes 
[246] 
[247] 
Lectin Monosaccharide Liposomes [248] 
LHRH-
receptor 
Protein Protein [249] 
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Tumor 
lymphatic 
vessel 
Peptide Polymer [250] 
Mesothelin Antibody Silica [223] 
Nucleolin Peptide Polymer [251-253] 
Nucleosome Antibody Liposomes [254] 
PSMA Antibody 
Small molecule 
 
Aptamer 
Quantum dots 
Quantum dots 
Polymer 
Polymer 
Polymer-Lipid 
Micelles 
[255] 
[211] 
[256] 
[257, 258] 
[259] 
[260] 
Sigma Small molecule Cyclodextrin 
Liposomes 
[261] 
[262, 263] 
SPARC Peptide Iron oxide [264] 
Transferrin 
receptor 
Glycoprotein Gold 
Cyclodextrin 
Polymer 
Silica 
Liposomes 
[265] 
[266, 267] 
[268] 
[223] 
[269] 
uPAR Peptide Iron oxide [270, 271] 
 
1.4.2 ‘Active’ targeting 
The expression of several cell surface receptors and transporters is 
upregulated in cancer cells [272]. Conjugating drugs to ligands that bind these 
receptors can potentially improve drug delivery to tumors. There are several 
research initiatives exploring the delivery of chemotherapeutics conjugated to 
antibodies or antibody fragments that bind to these cancer specific markers [273].  
A similar targeting approach has been applied to improve the delivery of 
nanoparticles to solid tumors as well. This strategy is commonly labeled as ‘active’ 
targeting [274]. This field has matured tremendously, wherein elegant synthetic 
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techniques have been devised to maximize the benefits of active targeting [215, 
256, 275]. A variety of targets have been explored. These include receptors 
overexpressed on the tumor cell surface [223, 240, 266], endothelial cells of 
angiogenic blood vessels [206, 209] and tumor lymphatic vessels [250]. Diverse 
types of ligands, ranging from small molecules to full length antibodies, have been 
immobilized on the nanoparticle surface for active targeting. A list of targets, 
ligands and the type of nanoparticles used for active targeting is summarized in 
Table 1-1. While this list is not exhaustive, it provides a good idea of the variety of 
ligands and targets used for active targeting. Other lists similar to this can be found 
in several review articles written about this subject [274, 276-279].  
Recently some aspects of active targeting have been called into question. 
These include the cost effectiveness and translatability of this approach [280], or 
if it should even be called ‘active’ targeting. One very important question is whether 
ligand conjugation can significantly (dramatically) improve the tumor 
accumulation/efficacy of nanoparticles. If it does/does not, why? The answer to 
most of these questions may be rooted in fundamental mechanisms involved in 
cellular uptake and transport of drug and nanoparticles. Hence, we carefully 
analyze these mechanisms and attempt to address important questions in active 
targeting.  
1.4.2.1 Mechanism of active targeting 
Nanoparticles enter the tumor microenvironment by passing through the pores 
of the tumor blood vessels. Once in the vicinity of the cell, nanoparticles are taken 
up by the process of endocytosis. This process is accelerated if the nanoparticles 
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are conjugated to a ligand (henceforth referred to as targeted nanoparticles) that 
binds to cell surface receptors [281]. Binding of the ligand to the tumor cell surface 
receptor triggers endocytosis. This has been supported by mathematical models 
that show that the energy released upon binding of the ligand to the cell surface 
receptor accelerates wrapping of cell membrane around the nanoparticle, leading 
to the formation of the endocytic vesicles [282]. Hence, targeted nanoparticles can 
be taken up at a faster rate as compared to non-targeted nanoparticles [283]. This 
may lead to enhanced intracellular drug concentration.  
Enhanced drug concentration in the tumor tissue can also be achieved because 
of enhanced retention of nanoparticles. According to this theory, targeted 
nanoparticles that are attached to the cell membrane are less likely to be 
eliminated from the tumor [284]. Consequently, they have a greater probability of 
entering the cells. Alternately, the exocytosis of targeted nanoparticles from tumor 
cells is also delayed as compared to that of non-targeted nanoparticles [285].  
However, current pharmacokinetic studies cannot help determine which of 
these mechanisms is operational in vivo.  
1.4.2.2 Active targeting vs. ligand mediated targeting 
There is considerable debate over whether the process should be referred to 
as active targeting or ligand mediated targeting. As stated by Prof. Bae, the term 
‘active targeting’ provides a false impression that the ligand is carrying the 
nanoparticle to the site of the tumor [286]. In fact, the ligand has no role to play in 
the targeting phenomenon until the nanoparticle is within a few nanometers of the 
tumor cell surface [276]. The term might have originated to differentiate this 
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phenomenon from the EPR effect, which is commonly referred to as passive 
targeting. However, even ‘actively targeted’ nanoparticles enter the tumor via the 
EPR effect. Also, similar to non-targeted nanoparticles [287], their cellular uptake 
is an energy-dependent, active process [283]. The only difference may be that their 
cellular uptake is triggered by the binding of the ligand to the cell surface receptor. 
Thus, it is well justified to change the terminology from active targeting to ligand 
mediated targeting.  
1.4.2.3 Impact of ligand conjugation on the biodistribution of nanoparticles 
It is often suggested that conjugation of a tumor targeting ligand may improve 
the selectivity of nanoparticles [177, 288, 289]. In other words, ligand conjugation 
may reduce the off-target accumulation of nanoparticles. In this section, we 
analyze if this is possible.  
Most studies comparing targeted and non-targeted nanoparticles are carried 
out in mouse xenograft models [290-293]. Though this model is imperfect, there is 
lack of clinical data available to understand this phenomenon. Hence, we present 
some calculations with respect to this model. We should also note that the 
calculations described here are based on concentrations and not area under the 
curves (AUCs), and therefore do not provide a complete picture.  
Pharmacokinetic experiments with the murine model are carried out when the 
tumor is ~100-400 mm3 in volume. These tumors weigh ~0.1-0.4 g. The highest 
tumor concentration that is achieved is at best ~5-10% injected dose/g tissue. This 
indicates that ~1-4% of the injected dose is in the tumor at tmax. On the other hand, 
liver concentrations at tmax range from 10-50% injected dose/g tissue, and the liver 
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weighs ~1.5 g. This indicates that ~15-75% of the injected dose is in the liver at 
tmax. As is evident, a very small fraction of the dose accumulates in the tumor. 
Additionally, this small concentration is also transient and is lower before or after 
tmax. Increasing the tumor accumulation of nanoparticles by 2-4-fold through ligand 
mediated targeting (as is commonly observed with these systems [222, 225, 251, 
293]) is unlikely to affect the overall biodistribution of nanoparticles in a favorable 
manner. 
Interestingly, conjugation of the ligand to nanoparticles can, in some cases, 
increase the off-target accumulation of nanoparticles [294, 295]. Typically, a ligand 
is conjugated to the terminal end of the hydrophilic polymer [such as poly(ethylene 
glycol) (PEG)] used to prevent opsonization. Conjugation of the targeting ligand to 
the nanoparticle surface can reduce the fraction of the nanoparticle surface 
occupied by PEG. This can increase the rate of opsonization and clearance of 
nanoparticles by the mononuclear phagocyte system (MPS). This will lead to an 
increased accumulation in the MPS-associated organs such as liver and spleen.  
Regardless of the mechanism, several studies have shown the beneficial effect 
of nano-encapsulation on the tumor accumulation of drugs. Additionally, many 
unique properties of nanomaterials enable them to overcome MDR, and improve 
the potency of the encapsulated drug. In the following sections, we discuss the 
various benefits of nano-encapsulation on treating MDR tumors.  
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1.4.3 Inhibition and evasion of drug efflux 
1.4.3.1 Use of excipients that inhibit efflux transporters 
NPs are multicomponent systems consisting of various excipients including 
polymers, lipids, and/or surfactants. While these materials have traditionally been 
considered inert, several studies have documented their ability to inhibit efflux 
activity.  
1.4.3.1.1 Surfactants 
Surfactants are amphiphilic molecules comprising both hydrophilic and 
hydrophobic groups. At concentrations above critical micellar concentration 
(CMC), surfactants self-assemble to form micelles. In aqueous solutions, the 
hydrophobic core of micelles can be used to solubilize lipophilic anti-cancer agents 
[296]. Surfactants are also used to stabilize the surface of polymeric or lipid NPs 
to form stable amphiphilic colloids in physiological fluids [228, 297, 298]. Thus, 
surfactants are arguably one of the most widely used excipients in nano drug 
delivery systems [299, 300].  
The potential of surfactants to sensitize resistant cells to chemotherapeutics 
was first reported in drug-resistant CHO cells [301]. Since then, many groups have 
investigated the use of surfactants to inhibit efflux transporters [302]. Woodcock et 
al. showed that various surfactants were capable of overcoming drug resistance, 
with Cremophor® EL being the most potent [303]. Pre-treatment or concomitant 
treatment of MDR cells with Cremophor® EL significantly increased the cellular 
uptake and retention of daunorubicin. This effect resulted from enhanced 
membrane fluidity in the presence of the surfactant. Using fluorescence anisotropy, 
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the authors observed a progressive decrease in membrane viscosity with an 
increase in surfactant concentration [304]. However, the use of Cremophor® EL 
has been associated with several toxicities including hypersensitivity and 
peripheral neuropathy [305]. This has significantly limited the use of this excipient 
in clinical practice.  
 Pluronics are another class of surfactants that are extensively used in NP 
formulations [306, 307]. Pluronics are A-B-A type of block co-polymers consisting 
of poly(ethylene oxide) and poly(propylene oxide) blocks. They have been shown 
to inhibit efflux transporters in different MDR-cell types [308]. In fact, multiple 
mechanisms have been attributed to their activity (Figure 1-3) (reviewed in [10]). 
In their seminal mechanistic studies, Batrakova et al. showed that pluronic-85 
brought about a concentration-dependent depletion in intracellular ATP levels 
[309]. This energy depletion led to a decline in the activity of efflux transporters. 
Using confocal microscopy, the same group later showed colocalization of 
fluorescently labeled pluronic-85 with mitotracker red, a fluorescent label for 
mitochondria [310]. This provided additional evidence supporting the role of 
pluronics in interfering with mitochondrial processes and cellular energetics. 
Similar to the studies with Cremophor® EL, pluronic-85 also showed an increase 
in cell membrane fluidization [310]. It is possible that the changes in membrane 
permeability induced by surfactants are relevant not only to the cell membrane but 
also to intracellular organelle membranes. This may cause a loss in polarity of 
mitochondrial membranes and a depletion of cellular ATP.  
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Figure 1-3. Schematic presenting multiple effects of Pluronic block 
copolymers displayed in MDR cell.  
These effects include (a) decrease in membrane viscosity (‘fluidization’); (b) ATP 
depletion; (c, d) inhibition of drug efflux transport systems; (e) reduction in 
GSH/GST detoxification activity; and (f) drug release from acidic vesicles in the 
cell. Effects of Pluronic block copolymers on apoptosis (g) are not sufficiently 
studied at present. Reprinted with permission from [10]. 
 
 
Based on pre-clinical efficacy data, a pluronic formulation of doxorubicin, 
SP1049C, is in clinical trials [311]. SP1049C contains a mixture of two pluronics, 
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L61 and F127. Results from a phase II clinical trial in patients with advanced 
adenocarcinoma of the esophagus and gastroesophageal junction were reported 
recently for this formulation [311]. These studies showed that the objective 
response rate in these patients was 47%. Previous clinical trials with doxorubicin 
have documented an objective response rate of ~20%. The improved response 
rate with SP1049C is highly promising and suggests that this formulation will likely 
have an impact on tumor drug resistance.   
Other surfactants have shown comparable efficacy in preclinical studies 
[302]. For example, polyoxyl 15 hydroxystearate (solutol HS15) has shown potent 
activity in overcoming drug resistance. Coon et al. showed that treatment of drug 
resistant KB8-5-11 carcinoma epidermoid cells with solutol HS15 increased their 
sensitivity to doxorubicin [312]. Similarly, a recent study showed that paclitaxel 
encapsulated in lipid NPs stabilized with polyoxyethylene 20 stearyl ether (Brij® 
78) had enhanced cellular uptake and efficacy. The authors confirmed that this 
action was due to ATP depletion caused by the surfactant [313, 314]. NPs 
stabilized with d-alpha tocopheryl polyethylene glycol 1000 succinate (Vitamin E 
TPGS) also showed a similar effect [315].  
With a multitude of surfactants demonstrating efflux inhibition, some studies 
have attempted to identify structural features of the surfactant that are key to 
achieving maximal activity [316]. One such study focused on various esters of 
ethylene oxide and fatty acids. Two variables were evaluated: the type of fatty acid 
and the molar ratio of ethylene oxide to fatty acid. The unsaturated version of C18 
fatty acid (oleic acid) resulted in better MDR modulation than the saturated C18 
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analog, stearic acid. In contrast to stearic acid, 12-hydroxy stearic acid did not 
show any effect on efflux transport [317]. Maximal efflux inhibition was found at a 
molar ratio of 20:1. This study shows that optimizing the ratio of the hydrophilic 
fraction (ethylene oxide) to hydrophobic fraction (fatty acid) is essential to 
maximizing the activity. In another study, Lo compared various surfactants ranging 
in HLB values from 4 to 40. A maximal inhibition of efflux transport was seen at 
HLB values between 10 and 17 [318]. Surfactants with different HLB values may 
vary in their ability to partition into the cell membrane, and this may explain the 
effect of HLB values on the MDR inhibitory activity of surfactants.  
1.4.3.1.2 Polymers 
Polymers lacking amphiphilic properties have also been shown to be useful 
in overcoming drug resistance. In particular, poly(alkyl cyanoacrylate) has been 
extensively studied for its ability to improve the intracellular transport of 
chemotherapeutics [319-321]. An interesting mechanism, distinct from the ones 
discussed before, was proposed by de Verdière et al. [322]. Doxorubicin, by itself, 
was ineffective against the drug-resistant P388-ADR leukemia cell line. However, 
NP-encapsulated drug showed a significantly higher toxicity. On further 
investigation, the authors found that NPs were not internalized effectively into cells, 
thus ruling out enhanced cellular uptake as a possible mechanism of improved 
efficacy. A degradation product of the polymer, poly(cyano acrylic acid), was found 
to form a complex with the cationic drug. This uncharged complex was transported 
into the cells much more efficiently than the charged drug molecule [322].  
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Another mechanism suggested by this research relates to saturation of 
efflux transport. NPs that rapidly release their entire payload near the cell 
membrane could achieve very high local drug concentration and thus saturate the 
efflux transporter. The authors showed that poly(isobutyl cyanoacrylate) NPs 
(showing rapid drug release) successfully overcame drug resistance through 
saturation of efflux activity. However poly(isohexyl cyanoacrylate) NPs (showing a 
slower drug release) were ineffective in saturating the efflux transporters. The 
proposed saturation mechanism is plausible in vitro where the concentration of the 
drug used was ~0.1-10 µg/mL [322]. However, such high local concentrations may 
not be achievable in vivo, potentially limiting the significance of this mechanism.  
It was later shown that doxorubicin encapsulated in poly(isohexyl 
cyanoacrylate) NPs could successfully overcome tumor drug resistance in vivo 
[323]. In a chemo-resistant transgenic mouse model of hepatocellular 
adenocarcinoma, the authors found that free doxorubicin showed a modest 
cytotoxic effect. However, there was almost a 3-fold increase in the apoptotic index 
when doxorubicin was encapsulated in NPs [323]. This was likely due the 
formation of an uncharged complex between the drug and the degradation product 
of the polymer, leading to higher intracellular drug concentrations.   
Another polymer with reported P-gp inhibitory potential is PEG [324-326]. 
PEG is extensively used in NP formulations to provide a hydrophilic corona, to 
stabilize carriers in physiological fluids, and to evade macrophage uptake [327]. In 
a rat intestinal model, Shen et al. showed that various molecular weights of PEG 
were capable of inhibiting the P-gp-mediated efflux of rhodamine-123 [328]. 
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However, PEG was not very potent in inhibiting P-gp. For example, PEG 20,000 
decreased the secretory transport of rat intestinal membrane by ~65% at a 
concentration of 5% w/w. In contrast, pluronic-85 showed a 50% depletion in ATP 
levels at a concentration as low as 0.00067% w/w [10]. Additionally, it remains to 
be seen if such an inhibition is capable of reversing drug resistance in tumor cells.  
1.4.3.2 Efflux bypass by altering sub-cellular localization of drug 
1.4.3.2.1 Endocytosis Vs. diffusion 
Most drug molecules enter cells by diffusion across the cell membrane 
[329]. This unprotected passage of drug through the cell membrane makes it 
vulnerable to the action of efflux transporters [329]. NPs are too large for diffusion-
mediated transport. NP-encapsulated drug is taken up through endoctytic vesicles, 
which deposit the drug in the perinuclear regions, away from the cell membrane 
and closer to its site of action [287, 330-332]. This can lead to a higher intracellular 
concentration of the drug and greater therapeutic activity (Figure 1-4). 
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Figure 1-4. Different intracellular localization of NPs and free drug.  
Confocal laser microscopic observation of MCF-7/ADR cells incubated with free 
doxorubicin (DOX) or DOX-tethered AuNPs for 24 and 48 h. The dose of 
doxorubicin or its equivalent was 5 μg mL1 in the cell culture. The cells were 
counterstained with DAPI (blue) for the cell nucleus and Alexa Fluor 488 phalloidin 
(green) for the cell membrane. Reprinted with permission from [333]. © 2011 
American Chemical Society. 
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Though altered drug distribution was regarded as one of the mechanisms 
for NP-mediated MDR reversal, there was a lack of convincing evidence 
supporting this hypothesis [332, 334, 335]. Recently, a lipid-polymer NP system 
developed by Wong et al. offered some interesting insights [336]. The authors 
showed that the excipients used in the system did not have any effect on the efflux 
transport process [337]. Only encapsulation of the drug within this “hybrid” carrier 
resulted in a change in the sub-cellular distribution of the drug. This led to a 
reversal of drug resistance in a human cell line MDA435/LCC6/MDR1, and a 
mouse cell line, EMT6/AR1. This reversal was attributed to altered route of entry 
of the drug into the cells [336]. In another study, surfactant-polymer NPs loaded 
with doxorubicin were tested in NCI-ADR/RES cells [338]. The authors found that 
NP-encapsulated doxorubicin was significantly more cytotoxic than the free drug. 
Previous reports had shown that the polymer (alginate) used in these studies had 
no effect on drug efflux [319].While the surfactant used in the formulation 
(docusate sodium) may have P-gp inhibitory activity, the mechanism  of efflux 
inhibition was not investigated. However, the intracellular localization of the drug 
was different when the drug was administered in the form of NPs.  
Additional evidence for the role of altered intracellular distribution was 
provided by extensive work done in the field of polymer-drug conjugates. Polymer-
drug conjugates, similar to NPs, are unable to enter the cell via diffusion. 
Omelyanenko et al. showed that the uptake of N-(2-hydroxypropyl) 
methacrylamide (HPMA) – adriamycin conjugate by endocytosis led to higher 
intracellular concentrations and higher potency in A2780/AD resistant ovarian 
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cancer cell line [329, 339]. Confocal laser scanning microscopy confirmed that the 
increased potency was due to an altered route of entry into the cells for the drug-
polymer conjugate.  
1.4.3.2.2 Triggered intracellular drug release  
An inherent limitation of NP systems is the leakage of drug while the carrier 
is in systemic circulation. As a result, a fraction of the drug is still subject to efflux. 
This decreases the targeted bioavailability and hence the effectiveness of the drug. 
An interesting approach to overcome this limitation is to trigger drug release in 
response to specific intracellular cues. Upon endocytosis, NPs are trafficked into 
early and late endosomes, which eventually fuse with lysosomes. This exposes 
NPs to a gradually decreasing pH environment. Several groups have utilized this 
low pH as a trigger to release drug from NPs [340-343]. These systems ideally 
show no or limited drug release at physiological pH.  
A detailed investigation of such a system was reported by Wang and 
coworkers [333]. This group used gold NPs covalently conjugated to doxorubicin 
using a PEG spacer. Conjugation of doxorubicin to PEG was done via either a pH-
sensitive hydrazone bond or a pH-insensitive carbamate bond. When conjugated 
to the NP surface, the close proximity of gold and doxorubicin quenched the 
fluorescence of the drug. This allowed for evaluation of the intracellular drug 
release. In comparison to that with the free drug, the intracellular concentrations 
achieved with NP-conjugated drug were higher in the drug resistant MCF-ADR 
cells but not in drug sensitive MCF-7 cells. However, drug conjugated via the pH-
sensitive hydrazone bond but not via the carbamate bond was successfully 
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released intracellularly. This resulted in a significant decrease in the IC50 values 
of doxorubicin encapsulated in the pH-sensitive formulation.  In fact, the IC50 
values of free drug and drug bound via the carbamate bond were identical. This 
report highlights two important properties a formulation should possess. First, it 
should be able to protect the drug from efflux pumps. Second, the formulation 
should be able to release the drug in the perinuclear regions, away from the efflux 
pumps and near the site of drug action [333].    
A similar phenomenon has been shown by other groups using iron oxide 
nanoparticles [344], polymer micelles [345], and liposomes [346]. All these reports 
suggest the need to protect the drug from the environment until the drug reaches 
its target site of action. 
1.4.3.2.3 Altering rate of drug release at the site of action 
The rate of drug release has also been shown to play an important role in 
overcoming drug resistance. Gao et al. reported an elegant example of NP-
engineering to improve drug delivery to resistant cancer cells [347]. This group 
synthesized doxorubicin loaded mesoporous silica NPs with varying pore sizes. 
With an increase in pore size, the rate of drug release from these particles 
increased. However, NPs showed drug release only under acidic conditions such 
as those found in late endosomes.  
The authors found that free drug and NP-loaded drug were taken up to the 
same extent by sensitive MCF-7 cells. However, encapsulation in NPs resulted in 
a dramatic increase in the uptake of doxorubicin in resistant cells. On further 
investigation, the authors found that there was a significant difference in the 
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intracellular drug concentrations and cytotoxicity achieved by the different NP-
formulations in resistant cells. NPs that showed rapid drug release resulted in the 
highest intracellular drug concentrations and hence highest potency. Faster 
release, following uptake, led to a rapid increase in intracellular concentrations and 
greater cytotoxicity in vitro [347]. It must be noted, however, that even under acidic 
conditions, NPs released only 30-35% of their cargo over 30 hours. Hence, a major 
portion of the drug would likely remain bound to NPs and be potentially unused.  
1.4.3.3 Simultaneous delivery of drugs and efflux inhibitors 
In addition to the serendipitous use of active excipients, multiple 
pharmacologically active agents have been used intentionally for inhibiting efflux 
transporters. Initial studies were performed with 'first generation' inhibitors such as 
cyclosporine and verapamil, which were already in use for other indications [348]. 
Clinical trials with these agents failed to prove the role of P-gp in drug resistance 
[349]. A number of factors such as absence of confirmation of P-gp expression in 
the tumors and unexpected dose-limiting toxicities of P-gp inhibitors could have 
contributed to this failure [6]. In 2001, List et al. published the long-term results of 
treatment of acute myelogenous leukemia with daunomycin in combination with 
the P-gp inhibitor cyclosporine [350]. These results were the first to indicate the 
survival advantage of the combination treatment. Second generation inhibitors 
(e.g., PSC 833, VX-710) were developed solely for the purpose of overcoming drug 
resistance [351]. These agents were tested in clinical trials in various malignancies 
for which there was evidence of P-gp expression or were associated with a poorer 
therapeutic outcome [352]. One major limitation of these trials, however, was the 
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reduction in anticancer drug doses that was required with concurrent 
administration of the inhibitor [7]. P-gp inhibitors increased the serum levels of the 
co-administered chemotherapeutic drug. Due to this pharmacokinetic interaction, 
the dose of the drug had to be reduced. A number of studies found that this 
reduction in dose led under-treatment of patients, which could have contributed to 
the failure of these combination treatments [7]. Pharmacokinetic interactions 
between the P-gp inhibitor and the drug could also result from inhibitors’ ability to 
inhibit other proteins involved in drug metabolism such as cytochrome P450 [8]. 
Third-generation inhibitors (tariquidar, zosuquidar, laniquidar, and ONT-093) have 
high potency and greater specificity for P-gp.  
A primary concern even with the third generation inhibitors is that these agents 
may increase the side effects of chemotherapy by blocking physiological 
anticancer drug efflux from normal cells [353]. This is a relevant concern, because 
P-gp plays important roles in the physiological regulation of endogenous 
compounds and xenobiotics in the body [354]. It is therefore important to limit the 
exposure of normal cells and tissues to the efflux inhibitor and anticancer drug 
combination. Secondly, the differences in physicochemical properties of the 
anticancer drug and efflux inhibitor may result in differences in the 
pharmacokinetics and tumor accumulation of the two agents. For optimal efficacy, 
both the drug and the inhibitor need to be temporally co-localized in the tumor cells.  
 Nano drug delivery platforms have the potential to overcome MDR by 
enabling simultaneous delivery of chemotherapeutics and efflux inhibitors. For 
example, administration of vincristine and verapamil in a single co-encapsulated 
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poly(lactic-co-glycolic acid) (PLGA) NPs was more effective means of reversing 
drug resistance in vitro, than either single agent in multiple MDR cell lines [355, 
356]. Similarly PLGA NPs loaded with both paclitaxel and tariquidar were effective 
in inducing cytotoxicity in drug resistant cell lines JC and NCI/ADR cells in vitro 
and in vivo (Figure 1-5) [9].  Polymer-lipid nanoparticle systems  containing 
tristearin and steric acid as lipid components, with pluronic F68 polymer, was able 
to efficiently coencapsulate doxorubicin and elacridar and overcome MDR in a 
drug-resistant breast cancer cell line [357]. 
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Figure 1-5. Enhanced cytotoxicity of dual agent nanoparticles in drug-
resistant cell lines.  
(a) JC and (b) NCI-ADR-RES cells were incubated with treatments for 24 h and 
the cell viability was determined by MTS assay. Legend: PX-NP—Nanoparticles 
containing paclitaxel; PXTAR-NP—Nanoparticles containing paclitaxel and 
tariquidar; PX-SOL—Paclitaxel in solution; PX-TAR-SOL—Paclitaxel and 
tariquidar in solution; and TAR-SOL—Tariquidar in solution. Data as mean ± S.D.; 
n = 10. Reprinted with permission from [9]. 
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Another strategy involves the use of NPs containing both a chemotherapeutic 
agent and siRNA targeting the P-gp transcript.  When using P-gp gene silencing 
to overcome drug resistance, the potential for kinetic differences in gene silencing 
and the availability of chemotherapeutic agents at the target site is a concern. 
Differences in size, biodistribution, and other physical characteristics of siRNA-
transfection complexes and small molecule chemotherapeutics could give rise to 
differences in biodistribution. However, for optimum efficacy, the 
chemotherapeutic agent should be available at its target site when the gene is 
silenced. The use of mesoporous silica nanoparticles  loaded with doxorubicin and 
siRNA targeting the P-gp transcript demonstrated synergistic inhibition of tumor 
growth than the single agent-loaded NPs in an orthotopic model of breast cancer 
[358]. In a similar study, poly(ethylene oxide)-modified poly(beta-amino ester) 
(PEO-PbAE) and PEO-modified poly(epsilon-caprolactone) (PEO-PCL) NPs were 
formulated to efficiently encapsulate MDR1 silencing siRNA and paclitaxel. 
Combination of MDR1 gene silencing and nanoparticle-mediated delivery 
significantly improved the cytotoxic activity of paclitaxel in SKOV3TR cells [359]. 
Active targeting of nanoparticles to cancer cells via biotin-functionalized PLGA NPs 
loaded with both P-gp-targeted siRNA and paclitaxel was able to overcome drug 
resistance in vitro as well as in vivo [360]. 
Encapsulation of efflux inhibitors in NPs can potentially limit the distribution 
of these agents and significantly limit their side effects. However, altered 
biodistribution of NP-encapsulated drug can have unintended consequences. As 
observed with Doxil, encapsulation of doxorubicin in liposomes was able to limit its 
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cardiotoxicity. However, new side effects such as hand-foot syndrome and 
mucositis were observed because of certain physicochemical properties of the 
formulation [361]. Hence, it is possible that the side effects of efflux inhibitors may 
not be completely eliminated with the use of nano-encapsulation. However, if these 
newer side effects are milder than the existing ones, nanotechnology may still be 
an attractive alternative. 
1.4.4 Improving transport 
The vast body of evidence supporting the reversal of drug resistance by 
NPs offers a promising strategy to overcome an important problem in cancer 
therapy. In order to maximize this potential, it is critical that NPs (or at least the 
released therapeutic agent) reach every tumor cell. However, NPs are often limited 
to regions immediately adjacent to the blood vessels [91, 93]. Paradoxically, it is 
the regions away from the blood vessels that are rich in drug-resistant and 
aggressive cells [94]. The ability of NPs to overcome MDR will hence be realized 
only if they reach these poorly-perfused regions. Thus, any discussion of the use 
of nanotechnology to overcome drug resistance is incomplete without considering 
the problem of transport resistance in tumors. Several adjunct therapies have been 
proposed to enhance the transport of molecules in the tumor ECM. We provide 
here a summary of the progress made in this field and their possible implications 
for overcoming MDR using nanotechnology.  
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1.4.4.1 Inhibition of angiogenesis to improve drug delivery to tumors  
Jain and co-workers proposed that the delivery of drugs to tumors is limited 
because of a faulty “delivery system” [111]. This “delivery system” referred to the 
blood vessels supplying the tumor. The leakiness of tumor blood vessels 
contributes to elevated IFP in tumors [116]. Consequently, it was hypothesized that 
repairing the tumor vasculature could reverse the elevated IFP. This would, in turn, 
lead to improved drug delivery and penetration. This process of inhibiting tumor 
vasculature and restoration of a normal phenotype has been termed as vascular 
normalization [111]. Such normalization includes various characteristics such as 
increased pericyte coverage, decreased vessel diameter, decreased blood 
volume, establishment of vessel hierarchy and enhanced tissue coverage by the 
blood vessels.  
 However, literature reports have been somewhat equivocal about the utility 
of this technique [362-365]. Some studies show that decreasing vascular 
permeability improves the delivery of drugs to the tumors [366]. Others suggest 
that increasing vascular permeability may improve drug delivery [367, 368]. Some 
of these conflicting results can be attributed to differences in tumor models used, 
and the inherent heterogeneity between tumors. Some reports suggest that lack 
of techniques to monitor and characterize the phenomenon of vascular 
normalization limits our understanding [111]. Nevertheless, a huge body of 
research has established that inhibiting angiogenesis is a highly effective but a 
temporary method to improve drug delivery and penetration into solid tumors [363, 
369, 370]. In the following sections, we will summarize the pre-clinical and clinical 
studies that have investigated different strategies for inhibiting tumor vasculature.  
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1.4.4.1.1 VEGF inhibitors 
Amongst several pro-angiogenic factors, VEGF is one of the most potent 
[109, 371]. It acts through tyrosine kinase receptors VEGFR1 and VEGFR2 [372, 
373]. Initial efforts to inhibit VEGF resulted in the discovery of bevacizumab, a 
humanized monoclonal antibody that binds to VEGF and prevents its activity [374]. 
It is the first anti-angiogenic approved by the FDA for multiple indications including 
colorectal, lung, renal cancers, and glioblastoma [374, 375]. Other VEGF inhibitors 
include pazopanib, sorafenib, sunitinib, and vandetanib. Although inhibitors of the 
VEGF pathway have shown only modest efficacy as a monotherapy [376, 377], 
they hold tremendous promise in improving the delivery of co-administered 
chemotherapeutics [378].  
The initial motive behind using VEGF inhibitors for monotherapy was to 
inhibit angiogenesis and ‘starve’ the tumor [379, 380]. The redundancy of 
angiogenic pathways has limited the clinical utility of this approach [381, 382]. Yet, 
certain transient morphological and functional changes to vasculature in response 
to VEGF inhibition (vascular normalization) leads to decreased IFP and improved 
drug delivery [383].   
Tong et al. showed that DC101 (VEGFR2 blocker) could cause vessel 
normalization in mouse xenograft models of small cell lung cancer and 
glioblastoma [384]. This resulted in a significant decrease in vascular permeability 
and IFP. The decrease in IFP led to improved penetration of macromolecules like 
albumin and lectin in these tumors. Using immunostaining, the authors determined 
that there was no change in the lymphatic drainage from the tumor, suggesting 
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that the decrease in tumor IFP was only due to the changes in the blood vessels 
[384].  
1.4.4.1.2  Other targets for vascular normalization 
Several other molecular targets have been explored for vessel 
normalization [13, 385]. The EGFR is upregulated in multiple cancers [386]. A 
consequence of EGFR activation is the increased secretion of VEGF. Thus, VEGF 
secretion can be decreased by inhibiting EGFR [387, 388]. In a recent report, 
Cerniglia and co-workers [389] showed that inhibiting the EGFR pathway could 
lead to vessel normalization. Treatment with erlotinib (an EGFR inhibitor) led to a 
decreased expression of VEGF, increased tumor perfusion and increased delivery 
of cisplatin. This resulted in enhanced therapeutic activity of cisplatin as compared 
to that with drug administration alone [389]. However, inhibiting the EGF pathway 
has resulted in a mixed response in clinical trials with no, moderate or good results 
[390-394].  
Phosphoinositol-3-kinase (PI3K), like EGF, is another element upstream of 
VEGF. Qayum et al. showed that inhibiting PI3K leads to vessel normalization and 
improved therapeutic response to doxorubicin [395]. Similarly, selenium agents 
have been shown to have anti-angiogenic effects. They elicit their effects by down-
regulating the expression of pro-angiogenic factors like cyclooxygenase-2 and 
nitric oxide synthase [396-398]. Bhattacharya et al. showed that treatment with 
methylselenocysteine led to an increased delivery of doxorubicin to human head 
and neck squamous carcinoma xenografts [399]. This effect was elicited through 
vessel maturation caused by methylselenocysteine [399].  
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The redundancy of angiogenic pathways can result in the development of 
resistance to therapies that rely on specific signaling pathways [373]. Escorcia and 
co-workers demonstrated that targeted radiation can be used to bring about vessel 
normalization [400]. The authors used a monoclonal antibody that identified 
specific epitopes on tumor neovasculature. This antibody was conjugated to 
actinium-225, which emits short range α particles. Pretreating tumors with targeted 
actinium 225 resulted in tumor vasculature normalization. This, in turn, led to an 
enhanced response to a combination treatment consisting of leucovorin and 5-
fluorouracil [400].  
1.4.4.1.3 Concentration and time dependency of vascular normalization 
There has been considerable debate about the mechanism by which anti-
angiogenic drugs improve the delivery of chemotherapeutics. Some reports 
suggest that inhibiting angiogenesis leads to decreased perfusion, while others 
have showed an increase. This has been complemented with data showing either 
decreased or increased drug delivery to the tumor [362].  
The disparities in therapeutic response to anti-angiogenic therapies may be 
due to the concentration and time dependence of this technique. This dependence 
has been termed as the normalization window [111]. At sub-therapeutic 
concentrations of VEGF inhibitors, there may not be any effect on the blood 
vessels or on drug delivery. At very high concentrations, these therapies may 
completely destroy the vasculature. This will diminish drug delivery to the tumor 
[401]. Additionally, vessel normalization is highly transient. If the anti-angiogenic 
therapy is prolonged, the tumor vasculature could become inadequate for drug 
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delivery [402]. Dickson et al. showed that the duration of vessel normalization 
depends on the physicochemical properties of the anti-angiogenic therapy as well 
as the type and location of the tumor [363]. The time dependence of vessel 
normalization also means that additional imaging techniques will be required to 
determine the normalization window for drug delivery. This somewhat limits the 
use anti-angiogenics. However, in a very interesting report, Rolny et al. presented 
a novel strategy to induce vascular normalization [403]. The authors showed that 
histidine-rich glycoprotein (HRG) could inhibit angiogenesis both directly and by 
converting tumor associated macrophages to an M1-like phenotype. The latter 
effect resulted in a longer vascular normalization window [404]. Such strategies 
with sustained responses hold significant promise in improving the delivery of 
chemotherapeutics [404].  
Another source of disparity in measuring the activity of anti-angiogenics 
may stem from the current methods of characterization. Anti-angiogenic drugs can 
alter two parameters associated with chemotherapeutics: drug deposition and drug 
penetration. When one measures drug deposition in the tumor, concentrations are 
assessed as a whole. These concentrations may be localized in particular foci 
within the tumor and may not be representative of the therapeutic activity. Drug 
deposition may be a function of blood supply and may decrease with declining 
perfusion. However, the presentation of drug to resistant and hypoxic cells 
(function of drug penetration) is governed by intratumoral transport, which 
increases in response to a decrease in IFP [405]. Therapeutic response to the drug 
is a combined effect of both drug deposition and drug penetration. Thus, in order 
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to comprehensively quantify the activity of anti-angiogenics, it is important to 
monitor both these parameters [405].  
1.4.4.1.4 Suitability of anti-angiogenic therapy to improve NP transport 
The use of anti-angiogenic drugs has been shown to have both positive and 
negative effects on the tumor delivery of nanomedicine. In a recent study, Vlahovic 
et al. found that pre-treatment with imatinib (a PDGFR-β inhibitor) led to enhanced 
accumulation of Doxil® in a mouse model of non-small cell lung cancer [406]. The 
same group later showed that treatment with pazopanib (inhibitor of VEGF and 
PDGF receptors) led to a decrease in the penetration of Doxil® in the same tumor 
model [407].  
A recent study by Chauhan et al. offers some directions for the use of anti-
angiogenics with nanotherapeutics [1]. The authors used DC101 as the VEGF 
blocker in combination with quantum dots of various sizes. In an orthotopic mouse 
mammary tumor model, the authors found that DC101 enhanced the penetration 
of NPs in a size-dependent manner. The advantage associated with the use of 
anti-angiogenic therapy was maximal for particles < 60 nm in size (Figure 1-6). 
The authors also found that there was a significant benefit of using DC101 in 
combination with Abraxane® (~10 nm diameter) but not with Doxil® (~100 nm 
diameter). The size dependence of this advantage is yet to be measured in 
different tumor models [1]. If the degree of normalization is variable amongst 
tumors, it is likely that this size dependence will also show a similar trend.  
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Figure 1-6. Effects of vascular normalization on nanoparticle delivery in 
tumors. 
Nanoparticle penetration versus particle size in orthotopic 4T1 mammary tumors 
in response to normalizing therapy with DC101. Nanoparticle concentrations 
(denoted by pseudocolor) are relative to initial intravascular levels, with vessels 
shown in black. Normalization improves 12 nm particle penetration while not 
affecting 125 nm penetration. Scale bar, 100 mm. Reprinted with permission from 
[1]. 
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1.4.4.2 Modifying tumor matrix to improve drug penetration 
Tumor vessel normalization is an attractive strategy for enhancing the 
penetration of small molecules and macromolecules. Nonetheless, vascular 
normalization results in a reduction in the vascular pore size. To effectively utilize 
this technique for improving the delivery and penetration of NPs, the particle size 
of NPs has to be in the ~20 nm size range [408]. However, drug loading is severely 
compromised in such small particles, making these formulations impractical for in 
vivo use.  Thus, alternative strategies to decrease IFP and to enhance intratumoral 
penetration of colloidal carriers are necessary. Altering the composition of the 
tumor ECM provides another route to improve the tumor tissue distribution of NPs. 
The tumor ECM can be modified by either using enzymes that degrade specific 
ECM components or by modifying the tumor-associated cells that directly affect 
the behavior of ECM components.  
1.4.4.2.1 Tissue digesting enzymes 
 
The tumor matrix is rich in collagen and hyaluronic acid [409], making them 
obvious targets for enhancing drug delivery. The effect of hyaluronic acid-digesting 
enzyme, hyaluronidase, was first reported by Maier et al. in patients with bladder 
cancer [410]. In their seminal studies, the authors found that co-administration of 
hyaluronidase with mitomycin-C significantly reduced the recurrence of bladder 
cancer in comparison to patients who received only the chemotherapeutic. Other 
groups later showed that the efficacy of chemotherapeutics could be enhanced by 
using hyaluronidase in multi-cellular spheroid models in vitro and in pre-clinical 
tumor models [411-414]. Brekken et al. were the first to show that intratumoral 
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injection of hyaluronidase decreased IFP in orthotopic osteosarcomas in mice 
without affecting the arterial pressure [415]. The resultant increase in transvascular 
gradient may have led to the observed enhancement in drug delivery. The same 
group later confirmed that periodic fluctuations in IFP brought about by 
hyaluronidase administration increased the delivery of antibodies [416]. 
Subsequently, the effect of hyaluronidase administration on the uptake and 
distribution of CaelyxTM (pegylated liposomal doxorubicin hydrochloride) was 
measured [417]. Intratumoral administration of hyaluronidase led to an increase in 
tumor deposition of the formulation. More importantly, the distribution profile of the 
delivery system was altered. In the absence of the enzyme, liposomes were 
regionalized to the rim of the tumor. However co-administration of the enzyme led 
to increased penetration of the liposomes to the core of the tumor (Figure 1-7). 
Recently, Provenzano et al. reported a novel mechanism that may operate in 
improving drug delivery in response to hyaluronidase administration [418]. The 
authors found that K-ras driven pancreatic tumors in genetically modified mice 
were nearly avascular. Systemic administration of pegylated hyaluronidase led to 
the opening up of previously dysfunctional blood vessels. This led to enhanced 
delivery and efficacy of co-administered gemcitabine. This is the first study to show 
that enzymatic ablation of tumor ECM can restore blood supply, leading to 
increased drug delivery [418].  
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Figure 1-7. Distribution of liposomal doxorubicin in hyaluronidase treated 
osteosarcomas.  
Distribution of liposomal doxorubicin in osteosarcoma xenografts treated with 
liposomal doxorubicin alone (16 mg kg-1) (A) or liposomal doxorubicin combined 
with hyaluronidase (1500 U) (B). Representative images of doxorubicin (green) 
relative to capillaries (red) are presented from the rim to the center of the tumor 
sections. Reprinted with permission from [417]. 
 
 
The other ECM target for improving tumor penetration of chemotherapeutics is 
collagen. In an orthotopic osteosarcoma mouse model, Eikenes et al. showed that 
systemic administration of collagenase led to a rapid decline in tumor IFP, with 
only minor effects on the arterial blood pressure [419]. The resulting transcapillary 
gradient was maintained for nearly 24 hours. This led to enhanced delivery and 
penetration of a fluorescently-labeled antibody [419]. McKee et al. examined local 
injection of collagenase to improve the intratumoral distribution of an oncolytic virus 
[420]. Transfection of tumor cells with the virus was detected by expression of 
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green fluorescent protein (GFP). Without collagenase co-administration, the virus 
was localized in regions that lacked collagen. Consequently, GFP expression was 
found only in limited regions within the tumor. Co-injection of collagenase 
significantly improved the distribution of the virus. This was confirmed by extensive 
GFP expression over the entire tumor. It is interesting to note that the virus had a 
hydrodynamic diameter of 150 nm, a size comparable to that of many NP 
formulations reported in the literature. Zheng and co-workers reported similar 
results [421]. The authors found that intratumoral administration of collagenase led 
to improved distribution of Doxil® in head and neck tumor xenografts. Interestingly, 
collagenase activity was observed only following local injections [421].  
The above study by Zheng et al. highlights some key issues [421]. First, the 
toxicity associated with the use of these tissue-degrading enzymes is an important 
issue. Both collagen and hyaluronic acid are ubiquitously expressed in the body 
[418]. They form important components of the ECM and are essential for the 
function of vital organs. Intratumoral administration of these enzymes may prevent 
systemic toxicity. However, many tumors that require chemotherapeutic 
intervention may not be accessible by such local treatment. Second, the 
improvements in drug transport achieved with ECM degradation are transient. 
Collagen and hyaluronic acid are replenished within 8-24 hours [419, 422]. Since 
NP accumulation in the tumor is a relatively rapid event (few hours), transient 
decrease in ECM levels will help improve NP delivery to tumors [215]. However, 
NP penetration within a tumor is a relatively slower event [423, 424]. Thus, the 
transient nature of this technique may not improve the tissue transport of NPs. One 
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possible strategy to overcome this problem is to immobilize the enzyme on the 
surface of NPs. This will ensure colocalization of NPs and the enzyme. Moreover, 
the passive targeting effect of NPs may limit the distribution and toxicity of the 
enzyme. An example of this approach was provided by Goodman et al.[425]. In 
that study, collagenase was physically adsorbed on the surface of polystyrene 
NPs. The adsorbed enzyme degraded collagen and improved the penetration of 
NPs in an in vitro multicellular spheroid model [425]. The study, however, did not 
examine the performance of this system in vivo. Rapid desorption of a physically 
adsorbed enzyme in the presence of plasma proteins may be a significant 
limitation of this approach. Covalent conjugation of the enzyme to the NP surface 
may overcome this limitation [426]. 
The choice of ECM component to be targeted for improving drug penetration is 
interesting. Collagenase administration has been unequivocally shown to increase 
drug penetration. However, there are conflicting reports regarding the utility of 
hyaluronidase for improving drug penetration [427]. In an interesting report, Netti 
et al. proposed that proteoglycans such as hyaluronic acid resemble “aqueous 
cages” [428]. These aqueous cages are passages through which the drug carrier 
can diffuse freely. Thus, eliminating these cages by degrading hyaluronic acid 
could hinder the transport of drug carriers. On the other hand, the solid collagen 
matrix may not offer a conducive environment for transport, and degrading 
collagen could, therefore, improve carrier distribution. The authors suggest that the 
amount of any ECM component does not dictate the magnitude of the effect it has 
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on transport resistance. The structural assembly and organization of the 
component could play a more important role [428].  
1.4.4.2.2 Modifying stromal cells  
 
In addition to degrading the tumor stroma, an interesting alternative is to inhibit 
the secretion of ECM components by the stromal cells. An elegant example of this 
hypothesis was shown by Olive et al. [429]. Using a genetically engineered mouse 
model, the authors determined that pancreatic cancers had very little vascular 
coverage and that drug delivery to these tumors was severely impeded. The 
hedgehog signaling pathway was constitutively active in tumor-associated stromal 
cells. This led to the secretion of large amounts of ECM components. The authors 
showed that concomitant administration of a hedgehog pathway inhibitor (IPI 926) 
greatly increased the delivery and therapeutic efficacy of gemcitabine. A very 
recent report showed the safety of the IPI 926 in phase I clinical trials [430].  
In another study, treatment with losartan was shown to decrease collagen I 
synthesis by fibroblasts in carcinomas [431]. Those effects were brought about 
through inhibition of the activity of transforming growth factor β (TGF β). The 
decrease in collagen content was sustained for a period of two weeks in a dose-
dependent manner. Decreased collagen content was associated with an increase 
in the tumor penetration of liposomal doxorubicin and an increased therapeutic 
response [431].  
1.5 Conclusions 
Development of resistance to multiple drugs is a key obstacle to achieving 
successful treatment outcomes in many cancers. Tumor cells overexpress efflux 
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transporters, which reduce intracellular drug accumulation and efficacy. NPs offer 
an attractive platform to overcome drug resistance. Many of the excipients used in 
fabricating NPs possess intrinsic efflux pump inhibitory activity. Intracellular 
distribution of NPs to specific loci in the cell, away from the activity of efflux pumps 
can also shield the encapsulated drug from transporters. An additional approach 
is to co-deliver specific inhibitors of transporter activity or function with the 
chemotherapeutic. However, poor intratumoral penetration of NPs limits their 
potential. Approaches that improve NP transport in tumors can significantly 
enhance their activity. Normalizing tumor vasculature has shown promising results 
with small molecules. Some NP formulations can also benefit from this approach. 
The field of ECM modification is relatively under-studied and holds tremendous 
potential for improving the therapeutic outcomes in hard-to-treat, avascular 
tumors. 
1.6 Statement of the problem and hypothesis 
Delivering chemotherapeutic agents in nano-sized carriers can potentially 
reduce the off-target distribution and increase the tumor accumulation of the drugs. 
However, the full potential of nanoparticle-based chemotherapy has not been 
realized yet. Several physiological barriers prevent the optimal performance of 
nanoparticles. In this thesis, we studied these barriers from the perspective of drug 
transport.  
Transport of nanoparticles from the site of administration to the site of action 
can be considered to occur in three distinct steps: systemic distribution, 
intratumoral distribution and cell uptake. Inefficiencies in each step lead to 
68 
 
decreased accumulation of nanoparticles within tumor cells and compromised 
therapeutic efficacy. The goal of this research was to improve nanoparticle-based 
chemotherapy by enhancing the efficiency of each of these steps.  
The specific aims for the thesis and their respective working hypotheses are as 
follows:  
Specific aim 1: Examine the effect of vascular properties of tumors and 
physicochemical properties of nanoparticles on the drug targeting index of 
nanoparticles 
We hypothesized that optimal drug targeting is achieved in a limited particle 
size range, and this particle size range depends on the vascular pore size of the 
tumor as well as of the site of toxicity. (Chapter 2) 
 
Specific aim 2: Determine the effect of fibrinolytic therapy on anti-cancer 
efficacy of nanoparticles 
We hypothesized that treatment with a fibrinolytic enzyme will improve the 
intratumoral distribution and anti-cancer efficacy of nanoparticles. (Chapter 3) 
 
Specific aim 3: Evaluate the performance of tylocrebrine encapsulated in 
EGFR-targeted nanoparticles 
The central hypothesis in this chapter was that encapsulation of tylocrebrine in 
EGFR-targeted nanoparticles will improve the drug targeting index by 
simultaneously enhancing the tumor cell uptake (and potency) and reducing the 
brain penetration of tylocrebrine. (Chapter 4)  
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Chapter 2 A Pharmacokinetic Model for Quantifying the 
Effect of Vascular Permeability on the Choice of Drug 
Carrier: A Framework for Personalized Nanomedicine2 
  
                                                           
2 This chapter is published elsewhere [527]. Reproduced with permission. 
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2.1 Summary 
Drug carriers in the ~100 nm size range are of considerable interest in the field of 
cancer therapy because of their ability to passively accumulate in tumors. Tailoring 
the physicochemical properties of these carriers to individual patient requirements 
will help exploit their full therapeutic potential. Here we present a pharmacokinetic 
model to explain how vascular physiology could be used to guide the optimal 
choice of specific formulation parameters. We find that in order to maximize the 
benefit-to-risk ratio, nano systems should be confined to a specific particle size 
range. The optimal particle size range is dictated by the vascular pore size of not 
only the tumor tissue but also of the normal organs. Additionally, the duration of 
drug release is a key variable that can be used to maximize the therapeutic benefit 
of nanomedicine. Our model further suggests that the enhanced permeability and 
retention (EPR) effect is not necessarily a universal outcome for every nano carrier 
in every tumor model but will only be observed for nanoparticles of a specific size 
range. This optimal size range, in turn, is governed by the vascular physiology of 
the tumor and of non-target organs.  
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2.2 Introduction 
Cytotoxic anticancer therapies are often characterized by severe dose-limiting 
toxicities, resulting from their poor discrimination between tumor and normal 
tissues. These side effects can be significantly reduced by delivering these drugs 
in nano sized carriers [432]. Nanoparticles (NPs) primarily extravasate from porous 
blood vessels found in tumors, thereby reducing drug exposure to non-target 
tissues. Additionally, because of underdeveloped lymphatic drainage, NPs are not 
cleared quickly from the tumor. This phenomenon, known as the enhanced 
permeability and retention (EPR) effect [174], has become the principal basis for 
the use of nano drug delivery systems for anticancer therapies [433]. 
Recent studies suggest that, in addition to patient-specific tailoring of 
anticancer drugs and drug doses [434, 435], there is a need to develop 
personalized drug carriers [436, 437]. In much the same way that tumor cell 
signatures can dictate the choice of drug, characteristics of the tumor blood 
vessels can affect the choice of drug carrier. Multimodal imaging techniques 
enable noninvasive characterization of tumor and normal organ blood vessels 
[401, 438, 439]. Moreover, the availability of facile synthetic approaches allows 
tailoring of physicochemical properties of drug carriers for specific needs [440, 
441]. However, there are currently no models available for guiding the selection of 
an optimal drug carrier based on particular tumor characteristics. The selection 
criterion for nano drug carriers is unique because it is expected that these systems 
not only enhance drug efficacy but also mitigate toxicity [442, 443]. Earlier efforts 
in this area have focused mainly on the deposition of NPs in the tumor and have 
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not considered their distribution in normal tissues where toxic effects may occur. 
Some normal organs including liver and spleen also have porous blood vessels 
(sinusoidal capillaries) that are permeable to NPs. Also, much of the previous 
modeling work has dealt with tracking only the NPs and not the free drug, whose 
release commences as soon as the NPs are introduced in systemic circulation 
[444-446].  
We report here a semi-physiologically based pharmacokinetic model to 
describe the disposition of NPs as well as the released drug in tumors and in 
normal organs that also have porous blood vessels (Figure 2-1) [447-449]. We 
use a metric called the drug targeting index (DTI) to measure the performance of 
nano delivery systems [450]. The DTI considers both efficacy and toxicity, and 
enables a comparison of the pharmacokinetic performance of NPs with that of the 
free drug and of two different delivery systems. We find that two critical 
physicochemical properties of the drug carrier, viz. particle size and drug release 
rate, play an important role in determining the DTI of nano delivery systems. 
However, the optimal particle size and drug release rate are dictated by vascular 
characteristics of the tumor and normal organs. Thus, our work describes 
quantitatively how individual vascular physiology can impact the choice of the drug 
carrier. It is expected that the results of our modeling studies will provide a 
framework for the future development of personalized nano therapeutics.  
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2.3 Methods 
2.3.1 Drug targeting index 
A nanoformulation can enhance the usefulness of a drug in two ways.  First, it 
can increase the exposure of free drug to sites of action in target tissues following 
Figure 2-1. Construction of pharmacokinetic model 
The model consists of 6 compartments, 3 compartments representing the 
nanoparticle-encapsulated drug and 3 compartments representing the free drug. 
The dose is administered in the central compartment and is shown by the red 
dotted arrow. The tumor is considered to be the target compartment and a normal 
organ is considered to be the toxicity compartment. 
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release from the NPs, compared to the exposure that occurs when drug is 
administered in its free form.  Second, the nanoformulation can reduce drug 
exposure to tissues associated with toxicity.  A simple metric that combines these 
benefits is the drug targeting index, DTI, defined as[450] 
 =  
 
  
                                                                                                                  (1) 
 
Where the subscripts free and nano refer to drug that is administered in its free 
form, and drug that is administered encapsulated in NPs, respectively 
 
 = " 	#$                                         % = 	&', 	)*;                                                           (2) 
 
with  referring to the concentration of free drug in the target (tar) or toxicity 
associated (tox) tissues. NP associated drug is assumed to be non-active. The 
numerator in Eq. (1) corresponds to the drug administered as a NP formulation, 
while the denominator corresponds to drug administered in its free form.  It is 
assumed without loss of generality that in either case, drug is administered as a 
bolus at time zero, and before that the body is void of drug.  Provided 
pharmacokinetics are linear, the doses used under the two circumstances cancel 
out when ratios are taken and hence do not affect DTI. 
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2.3.2 Pharmacokinetic model 
Only spherical monodisperse NPs are considered in the present work. We also 
assume that the shape, size and surface properties of the carrier remain constant 
while it is in circulation. Hence, the pharmacokinetic properties of the NPs are time 
independent. NPs are also assumed to release drug at the same first order rate 
within all compartments. Finally, we assume that exchange of free drug across 
porous capillaries is rapid and is rate-limited by perfusion to that compartment. 
A six compartment pharmacokinetic model, illustrated in Figure 2-1, has been 
chosen to account for the pharmacokinetic behavior of NPs and free drug. The 
central compartment represents NPs or drug in the vasculature (plasma), while the 
peripheral compartments represent parenchyma in organs involved in drug 
response and toxicity. All compartments are assumed to be well stirred.  While a 
more general multicompartmental model could be formulated, the results are 
insensitive to such detail.  It is important however that the target and toxicity 
associated tissues be separate.   
The concentration-time profiles of NPs in the central, target and toxicity 
compartments are generated using the mass balance equations listed below. NPs 
and drug are assumed to exchange between compartments with linear kinetics 
(constant clearance values), and with defined volume parameters for all 
compartments.  Elimination of NPs and drug is assumed to be first order and from 
the central compartment.  Free drug is assumed to be released by first order 
kinetics into the compartment in which its NP resides at the time. 
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The clearance and volume parameters for free drug are taken as given, since 
they would be assessed in independent pharmacokinetic studies.  Since fluid flow 
into and out of organ parenchyma is generally the same, we may take the 
deposition and exit clearances of free drug to be equal.  However, NPs tend to be 
blocked from flow through tissue parenchyma by the interstitial matrix, hence their 
deposition and exit clearances will differ. 
Parameter definitions are listed in Table 2-1. In the following equations, the 
subscript “i” designates the compartment (i=c, tar, tox and c, tar and tox indicate 
the central, target and toxicity compartments, respectively). The superscripts “nc” 
and “f” signify NP-encapsulated drug and free drug, respectively. For 
nanoencapsulated drug, the mass balances are 
 
--	 =  
∑ ,-  -/,-- −  
∑ ,-  --/,  -- −  (0 + 0- )--                 (3) 
 
-	 =  
,--  -- −  
,-- +  0 -;             % = 	&', 	)*;                                      (4) 
The mass balances for free drug are given by 
-	 =  ∑ 
/,- −  
 ∑  -/,- +  
0---  -
- − - -
               (5) 
 
	 =   

  5-
 −  6 + 7 0
-
 8 
-;                % = 	&', 	)*;                                     (6) 
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Because DTI is dose independent, the initial condition may be taken as --(0) =
1 when drug is administered in NPs, or -(0) = 1 when drug is administered in its 
free form.  All other compartments start with zero concentration. 
 
2.3.3 Exchange between the central compartment and target and the 
toxicity compartments 
The deposition and exit clearances of NPs into and out of well stirred 
compartments depend on blood flow, Qi, and the corresponding intrinsic clearance 
values, according to[451]  
 
,- =  ;,;+ ,                                          % = 	&', 	)*                                                     (7) 
 
,- =  ;,; + ,                                            % = 	&', 	)*                                                      (8) 
 
Both blood flow and intrinsic clearance correspond to capillary beds perfusing 
the relevant tissues.  Intrinsic clearances are determined using Starling’s 
approximation, as described by Chauhan et al. [1]  In that model, exchange of NPs 
between compartments occurs by convection and diffusion across porous capillary 
walls separating blood from parenchyma, with pores considered to be of constant 
radius, Ri, and length, Li. The capillary surface area and porosity (#pores/area) are 
designated by Si and γi respectively.   
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The effect of NP size on diffusion and convection in the pores depends on the 
NP’s size and the pore radius [452]. For spherical NPs of uniform radius, a, the 
relevant parameter is 
 
> = min B &C  , 1D                         % = 	&', 	)*                                                                             (9) 
 
which is bounded above by unity.  Transport is not possible for NPs with larger 
diameter than the pores.  In the following, we drop the subscript i  = tar, tox for 
notational clarity, realizing that in calculations, parameter values are compartment 
specific and the subscripts must be restored.  A nonzero value of λ indicates that 
transport of a NP across a pore will be hindered partially by frictional interactions 
between the particle and the pore wall.  The hindrance factors H(λ) and W(λ) 
corresponding, respectively, to diffusion and convection are determined according 
to the recently published correlations [452] 
 
F = 1 +  98  λ. ln λ − 1.56034λ + 0.528155 λI + 1.91521λJ − 2.81903λK
+  0.270788λL + 1.10115λM −  0.435933λN                                           (10) 
 
O = (1 − λ)I 1 + 3.867 λ − 1.907λI − 0.834λJ1 + 1.867λ − 0.741λI                                                          (11) 
 
The hindrance factor H is used in the following equation for diffusive permeability 
of the capillary wall: 
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P =  γFQ                                                                                                                                        (12) 
 
where  
 
 =  0R6πS&                                                                                                                                      (13) 
 
is the unhindered Stokes-Einstein diffusion coefficient of the NPs,  In calculating 
D, kB is the Boltzmann constant, T is absolute body temperature and μ is the 
viscosity of vascular fluid in the pores.  Convective transport across the capillary 
in response to transwall pressure gradient is accounted for by taking the product 
of the hydraulic permeability of the vessel wall, 
 
Q =  γCI8SQ                                                                                                                                      (14) 
 
and the reflection coefficient, σ = 1 − O, which quantifies the selectivity of the 
pores against NP convection. 
The relative importance of convection compared to diffusion of NPs across 
capillary walls for a given pressure gradient, T- − T, between the capillary 
lumen and the interstitial fluid, is determined by the Peclet number, 
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TU = Q(1 − V)(T- − T)P                                                                                                      (15) 
 
Combining diffusive and convective transport of NPs, and considering the total 
surface area, S, of capillaries perfusing a compartment (tissues/organs), exchange 
clearance parameters between capillaries and interstitium of a compartment are 
given by  
 
 = Q(1 − V)W(T- − T)1 − UXY = TUPW1 − UXY                                                                       (16) 
 
 = Q(1 − V)W(T- − T)UY − 1  =   TUPWUY − 1                                                                       (17) 
 
Evidently from Eqs. (7) - (17), compartmental clearances depend on 
physiological variables such as blood flow, vascular pore size, pore surface area, 
and pressure differences across the blood vessel wall, and on the size of the NPs. 
Calculated values of clearance are used as input functions in the rate equations of 
the pharmacokinetic model.   
Notice that  = UY, which suggests that when pressure in the 
capillaries exceeds that in the tissue parenchyma such that Pe >> 0, convection 
dominates diffusion across the pore walls and deposition is strongly favored over 
exit, and the “ex” terms in Eqs. (3) and (4) can be dropped. 
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2.3.4 Further Assumptions 
In the simulations carried out below, NPs were assumed to be administered to 
the central compartment, which was also assumed to contain the sites for free drug 
elimination. We  fit values reported in literature for PEG (5000 Da)-functionalized, 
silica-coated CdSe quantum dots of various sizes [1] to a polynomial (Figure 2-2), 
which was used in the simulations. While elimination of NPs from circulation can 
generally be through renal filtration or macrophage uptake, the diameter of NPs 
studied here was above the renal filtration cutoff of 5.5 nm [453]. Hence, in this 
model, we assumed that elimination of NPs is only by uptake into macrophages.  
 
Figure 2-2.Half-life of nanoparticles in the central compartment as a function 
of particle size  
The data points were extracted from previously reported values [1]. A curve was 
fitted to this data and the equation describing the curve is included in the list of 
equations. * indicates data points were extrapolated.  
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NPs that are phagocytosed by macrophages deposit in the liver [361].  
However, a quantitative estimation of the NP deposition through this process is 
difficult. Therefore, we assumed that NPs that are taken up by the macrophages 
are eliminated from the body and do not deposit in the toxicity compartment. 
Deposition of NPs in the toxicity compartment was assumed to occur only through 
the capillary fenestrae.  
2.3.5 Calculation of a closed loop solution of drug targeting index 
In order to develop a quantitative relation between NP properties, physiological 
parameters and DTI, we solve the pharmacokinetic model and develop an 
expression for DTI involving only rate constants.  We limit ourselves here to the 
case where deposition of NPs dominates exit of NPs, i.e. Pe >> 0 in both the target 
and toxicity compartments.  Eqs. (3)-(6), with terms corresponding to NP exit from 
the  target and toxicity compartments dropped, can be rewritten in terms of rate 
constants using the generic identification 0 = Q/. The result is 
--	 = − [ 0,-  --/, − (0 + 0
- )--                                                          (18) 
      
-	 =  0,-  --  − 0- ;           % = 	&', 	)*                                                             (19) 
-	 = [ 05 − -6/,  +  
---  0-
- − 0 -                                          (20) 
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	 =  0  5- −  6 + 7 
-
 8 0
-;                % = 	&', 	)*                                   (21)  
   
 
Integration of these equations, with proper initial conditions, will lead to a set 
of simultaneous equations for relevant AUCs, which can then be introduced into 
Eq. (1), with a resulting expression for DTI in terms of the system parameters.  This 
route is tedious and not necessarily revealing.  A more straightforward and intuitive 
procedure is to consider the average number (expected value) of visits that a drug 
molecule makes to the target and toxicity  compartments when drug is 
administered free or in a nanocarrier.  This average is proportional to the AUC of 
free drug in that compartment.  Hence, we may replace Eq. (1) with 
 =  \
< #_%`%	` >< #_%`%	` >b
\< #_%`%	` >< #_%`%	` >b  
= (< #_%`%	` >)/(< #_%`%	` >)       (< #_%`%	` >)/(< #_%`%	` >)       (22) 
     
To begin, we calculate the average numbers (expected values) of visits to the 
target and toxicity compartments for drug administered that is administered in its 
free form.   We consider first the target compartment.  Each visit to that 
compartment will be preceded by a visit to the central compartment.  The 
probability that such a visit will occur without drug being eliminated first is 
c = 0, /50, + 0 6, and the probability that there will be exactly n such 
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visits before elimination is c(1 − c).  Thus the expected number of visits is given 
by 
(< #_%`%	` >) = (1 − c) [ dc
e
/f
= c1 − c =
0,0                                        (23) 
   
and by similar reasoning, 
 
(< #_%`%	` >) = 0,

0                                                                                            (24) 
         
Now let Ftar, Ftox and Fc  denote the fractions of drug that are released from the 
NPs into the target, toxicity and central compartments, respectively.  Since drug is 
not removed from the toxicity compartment, drug molecules released from NPs 
into the central and toxicity compartments will look, to the target compartment, like 
drug administered in its free form, and these molecules will, on average, visit the 
target compartment (< #_%`%	` >)  times.  Drug released from NPs into the 
target compartment will visit that compartment once before returning to the central 
compartment, and thereafter it will return to the target compartment, on average, 
(< #_%`%	` >) times.   We therefore assert that 
(< #_%`%	` >)
= gh1 + (< #_%`%	` >)i + (g + g-)(< #_%`%	` >) 
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and by similar steps, 
(< #_%`%	` >)
= gh1 + (< #_%`%	` >)i + (g + g-)(< #_%`%	` >) 
Introducing these expressions into Eq. (A.5) and rearranging, 
DTI = 1 + \
gg + g + g-b 1(< #_%`%	` >)
1 + \ gg + g + g-b (< #_%`%	` >)
                                                      (25)  
       
We now derive expressions for Ftar, Ftox, and Fc.   Here the assumption that 
NPs, once having entered the target (or toxicity) compartment remain there without 
back transfer to the central compartment (Pe >> 0), simplifies matters.  Following 
injection at time 0, the fraction of NPs remaining in the central compartment at time 
t will be exp (−0- 	), where 0- = 0,- + 0,- + 0- .  The fraction of drug 
remaining in these NPs at that time will be exp (−0	).  Since 
p 0- exp (−0- 	)	e$ = 1 accounts for the final disposition of of all the NPs, the 
fraction of NPs transferred to the target compartment will be 
p 0,- exp (−0- 	)	e$ = 0,- /0- , and the fraction of drug released into the 
target compartment will be 
g = " 0,- eXqrsrtu  eXqvwx	e$ =
0,-0- + 0                                                             (26) 
Similarly, 
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g = 0,-0- + 0                                                                                                                    (27) 
         
At any time, the fraction of drug still remaining in the NPs in the central 
compartment that will be released will be 
g- = 00- + 0                                                                                                                        (28) 
            
Combining Eqs. (25)-(28) and rearranging, we obtain Eq. (29).  This relatively 
simple result relies in the assumed unidirectional transfer or NPs to the target and 
toxicity compartments from the central compartment, and the assumption that free 
drug is eliminated only from the central compartment. 
 =
1 + 0 7 0,
- /0,0,- + 0,- + 08
1 + 0 7 0,
- /0,0,- + 0,- + 08
                                                                     (29) 
Where 0, = Q, /-- and 0, = Q, /-- are rate constants 
associated with deposition on NPs into the target and toxicity compartments, 
respectively.   
2.4 Results and discussion 
2.4.1 Definition of DTI 
The DTI, which quantifies the overall benefit of using a nanoformulation over 
free drug, is a ratio of ratios, which can be interpreted as a multiplier for the 
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therapeutic index of the drug due to nanoencapsulation [450]. A large DTI can 
result from improved targeting to the target compartment (here the tumor), reduced 
exposure of the toxicity compartment (here the “normal” organs), or both.  For the 
model depicted in Figure 2-1, with all transfers assumed to be first order, and 
neglecting back transfers of NPs from the tumor and normal organs to blood, a 
closed form solution for DTI is obtained (shown in Eq. 29).      
According to Eq. 29, DTI increases when NPs are more rapidly transferred to 
the tumor than to normal organs (increasing 0,- /0,- ), when free drug 
enters the normal tissues more rapidly than into tumor (increasing 0, /
0, ), with increasing elimination rate of free drug (0 ), and with decreasing 
rate of drug release from the NPs (0).  
2.4.2 Effect of vascular pore size and pore fraction of the target 
compartment 
The EPR effect exists because of the porous nature of tumor vasculature. 
Porosity is highly heterogeneous and depends on the type, size and location of the 
tumor [454]. Inter- and intra-patient differences can have a significant impact on 
the tumor accumulation of NPs. To examine these effects, four different tumor 
vascular pore sizes (100, 200, 300 and 600 nm) were studied (the tumor vascular 
pore size in humans has not been studied rigorously; however, extensive work with 
mouse xenograft models of human tumors have shown that the tumor vascular 
pore size can vary from 100 nm-1 μm) [186, 454].  The pore size of the toxicity 
compartment (75 nm), rate constant for drug release from NPs (8x10-5 s-1), and 
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fraction of the tumor vasculature occupied by the pores (5%) were held constant. 
We used Starling’s approximation to model the effect of the size of pores and pore 
fraction on the NPs’ pharmacokinetics [1]. Although the interstitial fluid pressure 
can be affected by the difference in the blood vessel porosities [116], in our 
calculations we assumed that interstitial fluid pressures are independent of pore 
size. Detailed transport models for NPs can be refined within the framework of the 
general pharmacokinetic model of Figure 2-1.  
We first determined the deposition clearance of NPs into the tumor as a 
function of particle size at various tumor vascular pore sizes (Figure 2-3 A). 
(Deposition clearance is converted to the deposition rate constant upon division by 
the central compartment volume.) Regardless of the pore size, the smallest NPs 
show the highest deposition clearance in the tumor. Also, the tumor deposition 
clearance of NPs increases with increasing vascular pore size. Figure 2-3 B 
shows the deposition clearance of NPs in the toxicity compartment. In our model, 
we assumed that the toxicity compartment, liver for example [455], is characterized 
by pores that are permissive to NP entry [447, 449].  However, the volume of this 
compartment and its blood supply are assumed to be larger than those of the tumor 
compartment. The deposition clearance for NPs in the toxicity compartment 
followed the same trend as those seen in the tumor.  
Although deposition clearance provides vital mechanistic information about the 
ease of NP accumulation into the two peripheral compartments, this metric 
provides a very limited description of the overall pharmacokinetics of the drug 
carrier or the released drug. To assess the on-target exposure to the drug, we 
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calculated the area under the curve (AUC) of released drug in the target 
compartment (Figure 2-3 C). Though the deposition clearance of the smallest 
particles was the highest, this did not translate into the highest intratumoral AUC. 
For all pore sizes, the AUC was maximal at an intermediate particle size. This 
intermediate particle size (~70 nm) was close to the pore cutoff size of the toxicity 
compartment. The DTI profiles (Figure 2-3 D) show that in addition to maximal on-
target accumulation, intermediate sized NPs also showed minimum off-target 
accumulation.  
The larger toxicity compartment can strongly affect the deposition of NPs in the 
smaller target compartment. The availability of 20 nm NPs for deposition in the 
toxicity compartment and a higher blood supply to the toxicity compartment 
predisposes a large fraction of these NPs to be deposited in the toxicity 
compartment. Consequently, the fraction available for deposition in the tumor is 
low. On the other hand, the deposition clearance of 70-nm NPs in the toxicity 
compartment is close to zero, rendering a higher fraction available for deposition 
in the tumor. Thus, 70-nm NPs have a higher targeted bioavailability in the tumor 
as compared to the 20-nm NPs. This translates into greater deposition of 70 nm 
NPs in the tumor and a higher AUC for the free drug.  
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Longer retention and slower venous drainage of 70 nm NPs in comparison with 
20 nm NPs can also result in a higher AUC. However, this is not likely. In our 
model, elimination clearance of NPs from the tumor compartment, though size-
dependent, was very low. In fact, the decline in NP encapsulated drug 
concentration from the tumor compartment was due to release of the drug from 
NPs. This decrease is identical for all particle sizes (Figures 2-4 A-D).  
Figure 2-3. Effect of vascular pore size of the target compartment 
(A) Deposition clearance of nanoparticles in the target compartment. (B) 
Deposition clearance of nanoparticles in the toxicity compartment. (C) AUC of 
the free drug in the target compartment. (D) DTI of nanoparticles of different 
sizes. The legend in A, C and D indicates the diameter of the pores in the tumor 
vasculature. 
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Above a particle size of 70 nm, deposition clearance into the toxicity 
compartment is zero. On the other hand, deposition clearance into the target 
compartment either decreases or remains constant as the particle size increases. 
Above 70 nm, the deposition clearance and the circulation half life of NPs dictate 
NP accumulation in the target compartment. These differences are evident in the 
concentration-time profiles of different size NPs in tumors with different pore sizes. 
Figure 2-4. Concentration-time profiles of nanoparticles in the target 
compartment on a semi-log scale 
The target compartment was assumed to have a pore size of (A) 100 nm, (B) 200 
nm, (C) 300 nm, and (D) 600 nm. The figure legends indicate the size of 
nanoparticles.  
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For example, for a pore size of 300 nm (Figure 2-5 A), there is an appreciable 
difference in the concentration-time profile of 70 nm and 120 nm NPs. However, 
for a pore size of 600 nm (Figure 2-5 B), the concentration-time profiles of 70 and 
120 nm NPs virtually overlap.  
 
In addition to the vascular pore size, vascular pore fraction can also affect the 
degree of porosity. We modeled the effect of varying the vascular pore fraction of 
the target compartment. These results are summarized in Figure 2-6 A-C. The 
tumor AUC of the free drug and DTI increased with increasing pore fraction. 
However, similar to our previous results, the highest tumor AUC and DTI are 
achieved for NPs having a particle size that is close to the vascular pore size of 
the toxicity compartment.  
Figure 2-5. Concentration-time profiles of nanoparticles in the target 
compartment  
The target compartment was assumed to have a pore size of (A) 300 nm and (B) 
600 nm. The figure legends indicate the diameter of nanoparticles.  
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Our data thus suggests that the optimal particle size depends on the vascular 
characteristics of both the toxicity and target compartments. In agreement with 
previous reports, a small particle size is desirable for maximal on-target effect [1, 
424]. However, there is a lower limit to the particle size, and this is dictated by the 
pore size of the toxicity compartment. On the other hand, the highest particle size 
Figure 2-6. Effect of vascular pore fraction of the target compartment  
(A) Deposition clearance of nanoparticles in the target compartment, (B) AUC 
of the free drug in the target compartment, (C) DTI of various sized 
nanoparticles. Figure legend indicates the fraction of the tumor blood vessel 
surface area occupied by pores. 
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at which the maximum on-target effect is maintained is a function of the pore size 
of the target compartment and the circulation half-life of the NPs. Thus, patients 
with highly porous tumors are better candidates for treatment with NPs. For tumors 
with smaller pore sizes or lower pore fractions, a careful consideration of the 
vascular pore size of the toxicity compartment(s) is necessary to minimize off-
target toxicity. 
2.4.3 Effect of the vascular pore size of the toxicity compartment 
Results from the previous section show that the site of toxicity plays an 
important role in determining the optimal particle size range. The major site of 
toxicity differs from one drug class to another. Hence, the optimal particle size 
range for the nano-carrier also depends on the drug of interest. We modeled the 
effect of varying the vascular pore size of the toxicity compartment. We evaluated 
pore sizes of 20, 75, 150 and 300 nm. The pore size (300 nm) and pore fraction 
(5%) of the target compartment and the rate constant for drug release from NPs 
(8x10-5 s-1) were held constant.  
NP deposition clearance into the tumor is unaffected by changes in pore size 
of the toxicity compartment (Figure 2-7 A). The deposition clearance of NPs in the 
toxicity compartment increases with increasing pore size (Figure 2-7 B). 
95 
 
  
Both the AUC of the target compartment and the DTI show a maximum at an 
intermediate particle size, at least in the cases where the pore size of the toxicity 
compartment is smaller than that of the target compartment (Figure 2-7 C and D). 
The particle size for maximum tumor AUC and DTI shifts with a change in the pore 
size of the toxicity compartment. These results help confirm that the optimal 
particle size is indeed a function of the vascular pore size of the toxicity 
Figure 2-7. Effect of vascular pore size of the toxicity compartment  
(A) Deposition clearance of nanoparticles in the target compartment (B) Deposition 
clearance of nanoparticles in the toxicity compartment (C) AUC of the free drug in 
the target compartment (D) DTI of various sized nanoparticles. The legends 
indicate the diameter of the vascular pores of the toxicity compartment. 
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compartment. When the toxicity compartment has a vascular pore size equal to 
that of the target compartment, there is minimal effect of particle size on the AUC 
of the target compartment (Figure 2-7 C and 2-8). These results indicate that a 
careful consideration of the role of peripheral organs in the distribution of NPs is 
required.  
 
Figure 2-8. Concentration-time profiles of nanoparticles in the target 
compartment 
The toxicity compartment was assumed to have a pore size of (A) 20 nm, (B) 
75 nm, (C) 150 nm and (D) 300 nm. The figure legends indicate the diameter 
of nanoparticles. 
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2.4.4 Effect of rate of drug release 
The rate of drug release from NPs is an important determinant of the 
performance of nano formulations [456]. An ideal formulation should not release 
any fraction of the encapsulated drug while in circulation or in the toxicity 
compartment, and should release the entire drug content once it reaches the target 
compartment. However, this is seldom possible. Most formulations release the 
drug irrespective of location. We considered four formulations that release their 
payload at different rates (first order) independent of their location, and examined 
the effect of release rate for tumor vascular pore diameters of 300 nm and 100 nm. 
In both cases, we assumed that the pore fraction is 1%.  
The joint effect of NP size and release rate on DTI, when the tumor vasculature 
pore size is 300 nm, is shown in Figure 2-9 A. For particles below the pore cutoff 
size of the toxicity compartment (<70 nm) and above the pore cutoff size of the 
target compartment (>280 nm), there is no effect of drug release rate on the DTI. 
However, at intermediate particle sizes the DTI increases as the release rate 
decreases. Similar results are obtained when the tumor vascular pore size is 
assumed to be 100 nm (Figures 2-9 B).  
We then studied the first case (300 nm pore size) in more detail to develop a 
mechanistic understanding of this effect. For particle sizes <70 nm, below the 
cutoffs of both the target and toxicity compartments, NPs are deposited in both 
compartments. Thus, with a slower release, there is an increase in AUC of the free 
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drug in both the target and toxicity compartments (Figures 2-9 C-D). Therefore, at 
very small particle sizes, prolonging drug release may not yield beneficial results.  
At an intermediate particle size (between 70 nm and 280 nm), a complex 
interplay of deposition and elimination processes occurs. When the drug is in the 
NP form, it has two clearances acting upon it. One of these clearances drives NPs 
into the target compartment and the other eliminates it from the body. Once the 
drug is released in the central compartment, it is acted upon by three clearances, 
one elimination clearance and two distribution clearances, driving it into either the 
target or toxicity compartments. Based on these clearances, the probability of the 
drug depositing in the tumor is greater if it is encapsulated in NPs than if it is in the 
free form (Figure 2-9 E). Hence, if a drug is held in the nanoparticulate form for a 
longer period of time, it has a greater probability to enter the target compartment. 
This will translate into higher drug deposition into the tumor and an increased AUC. 
This is in agreement with previous studies that have shown higher tumor 
concentrations with more sustained drug release [175]. This prolonged 
confinement in the NP form will also decrease the amount of drug that can be 
deposited into the toxicity compartment after the drug is released (Figure 2-9 D).  
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Figure 2-9: Effect of rate of drug release  
(A) DTI of various sized nanoparticles in tumors with a vascular pore size of 300 
nm (B) DTI of various sized nanoparticles in tumors with a vascular pore size of 
100 nm (C) AUC of the target compartment as a function of particle size at various 
release rates (D) AUC of the toxicity compartment as a function of particle size at 
various release rates. The legend in A-D indicates rate of drug release. Rate 1 = 
16x10-5 s-1, Rate 2 = 8x10-5 s-1, Rate 3 = 4x10-5 s-1, Rate 4 = 2x10-5 s-1 (E) 
Probability that the drug enters the target compartment when it is either bound 
inside the nanoparticles or as free drug. 
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2.4.5 Comparison of drug targeting index determined using AUCs and 
average number of visits 
One way to view these results is in terms of the average number of visits of the 
drug molecule into the tumor and toxicity compartments when the drug is 
administered in its free state or encapsulated in NPs. By avoiding key organs and 
being in circulation for a longer time, NP-encapsulated drug will more likely deposit 
in the tumor, and therefore will have a greater average number of visits into the 
tumor as compared to the free drug. Thus, confining the drug in NPs for a longer 
period of time increases the average number of visits of the drug molecule to the 
tumor.  
We solved for DTI using AUCs of the drug in the target and toxicity 
compartment (Eq. 1) and compared it to DTI obtained by using average number of 
visits of the drug to various compartments (Eq 29). Solutions for DTI obtained using 
Eqs. (1) and (29) are identical (Figure 2-10).  More complicated expressions 
obtained after relaxing these two assumptions will be published elsewhere. 
2.4.6 Key findings of the model and future directions 
Our results highlight several important points. First, it is necessary to 
understand the key sites of toxicity for a given drug. Subsequently, these organ 
sites need to be carefully analyzed for their possible vulnerability to NP deposition. 
If these organs welcome NP deposition, then particle size can be an important 
variable that can be tuned to mitigate toxicity. The smallest NPs may not always 
be optimal.  
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Much effort has been focused on achieving sustained drug release from NPs, 
a nontrivial task [330, 457].  However, our results show that altering the rate of 
drug release may not always be advantageous. NPs that deposit in both the target 
and toxicity compartments are likely to cause changes in both efficacy and toxicity 
Figure 2-10. Comparison of DTI of various NP formulations determined using 
the AUC method and ‘average number of visits’ method 
DTI was calculated as the ratio of AUCs and based on the average number of visits 
to each compartment. Drug encapsulated in intermediate sized particles have the 
highest number of average visits into the tumor. Legend indicates rate of drug 
release from nanoparticles. Rate 1 > Rate 2 > Rate 3 > Rate 4. 
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that depend on drug release rate. NPs large enough to avoid the toxicity 
compartment but small enough to deposit in the target compartment will benefit 
the most from sustained drug release.  
Our results also suggest that it is essential to classify drugs based on their 
suitability for nano drug delivery. This classification system can likely predict and 
limit the failures of nanotherapeutics earlier in the development pipeline. The site 
of toxicity of the drug can be the basis of such a classification system. For example, 
a drug that causes toxicity in a non-fenestrated organ is a good candidate for 
delivery using NPs. Conversely, NP-form of a drug should be used to treat only 
those tumors that have a larger pore size than that of the toxicity compartment.  
The EPR effect has been the key inspiration for using NPs to deliver anticancer 
agents [173]. EPR theory suggests that NPs can accumulate to a greater extent in 
tumors than in normal tissues. However, if the major site of drug toxicity is an organ 
with fenestrated capillaries similar to those found in tumor tissues then the 
permeability component of the EPR effect may also apply to the toxicity site. 
Whether or not the EPR effect is operational and beneficial may depend on the 
particle size, the location and properties of the tumor, and properties of the site(s) 
of toxic action.  The DTI statistic offers a means to evaluate the relative EPR effects 
in tumor and toxicity site.  
In this report, we used AUC of the drug in the tumor and toxicity compartments 
as a measure of its efficacy and toxicity. However, time courses of concentrations 
of the drug in the various compartments may be a better determinant [175]. 
Prolonged exposure to low drug concentrations may yield high AUCs, but may not 
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translate into increased efficacy or toxicity. Secondly, in our model we assumed 
that the tumor is a single well-stirred compartment. Impaired interstitial transport in 
the tumor and differences in drug activity against a heterogeneous tumor cell 
population may challenge this assumption [94, 458-460]. Thirdly, we have 
assumed that elimination of free drug and NPs is carried out only in the central 
compartment.  This may not be true, as drug metabolism and excretion, or NP 
elimination could occur in either tumor or toxicity related organs, especially the 
liver.  Incorporating these processes provides no analytical difficulties, but would 
require more kinetic parameters.  
An important assumption in our model is that macrophage uptake of NPs 
results in the elimination of both NPs as well as the encapsulated drug. However, 
upon phagocytosis, the encapsulated drug can be released in the organ harboring 
the macrophages, or can cause toxicity to the macrophages. Our model does not 
consider either of these cases, because quantification of the extent of these 
processes is difficult. However, some specific effects of macrophage clearance 
can be speculated. Since larger NPs are taken up by macrophages more 
efficiently, our model would underestimate the toxicity caused by these NPs. 
Hence, the ideal particle size may shift to a smaller value based on the extent of 
toxicity caused by the phagocytosed NPs.  
While the model is more general, we specialize it here by assigning the “Target” 
compartment to tumor and the “Toxicity” compartment to liver.  Both tumor and 
liver contain rather large fenestrae in their capillaries [186, 461], allowing 
significant NP deposition and accumulation [447]. It must be noted here that the 
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liver may not be the major site of toxicity for all chemotherapeutic drugs. However, 
in this special case, we have considered the liver as the toxicity organ because it 
is highly vascularized and shows porous capillaries. Such an organ can have a 
significant impact on the overall pharmacokinetics of NPs and the released drug. 
We have also assumed that the rate of drug release is the same in all 
compartments. This need not be so, as drug release can be enhanced, for 
example, in the relatively acidic tumor environment [340]. With some effort, and 
with advances in synthetic chemistry and physicochemical understanding of 
release rates from NPs in different tissue environments, the present model can be 
extended to include these effects. Additionally, particle size can have a significant 
impact on the rate of drug release. The large surface area to volume ratio of smaller 
NPs may result in rapid release of the encapsulated drug. However, in the current 
case, we assumed that the rate of drug release was independent of particle size. 
This was done to delineate the effects of the individual parameters. Finally, release 
rates from NPs have been assumed to obey first order, decaying exponential 
kinetics. Expressions are possible for DTI for more general release profiles, many 
of which can be decomposed with good accuracy to polyexponential forms. 
2.5 Conclusion 
The physicochemical properties of nano drug delivery systems can have a 
significant impact on their in vivo performance. We presented here a 
pharmacokinetic model to explain the effects of particle size, rate of drug release 
and vascular physiology on the effectiveness of nano delivery. We found that the 
optimal particle size and/or drug release rate is strongly dictated by vascular 
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characteristics of the tumor and toxicity compartments. Additionally, the model 
identified key factors that may help in selecting these formulation parameters for 
an individual patient. The use of pharmacokinetic modeling to understand the 
behavior of nanoparticulate systems in vivo has tremendous potential to impact 
the field of cancer therapy. 
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Table 2-1. Table of constants and symbols 
Symbol Parameter Value Units 
a Radius of NPs (5-240) x 10-7 cm 
R Radius of pore in blood 
capillary 
(50-300) x10-7 (target) 
37.5x10-7 (toxicity)[455] 
cm 
λ Ratio of particle size to 
pore size 
Calculated  
H Hindrance factor to 
diffusion 
Calculated  
W Hindrance factor to 
convection 
Calculated  
σ Reflection co-efficient Calculated  
kB Boltzmann constant 1.38 x10-16 cm2g/ s2 K 
T Absolute temperature 310 K 
μ Viscosity of blood 3.5 x 10-2     [462] g/cm.s 
D Diffusivity Calculated  
L Thickness of blood 
capillary wall 
5 x10-4 cm 
γ Pore fraction 0.01-0.2 (target) 
0.075 (toxicity)[455] 
% 
P Permeability Calculated cm/s 
Lp Hydraulic conductivity Calculated cm2s/g 
Pcap Capillary pressure 2.6664 x 104 [13] g/cm.s2 
Pif Interstitial fluid pressure 1.9998x104 (target)[13] 
2.6664x 103 (toxicity)[13] 
g/cm.s2 
Pe Peclet number Calculated  
S Blood vessel surface 
area 
16 (target)[463] 
5.2 (toxicity)[464]a 
cm2/g 
i Used as a subscript to 
designate the 
compartment 
c (central) 
tar (target) 
tox (toxicity) 
 
,  Intrinsic clearance of NPs 
into compartment i (i = tar 
or tox) 
Calculated mL/s 
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,  Intrinsic clearance of NPs 
out of compartment i (i = 
tar or tox) 
Calculated mL/s 
; Blood flow to 
compartment i (i = tar or 
tox) 
3.33x10-3(target)[463] 
1.33x10-2(toxicity) 
mL/s.g 
,-  Total clearance of NPs 
into compartment i (i = tar 
or tox) 
Calculated mL/s 
,-  Total clearance of NPs 
out of compartment i (i = 
tar or tox) 
Calculated mL/s 
-  Elimination clearance of 
NPs from the central 
compartment 
Calculated[1] mL/s 
  Elimination clearance of 
free drug from the central 
compartment 
10.59 mL/s 
0 Rate constant for drug 
release 
2x10-5 – 16x10-5 1/s 
- Volume of distribution of 
NPs in compartment i 
3000 (Central) 
0.2 (target) 
1650 (toxicity) 
mL 
 Volume of distribution of 
free drug in compartment 
i 
42000 (Central) 
0.2 (target) 
1650 (toxicity) 
mL 
- Concentration of drug in 
NP form in compartment i 
Calculated g/mL 
 Concentration of drug in 
free form in compartment 
i 
Calculated g/mL 
  Area under the curve for 
drug in compartment i 
Calculated g.s/mL 
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Chapter 3 Fibrinolytic Enzyme Therapy to Improve Tumor 
Perfusion and Chemotherapeutic Efficacy of 
Nanoparticles 
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3.1 Summary 
Elevated interstitial fluid pressure and a high degree of solid stress within 
tumors contribute to poor intratumoral distribution of nanomedicine and inadequate 
drug delivery. We hypothesized that the presence of fibrin in tumors contributes to 
hindered intratumoral distribution of nanocarriers, and that this can be overcome 
with the use of a fibrinolytic enzyme such as tissue plasminogen activator (tPA). 
We first conducted a systematic analysis of fibrin(ogen) expression in human 
tumor biopsies. Fibrin staining was found to be heterogeneous across and within 
tumor types. On an average, ~20-90% of the tumor area was stained for fibrin. 
Further analysis in lung carcinomas revealed that a high degree of staining was 
observed regardless of disease stage or type. We then studied the influence of 
fibrin degradation on the in vitro and in vivo performance of a model formulation of 
paclitaxel nanoparticles. Using Transwell® studies, we found that the diffusivity of 
nanoparticles in fibrin matrices was poor. However, the resistance offered by the 
fibrin gel was dramatically reduced in the presence of tPA. We further 
characterized the efficacy of a combination therapy of tPA and paclitaxel 
nanoparticles in an orthotopic model of human lung cancer and a syngeneic mouse 
melanoma model. In both models, co-administration of tPA led to a significant 
improvement in the activity of paclitaxel nanoparticles. We then used 
immunohistochemistry and ultrasound analyses to probe into the anatomical and 
physiological ramifications of tPA treatment on tumor blood vessels. These studies 
showed that tPA treatment led to an increase in median blood vessel diameter and 
improved perfusion. In summary, we show here that treatment with tPA improves 
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tumor perfusion and anticancer efficacy of nanoparticle-encapsulated 
chemotherapeutic drugs.   
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3.2 Introduction 
Poor intratumoral distribution of the drug carrier and inadequate drug delivery 
to tumors are significant challenges in chemotherapy [98]. Prolonging circulation 
times [465, 466] or altering particle size, shape, charge and other physicochemical 
properties of the drug carrier address these challenges [424, 440, 467, 468] but 
only to a limited extent. The benefits of these approaches are limited by the erratic 
blood supply often observed in tumors.  
Several peculiar characteristics of tumor blood vessels render them suboptimal 
for drug delivery. These include inadequate coverage of the tumor, lack of 
transvascular pressure gradients, and their collapsed nature [181, 202, 468, 469]. 
Blood vessels in the core of the tumor are compressed under solid stress exerted 
by fast-dividing cells [470] and large amounts of extracellular matrix (ECM) [202]. 
Treatment with enzymes that degrade ECM components such as collagen [419] 
and hyaluronic acid [418] improves vascular characteristics and enhances blood 
supply to tumors. However, the ubiquitous expression of collagen and hyaluronic 
acid in the body may limit the systemic use of these enzymes.  
Due to the leaky nature of tumor blood vessels, fibrinogen, a soluble vascular 
protein, is deposited in the tumor matrix. The prothrombogenic activity of tumor 
cells leads to the conversion of fibrinogen to cross-linked fibrin, the principle 
ingredient of blood clot [127, 130]. In fact, due to the constitutive activity of 
coagulation factors in tumors, they are often considered ‘overhealing wounds’ 
[141]. We hypothesized that the presence of significant amounts of fibrin in the 
tumor matrix contributes to increased solid stress often observed in tumors. 
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Additionally, the tumor specific presence of fibrin makes it an excellent target for 
therapeutic interventions. However, the role of fibrin in limiting the transport of drug 
carriers has not been previously studied.  
We show here that administration of a fibrinolytic enzyme improves tumor 
perfusion by decompressing blood vessels. This leads to an increase in 
chemotherapeutic activity of paclitaxel encapsulated in polymeric nanoparticles 
(NPs). These results were observed in both a syngeneic mouse model of 
melanoma and an orthotopic human lung cancer model.  
3.3 Materials and Methods 
3.3.1 Materials 
Tissue microarrays of various human tumor biopsies were obtained from Folio 
Biosciences (Ohio, USA). Anti-human fibrin(ogen) antibody was purchased from 
Dako (California, USA). Poly(lactide-co-glycolide) (PLGA) was purchased from 
Lactel (Alabama, USA). L-lactide, bovine fibrinogen, and thrombin were obtained 
from Sigma Aldrich (Missouri, USA). Tissue plasminogen activator (tPA) was 
obtained from Abcam (Massachusetts, USA). Poly(ethylene glycol) was purchased 
from Laysan Bio Inc. (Alabama, USA). Potassium salt of D-luciferin was purchased 
from Gold Biotechnology, Inc. (Missouri, USA).  
3.3.2 Staining, microscopy and analysis of human tissue microarrays 
Tissue microarrays were digested with Proteinase K and stained with a 
polyclonal rabbit anti-human fibrin(ogen) antibody at a dilution of 1:1000. 
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Representative images were acquired using an Eclipse TS100 microscope (Nikon 
instruments, New York, USA) under 400X magnification. Fraction of the area 
stained for fibrin(ogen) was quantified using ImageJ v1.48 software.  
3.3.3 Synthesis and characterization of paclitaxel loaded PLGA 
nanoparticles 
A block copolymer of poly(lactide) and poly(ethylene glycol) was synthesized 
via ring opening polymerization reaction as described before [210]. The block 
copolymer was characterized using 1H-NMR (Varian 400 MHz) [210].  
PLGA NPs loaded with paclitaxel were synthesized by a single emulsion 
technique as described before [210]. Briefly, PLGA (32 mg) and paclitaxel (5 mg) 
were dissolved in 1 mL of chloroform. The chloroform solution was added to 8 mL 
of 2.5 %w/v poly(vinyl alcohol). The mixture was sonicated on an ice bath at an 
output of 18-21 W for 5 minutes (Sonicator XL, Misonix, New York, USA). The 
emulsion was then stirred using a magnetic stir plate. The block co-polymer (8 mg) 
of poly(lactide) and poly(ethylene glycol) was dissolved in 0.2 mL chloroform and 
added to the emulsion while being stirred. The mixture was stirred overnight under 
ambient conditions and then for 2 h under vacuum. NPs were then washed thrice 
with deionized water by ultracentrifugation, and lyophilized. PLGA NPs loaded with 
fluorescent dye (coumarin 6) were synthesized similarly [33].  
To determine particle size and zeta potential, NPs were dispersed in deionized 
water and analyzed using dynamic light scattering (Delsa Nano C, Beckmann 
Coulter, California, USA).  
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To determine drug loading, NPs were dispersed in methanol (~1 mg/mL) and 
the drug was extracted overnight. NPs were separated from free drug by 
centrifugation (14000 RPM, 15 minutes). Drug concentration in the extract was 
analyzed using HPLC (Beckmann Coulter, California, USA) [9].  
3.3.4 Migration across fibrin matrix 
A Transwell assay was used to determine the rate of migration of NPs across 
fibrin matrices. In these studies, fibrin matrix was formed in situ in the upper insert 
of a Transwell® plate (12 mm diameter, 0.4 μm pore size, polycarbonate 
membrane). Fibrinogen (3 mg/mL) was dissolved in 0.9% w/v saline at 37°C. 
Plasminogen (0.1 U/mL) and thrombin (1 U/mL) were added to the fibrinogen 
solution. A 750-μL aliquot of the solution was quickly transferred to the inserts. The 
plate was placed in a cell culture incubator overnight to allow fibrin gel formation.  
At the beginning of the experiment, the bottom well was filled with 1 mL of 0.15 
mM phosphate buffered saline (pH 7.4, 1X PBS). The tPA stock solution was 
diluted in 1X PBS, mixed with NPs (0.5 mg NPs dispersed in 0.1 mL deionized 
water), and added on top of the fibrin matrices. At various time points, contents of 
the bottom well were collected and lyophilized. The bottom well was replenished 
with fresh 1X PBS. The lyophilized samples were extracted overnight with 
methanol. Concentration of paclitaxel in the extract was determined using HPLC.  
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To determine the lag time for the appearance of drug in the bottom chamber, a 
curve given by the following equation was used to fit the data: 
 =  $[1 − UXq5Xxz{6] 
where A is the cumulative amount of drug in the bottom chamber, $is the amount 
of drug added to the top chamber, k is the rate constant for transport across the 
insert and 	} is the lag time. Model fitting was performed using Matlab software 
(Mathworks, Massachusetts, USA).  
3.3.5 Cell culture 
B16F10 murine melanoma cells, J774 murine macrophages, and A549 human 
lung cancer cells transfected with firefly luciferase gene (A549-luc) were used in 
these studies. All cells were cultured in Roswell Park Memorial Institute (RPMI) 
1640 medium supplemented with 10% v/v fetal bovine serum and 1% v/v penicillin 
and streptomycin under humidified atmosphere with 5% CO2 at 37°C.  
3.3.6 Cell uptake across fibrin matrix 
Cell uptake of NPs across fibrin matrices was determined using a Transwell 
assay. Fibrin matrices were formed in the upper inserts of the Transwell® plate as 
described before. B16F10 cells were seeded in the bottom well (1X106 cells/well) 
and allowed to adhere overnight. On the day of the experiment, media was 
replaced with serum free media (1 mL/well). Coumarin 6 loaded NPs (0.25 mg 
dispersed in 0.05 mL deionized water) were mixed with increasing amounts of tPA 
and added on top of the fibrin matrix. After 4 h, cells were trypsinized, collected in 
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flow tubes and centrifuged at 1000 RPM for 5 minutes. The supernatant was 
removed and cells were suspended in cold 1X PBS. Cellular fluorescence was 
analyzed using flow cytometry (BDCalibur flow cytometer).  
3.3.7 Assessing the safety and tolerability of combination therapy 
We determined the safety of the combination treatment consisting of tPA and 
paclitaxel NPs in a mouse model. Female C57Bl/6 mice, 4-6 weeks old, (Charles 
River laboratories, USA) were randomized in three groups and treated with 
paclitaxel solution (20 or 40 mg/kg), paclitaxel NPs, or combination of paclitaxel 
NPs and tPA (218 or 436 μg/kg). Animals received three doses of each treatment 
at 96 h interval intravenously. Animal weights were monitored throughout the 
study.  
Paclitaxel solution (40mg/mL) was prepared by dissolving paclitaxel in a 
mixture of Cremophor EL and ethanol (1:1 v/v). This solution was diluted to 2-4 
mg/mL with 1X PBS immediately prior to injection.  
The dispersion of paclitaxel NPs was prepared by adding 1X PBS to NPs. The 
dispersion was probe sonicated thrice (18 W for 30 s each) on an ice bath. The 
dispersion was used immediately after sonication. For combination treatment, tPA 
was added to the dispersion immediately before injection.   
One week after the final dose, animals were sacrificed using CO2 asphyxiation. 
Blood was collected using cardiac stick and transferred to heparinized tubes. Blood 
cells were separated by centrifugation. Serum concentrations of various markers 
of liver function were analyzed.  
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3.3.8 Anti-cancer efficacy of combination therapy in orthotopic lung cancer 
model 
The efficacy of the combination therapy was evaluated in a xenograft mouse 
model of lung cancer. The lung tumor model was set up as described before [228], 
with some changes. A549-luc cells (~6X105 cells/mouse) were dispersed in 1X 
PBS and injected in 4-6 week old, female severe compromised immunodeficient 
(SCID) mice (Charles River Laboratories, USA) via the lateral tail vein. Tumor 
growth in the lungs was monitored by measuring bioluminescence using IVIS 
spectrum in vivo imaging system.  
Treatment was initiated 4-5 weeks after cell injection. Animals were 
intravenously treated with saline or paclitaxel (40 mg/kg) or a combination of 
paclitaxel and tPA (436 μg/kg). The treatments were administered thrice every 96 
h. Tumor bioluminescence was monitored every 3-4 days.  
3.3.9 Anti-cancer efficacy of combination therapy in syngeneic melanoma 
model 
B16F10 cells (1x106 cells dispersed in 0.05 mL 1X PBS) were injected 
subcutaneously in 4-6 week old female C57Bl/6 mice. Tumor dimensions were 
measured daily using a digital caliper. Tumor volume was calculated as 0.5 x 
length x width2. Treatment was initiated when the tumor volume reached ~100 
mm3. Animals were treated intravenously with saline or various formulations of 
paclitaxel (40 mg/kg) or a combination of paclitaxel and tPA (436 μg/kg). Animals 
were treated with three doses administered 96 h apart.  
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Formulations of paclitaxel solution and paclitaxel NPs were prepared as 
described in the safety study. A dispersion of Abraxane® was prepared by adding 
1X PBS. The dispersion was sonicated in a water bath for 5-10 minutes. The 
dispersion was stored on ice and was used within 1 h.  
3.3.10 Immunohistochemistry analysis of CD31+ blood vessels 
Tumors from the B16F10 efficacy study were collected and fixed in 5% formalin 
in PBS for 48 h. After 48 h, formalin was removed and the fixed tumors were 
washed thrice with 1X PBS. The tumors were then stored in 70% ethanol until 
further processing. Tumor sections were stained with a goat anti-mouse CD31 
antibody (Santa Cruz Biotechnology, TX, USA).  
Fifty random images of each tumor section were obtained using an optical 
microscope at 400X magnification. Diameters of the CD31+ blood vessels were 
measured using ProgRes® Capture software (Jenoptik AG, Germany). On 
average, each image contained 2-3 blood vessels. Six sections from each 
treatment group were analyzed. Hence, results represent ~600-900 blood 
vessels/treatment group.  
3.3.11 Ultrasound imaging of B16F10 tumors 
C57Bl/6 mice were shaved and inoculated with B16F10 cells as described in 
the efficacy study. When tumors reached a volume of ~100 mm3, animals were 
randomly assigned to two groups and treated with three doses of either saline or 
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tPA every 96 h. About 1 h after treatment, tumor perfusion was analyzed using 
ultrasound imaging.  
Ultrasound imaging was performed using a Vevo® 2100 system (FujiFilm 
VisualSonics Inc.). Animals were anesthetized using isoflurane, and were 
maintained on the gas throughout the imaging. Any hair on the tumor was removed 
using Nair (Church and Dwight Co Inc.). Using a motorized stage, an MS550 probe 
was placed on top of the tumor. Exact position of the tumor was determined by 
monitoring tumor boundary and location in B-mode. Perfusion area was visualized 
by switching to the Power Doppler mode. Power Doppler images were analyzed 
using the ImageJ v1.48 software.  
3.3.12 Synthesis and characterization of tPA functionalized polymeric 
nanoparticles 
PLGA NPs loaded with paclitaxel and surface functionalized with tPA were 
synthesized using maleimide-thiol chemistry as described before [218]. Briefly, 
NPs (~25 mg) functionalized with maleimide-terminated poly(ethylene glycol) were 
dispersed in ~1.5 mL deionized water. tPA (1.9 μg/mg NPs) was added to the NP 
dispersion, and the reaction mixture was incubated on a shaker overnight. On the 
next day, unbound tPA was separated from the NPs by ultracentrifugation. NPs 
were lyophilized and stored at -20°C until further use. 
Particle size, zeta potential and drug loading were determined as described 
before. The amount of tPA on the NP surface was measured using bicinchoninic 
acid (BCA) assay. Activity of tPA was determined using an enzymatic assay kit 
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that measures plasmin generation (Sigma Aldrich Co., MO, USA, product #0882). 
Different concentrations of tPA were used to prepare the calibration curve, and the 
assay was run according to the manufacturer’s instructions.  
The migration of tPA functionalized NPs across fibrin matrix was determined 
using a Transwell® assay as described before.  
3.3.13 Anti-cancer efficacy of tPA functionalized nanoparticles 
Tumor inhibition of tPA functionalized NPs was determined in an orthotopic 
lung cancer model and a syngeneic melanoma model as described before. 
Animals were treated with 3 doses of tPA functionalized paclitaxel NPs (40 mg 
paclitaxel/kg) every 4 days.  
3.3.14 Accumulation of paclitaxel in lung tumors 
Orthotopic lung tumors were established in SCID mice as described in the 
efficacy study. After 4-5 weeks of cell injection, animals were randomly assigned 
to various treatment groups. Different formulations of paclitaxel (20 mg/kg) were 
administered via the lateral tail vein. Animals were sacrificed 2 h or 6 h after 
treatment administration. Lungs, liver and spleen were collected and weighed. The 
organs were homogenized in ~1 mL deionized water and lyophilized. Paclitaxel 
was extracted overnight from the lyophilized organs using methyl tert-butyl ether. 
The ether was separated from the tissue homogenate by centrifugation and 
evaporated to dryness under nitrogen. The dried samples were reconstituted in 
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methanol, centrifuged (14000 RPM, 15 min), and transferred to HPLC vials. 
Paclitaxel concentration was analyzed using LC-MS/MS as described before [215].  
3.3.15 Effect of tPA on macrophage uptake of nanoparticles 
J774 murine macrophage cells were seeded in a 24-well plate (50000 
cells/well) and allowed to adhere overnight. On the next day, cells were treated 
with tPA (10 nM) or saline. After 4 h, coumarin-6 loaded nanoparticles were added 
to all cells. At different time points, treatments were removed, and the cells were 
washed thrice with cold 1X PBS. Cells were lysed by incubating with RIPA buffer 
at 37°C for 15 minutes. The cell lysate was divided into two parts. One part was 
extracted overnight with methanol, and coumarin 6 concentration in the extract 
was analyzed using HPLC. The other part was used to determine cell protein 
concentration using BCA assay.  
3.4 Results 
3.4.1 Extensive fibrin(ogen) deposition in various tumors 
Several solid tumors have leaky blood vessels. This leads to the deposition of 
vascular proteins in the tumor matrix. We were particularly interested in analyzing 
the deposition of fibrin, an important vascular protein involved in blood clotting.  
We examined the occurrence of fibrin in an array of human tumor biopsies. We 
found that all tumors considered in our studies showed significant fibrin deposition 
(Figure 3-1A-H). Fraction of the tumor area stained for fibrin ranged from ~20-90% 
(Figure 3-1I). To address the question of whether fibrin levels were affected by the 
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stage of the disease, metastatic status or type of cancer, we focused on lung 
carcinomas. We found that all lung carcinomas (adenocarcinoma, non-small cell 
lung carcinoma and squamous cell carcinomas) had comparable amounts of fibrin 
(Figure 3-1J). These levels were unaffected by stage of the disease (Figure 3-
1K) or the presence of lymph node metastasis (Figure 3-1L).  
We also analyzed expression of fibrin in several human and murine tumors 
grown in mice. Similar to our results with the human tumor samples, high levels of 
fibrin were found in these tumors as well (Figure 3-2). These results corroborated 
well with previous work that showed that fibrin is an important component of the 
tumor ECM [131, 471].  
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 Figure 3-1. Fibrin(ogen) staining in human tumor biopsies 
Tissue microarrays of human tumors were stained for fibrin(ogen). Shown 
here are representative images of fibrin(ogen) staining in cancers of (A) 
breast (B) colon (C) esophagus (D) kidney (E) liver (F) lungs (G) 
melanoma and (H) stomach. (I) shows fraction of area stained for 
fibrin(ogen). (J-L) show fibrin(ogen) staining in lung carcinomas as a 
function of type, stage and lymph node involvement. 
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3.4.2 tPA improves diffusivity of nanocarriers in vitro 
Previous reports have shown that degrading the components of tumor ECM 
(such as hyaluronic acid and collagen) can improve delivery of drugs to tumors. 
This result is manifested as both improved intratumoral distribution of the drug as 
well as improved tumor perfusion [417, 418, 472]. We determined whether 
degrading fibrin in tumors had a similar effect. To degrade fibrin within tumors we 
used tPA, an enzyme that is used clinically to treat patients with myocardial 
infarction and stroke. 
Figure 3-2. Fibrin(ogen) staining in tumors grown in mice 
Various tumors grown in mice were excised and fixed in 10% formalin. Tumors were 
sectioned and stained for fibrin(ogen) expression. Figure shows (A) MIA PaCa (B) 
H2009 (C) 4T1 (D) MDA-MB-231 (E) A549 and (F) B16F10 tumors 
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PLGA NPs loaded with paclitaxel and surface-functionalized with a block co-
polymer of poly(lactide) and poly(ethylene glycol) were used as model drug 
carriers. The results of the physicochemical characterization of block copolymer 
and NPs are summarized in Figure 3-3 and Table 3-1. 
 
 
Figure 3-3.1H-NMR of block copolymer of poly(lactide) and poly(ethylene glycol) 
Block copolymer of poly(lactide) and poly(ethylene glycol) was dissolved in CDCl3 and 
analyzed by 1H-NMR. Conjugation of lactide was confirmed by peaks detected at δ= 1.6 
and 5.2 ppm.  
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Table 3-1. Physicochemical characterization of paclitaxel nanoparticles 
Data represented as mean ± S.E.M 
 
To study the diffusion of NPs in fibrin matrices, we used a Transwell® assay. 
We found that the mobility of NPs across the Transwell® inserts was significantly 
compromised by the presence of the fibrin matrix. No detectable drug levels could 
be found in the receiver chamber through the time course of the experiment 
(Figure 3-4A). However, addition of tPA significantly improved the movement of 
NPs. With an increase in the amount of tPA, the lag time (tlag) for the appearance 
of drug in the receiver chamber decreased significantly (Figure 3-4B). After t=tlag, 
the rate of migration of NPs was unaffected by the concentration of tPA. 
In another study, we analyzed the cell uptake of NPs across fibrin gels. In these 
studies, NPs were separated from a monolayer of B16F10 cells by fibrin matrix. 
As a positive control, we added NPs directly to the cells. This resulted in a rapid 
uptake of NPs. However, in the presence of fibrin matrix, NP uptake was 
significantly reduced (Figure 3-4C). Addition of tPA resulted in a dose-dependent 
increase in cell uptake (Figure 3-4C-D). tPA had no effect on cell uptake in the 
absence of the fibrin matrix (Figure 3-5).  
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Figure 3-4. Effect of tPA on in vitro mobility of nanoparticles in fibrin gels  
A Transwell® study was used to analyze the migration of NPs (with or without tPA) 
across a fibrin matrix. (A) Cumulative amount of paclitaxel in the bottom chamber 
as a function of time (B) Lag time for first appearance of paclitaxel in the bottom 
chamber with increasing amounts of tPA. Results are represented as mean ± S.D., 
n=3, *p<0.05, one-way ANOVA. Cell uptake of NPs across fibrin gels was 
determined in Transwell® study. (C) Representative histograms indicating cell 
uptake of fluorescently labeled NPs (D) Average results of cell uptake of NPs as 
function of tPA concentration. Results are represented as mean ± S.D., n=4, 
*p<0.05, one-way ANOVA. 
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Figure 3-5. Effect of tPA on cell uptake of nanoparticles in B16F10 cells 
NPs, with or without tPA, were incubated with B16F10 cells for 4 h. Cell uptake 
was measured by determining cellular fluorescence using flow cytometry. NP 
uptake was unaffected by the presence of tPA. 
 
These experiments showed that the fibrin matrix could significantly retard the 
movement of polymeric NPs, and this effect could be reversed, at least partially, 
by co-treatment with tPA.  
3.4.3 Safety and efficacy of combination therapy of paclitaxel nanoparticles 
and tPA 
We determined the safety and tolerability of a combination of paclitaxel NPs 
and tPA. Treatment with paclitaxel (as single therapy or in combination) led to a 
slight loss in body weight (~5%), which was recovered within 48 h (Figure 3-6 A-
B). The levels of all the markers of liver function were elevated in response to 
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paclitaxel therapy. Co-administration of tPA did not have a significant impact on 
the level of these markers (Figure 3-6C-D). 
We then tested the efficacy of the combination of tPA and paclitaxel NPs in a 
mouse orthotopic model of human lung cancer. Animals treated with paclitaxel in 
solution had a slower tumor growth rate as compared to saline treated animals. 
Paclitaxel in NPs reduced the tumor growth rate even further. However, greatest 
tumor growth inhibition was seen when paclitaxel NPs were administered in 
combination with tPA (Figure 3-6E).  
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Figure 3-6. Safety and efficacy of paclitaxel nanoparticles-tPA combination 
therapy  
Body weights of animals treated with (A) paclitaxel (20 mg/kg) and tPA (218 μg/kg) 
and (B) paclitaxel (40 mg/kg) and tPA (436 μg/kg). Biochemical tests for liver 
function tests in animals treated with (C) paclitaxel (20 mg/kg) and tPA (218 μg/kg) 
and (D) paclitaxel (40 mg/kg) and tPA (436 μg/kg). Concentrations of albumin, 
globulin and total protein expressed in units of g/dL. Concentrations of hepatic 
enzymes expressed in units of U/mL. Data shown as mean ± S.E.M., n=5. (E) 
Tumor growth kinetics of A549 lung tumors in animals treated with various 
formulations. Results shown as mean ± S.E.M, n=6, *p<0.05 compared to 
paclitaxel NPs, Student’s t test  
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3.4.4 tPA improves the anti-cancer efficacy of large nanoparticles in a 
murine melanoma model 
 
Figure 3-7. Effect of co-administration of tPA on the anti-cancer efficacy of 
various formulations of paclitaxel 
C57Bl/6 mice bearing B16F10 tumors were treated with (A) paclitaxel in solution 
(B) Abraxane® or (C) paclitaxel NPs with or without tPA. Tumor growth was 
monitored as a function of time. (D) shows slopes of log transformed tumor growth 
profiles. Results represented as mean ± S.E.M., n=6-9. *indicates p<0.05 
compared to paclitaxel NPs, Student’s t-test.  
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To determine whether co-administration of tPA affected the anti-cancer efficacy 
of other paclitaxel formulations, we used three different formulations of paclitaxel 
viz. paclitaxel in a micellar/cosolvent solution, Abraxane® and PLGA NPs. The 
three formulations used in our studies differed significantly in their particle size and 
hence their efficiency and mechanisms of transvascular and intratumoral transport.  
We found that administration of paclitaxel in any of the three formulations 
significantly decreased tumor growth rate in the aggressive B16F10 model of 
mouse melanoma. Co-administration of tPA with paclitaxel in solution (~800 Da) 
did not improve its efficacy (Figure 3-7A). When co-administered with Abraxane® 
(particle size ~5 nm), there was a small improvement (not statistically significant) 
in its anti-cancer efficacy (Figure 3-7B). However, when administered in 
conjunction of PLGA NPs (particle size ~200 nm), there was a significant 
improvement in anti-tumor efficacy (Figure 3-7C). Slopes of the log-transformed 
tumor growth profiles are shown in Figure 3-7D. Administration of tPA reduced the 
rate of tumor growth for both colloidal formulations of paclitaxel (Abraxane® and 
PLGA NPs). However, the advantage was more pronounced for the formulation 
with the larger particle size.  
3.4.5 Administration of tPA increases blood vessel diameter and tumor 
perfusion 
Blood vessels in solid tumors are compressed due to the presence of copious 
amounts of ECM components and a fast growing cell population. Previous 
experiments have shown that administration of cytotoxic therapies [470, 473] or 
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ECM degrading enzymes [418] can decrease solid stress and restore vascular 
function. We were interested in determining if tPA had such an effect on B16F10 
tumors.  
Like other solid tumors, we found that B16F10 tumors showed a significant 
number of collapsed blood vessels (Figures 3-8A, C and D). Most blood vessels 
were <10 μm in diameter. After treatment with paclitaxel NPs, there was an 
increase in median blood vessel diameter. When treated with a combination of 
paclitaxel NPs and tPA, the median vessel diameter was found to increase even 
further (Figure 3-8B, C and F). It is interesting to note that regardless of treatment, 
the diameter of most blood vessels was <10 μm. However, treatment with 
paclitaxel alone or in combination with tPA led to the appearance of blood vessels 
in the 10-20 μm diameter range (Figures 3-8E-F).  
We were further interested in obtaining real-time physiological information 
regarding blood perfusion in response to fibrinolytic therapy. Ultrasound imaging 
was used to track blood vessels in subcutaneous B16F10 tumors.  
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Figure 3-8. Effect of tPA treatment on tumor blood vessel diameter and tumor 
perfusion 
(A) Compressed blood vessel in saline-treated tumor (B) Decompressed blood 
vessel in tumor treated with combination therapy (C) shows median blood vessel 
diameter in animals treated with different treatments Representative histograms 
showing blood vessel diameter in animals treated with (D) saline (E) paclitaxel NPs 
and (F) paclitaxel NPs and tPA. Representative sonograms of B16F10 tumors 
treated with three doses of (G-I) saline and (J-L) tPA (M) mean perfusion area in 
saline and tPA treated tumors. Data represented as mean ± S.E.M., n=3-5, 
*p<0.05, Student’s t-test.  
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In saline treated animals, tumor perfusion area reached a maximum of ~1% 
after the second dose (Figure 3-8G-I). At all time points analyzed, tPA-treated 
tumors displayed a greater perfusion area (~3-4 fold higher) as compared to saline 
treated animals. In animals treated with tPA, tumor perfusion area was maximal 
after the second dose (~4% of tumor area) (Figure 3-8J-M). Difference in perfusion 
area was statistically significant after the second dose (p<0.05).  
3.4.6 Migration of tPA functionalized nanoparticles across fibrin matrix 
In an effort to co-localize the enzyme and NPs, we surface functionalized PLGA 
NPs with tPA. tPA functionalized NPs had a particle size of ~250 nm and a net 
negative zeta potential. The conjugation efficiency of the reaction was found to be 
~50-60% (Table 3-2). Additionally, 94% of the enzyme was found to be active after 
the conjugation procedure.  
Table 3-2. Physicochemical characterization of tPA functionalized 
nanoparticles 
Data represented as mean ± S.E.M 
 
 
We determined the ability of tPA functionalized NPs to migrate across a fibrin 
matrix using a Transwell® assay. Enzyme functionalized NPs were able to migrate 
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across fibrin gels more efficiently than non-functionalized NPs (Figure 3-9). After 
an initial lag time, tPA functionalized NPs accumulated in the bottom chamber. 
 
Figure 3-9. In vitro mobility of tPA functionalized nanoparticles 
Mobility of tPA functionalized NPs was measured in a Transwell® study as 
described before. The mobility of enzyme functionalized NPs was significantly 
improved as compared to non-functionalized NPs. Results represented as mean ± 
S.D., n=3.  
 
3.4.7 Anti-cancer efficacy of tPA functionalized nanoparticles 
We determined the anti-cancer activity of tPA functionalized NPs in an 
orthotopic lung cancer model (Figure 3-10A) and in a syngeneic mouse model of 
melanoma (Figure 3-10B). tPA functionalized NPs successfully inhibited tumor 
growth in both models. However, the treatment efficacy was comparable to that of 
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non-functionalized NPs. Thus, surface functionalization with tPA did not result in 
any improvement in anti-cancer activity. 
 
 
Figure 3-10. Anti-cancer activity of tPA functionalized nanoparticles 
The anti-cancer efficacy of tPA functionalized NPs was determined in (A) 
orthotopic lung cancer model and (B) syngeneic melanoma model. The anti-cancer 
efficacy of enzyme functionalized NPs was comparable to that of non-
functionalized NPs. Results represented as mean ± S.E.M., n=6-10 animals/group. 
Tumor inhibition of tPA functionalized nanoparticles was determined with other 
treatment groups reported in Figures 3-6 and 3-7. Data for saline and paclitaxel 
nanoparticle treated groups from Figures 3-6 and 3-7 are plotted here again.  
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3.4.8 Accumulation of paclitaxel in lung tumors 
 
Figure 3-11. Lung tumor accumulation of paclitaxel 
SCID animals bearing lung tumors were treated with various formulations of 
paclitaxel. Animals were sacrificed 2 h and 6 h after treatment administration. 
Paclitaxel concentrations in the (A) lungs (B) liver and (C) spleen were measured 
using LC-MS/MS. Results reported as mean ± S.E.M., n=3 animals/group. 
*indicates p<0.05 vs. PTX-tPA- NPs and PTX NPs + tPA, one-way ANOVA, post-
hoc Tukey.  
 
We determined the lung tumor accumulation of various formulations of 
paclitaxel. Treatment with NP formulations led to higher lung concentration than 
treatment with drug solution. Animals treated with a combination of paclitaxel NPs 
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and tPA or tPA functionalized NPs had a ~10-fold lower accumulation of paclitaxel 
in the lungs as compared to those treated with paclitaxel NPs alone (Figure 3-
11A). Accumulation of the NPs in the liver and spleen was comparable (Figure 3-
11B and C). 
3.4.9 Effect of tPA on macrophage uptake of nanoparticles 
 
Figure 3-12. Effect of tPA on macrophage uptake of nanoparticles 
Coumarin-6 loaded NPs were incubated with J774 cells in the presence or 
absence of tPA. NP uptake in the cells was determined using HPLC and cell 
protein content was determined using BCA. Results represented as mean ± S.D., 
n=4.  
 
Previous reports suggest that tPA can affect macrophage function. These 
include polarization of macrophages to a M1 phenotype and production of NF-kB 
[46, 474]. We were interested in determining if the decreased lung accumulation 
of tPA conjugated NPs was mediated via an increased macrophage uptake. We 
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measured the macrophage uptake of NPs in the presence and absence of tPA. 
Macrophage uptake of NPs with or without tPA was similar (Figure 3-12).  
3.5 Discussion 
Incomplete elimination of tumor cells and disease recurrence are important 
limitations of current anticancer therapies. There are several factors responsible 
for this. These include overexpression of efflux transporters on the tumor cell 
surface, acidity of the tumor microenvironment, instability or lack of drug activity in 
hypoxic or reducing microenvironment of the tumor [460]. An under-studied yet 
significant factor responsible for poor efficacy is limited drug delivery to large 
regions within the tumor [92, 460].  Parts of the tumor that receive low drug 
concentrations also receive low concentrations of oxygen [93]. These hypoxic 
regions harbor more aggressive and resistant tumor cells [475]. Hence, it is even 
more important to deliver high drug concentrations to these under-supplied regions 
of the tumor.  
Tumor blood vessels are formed in response to pro-angiogenic factors secreted 
by tumor cells [110]. An imbalance in pro- and anti-angiogenic factors within the 
tumor tissue results in the formation of blood vessels that are abnormal and porous 
[111]. Fluid from these porous blood vessels leaks out into the tumor 
microenvironment. Due to the lack of functional lymphatics in the core of the tumor, 
fluid accumulates in the tumor [13]. This results in diminished transvascular 
pressure gradient in certain regions of the tumor [13]. Additionally, because of fast 
dividing cells in a limited area and a highly dense ECM, blood vessels in the core 
of the tumor are compressed and non-functional [202]. Consequently, drug 
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exchange through convection is highly compromised [181]. Improving fluid 
dynamics in the tumor is therefore likely to have a significant impact on the delivery 
of drugs to tumors and can progress the state of chemotherapy. 
Several strategies have been used for improving drug transport within the 
tumor[460]. Anti-angiogenics have been used to modify the faulty vascular 
architecture in the tumor. The use of anti-angiogenics results in the normalization 
of blood vessels, leading to a reduced fluid leakage out of the blood vessels, and 
a decrease in interstitial fluid pressure [111]. Consequently, convectional transport 
across blood vessels increases. On the other hand, decreasing the production or 
degrading the ECM in the tumor has also been shown to improve drug delivery. 
Decreasing the density of ECM can improve the diffusivity of the carrier/drug in the 
tumor matrix. Moreover, it can lead to decompression of the collapsed blood 
vessels in the tumor. This increases the perfusion area within the tumor and 
improves the efficiency of drug delivery [418, 419].  
Due to the leaky nature of tumor blood vessels, there is significant fibrinogen 
deposition within the tumor. The prothrombogenic activity of the tumor 
microenvironment leads to the activation of fibrinogen to fibrin. The role of fibrin in 
tumor growth and metastasis has been well studied [476-479]. During the initial 
stages of tumor growth, fibrin provides a scaffold for the growth of tumor cells. 
Fibrin also plays an important role in the angiogenesis, modulating the influx 
macrophages and in the storage of growth factors [126, 480]. Depletion of 
fibrinogen has also been shown to reduce formation of pulmonary metastatic foci. 
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This effect is likely due to the loss of fibrinogen mediated protection of tumor cells 
against NK cells [478].  
However, the role of fibrin in limiting drug delivery to tumors has not been 
studied previously. In the current study, we hypothesized that degrading fibrin 
within the tumor ECM may reduce solid stress within the tumor and improve the 
intratumoral distribution of drug carriers. Through immunohistochemistry studies, 
we found that treatment with tPA led to an increased blood vessel diameter. This 
data was supported by increased tumor perfusion as noted by ultrasound imaging. 
Importantly, co-administration of tPA led to an improved chemotherapeutic activity 
of paclitaxel nanoparticles in a syngeneic model of mouse melanoma and 
orthotopic human lung cancer model.  
Fibrin expression in tumors has been a topic of considerable interest. 
Consequently several studies have analyzed the expression of fibrin in different 
animal tumor models [131, 471]. However, a systematic analysis of fibrin 
expression in human tumors has not been conducted. We examined the level of 
fibrin expression in several human tumor biopsies. Fibrin levels were found to be 
variable, with no tumor type showing either a complete lack or consistently high 
level of fibrin. There are several reasons cited for this heterogeneity in fibrin 
expression. Current immunohistochemistry techniques cannot distinguish between 
fibrinogen and cross-linked fibrin. Additionally, bleeding during the collection of the 
tumor biopsy can also significantly affect the results [126]. Accurately quantifying 
fibrin levels in tumors is important to successfully advance adjuvant fibrinolytic 
therapy. Novel peptides that specifically identify fibrin may be useful [481, 482].  
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The clinical use of anti-coagulants and fibrinolytic therapies in cancer patients 
has been reported before [483-487]. These studies have shown that administration 
of anti-coagulants such as heparin and warfarin improve mean survival in patients 
with small cell lung cancer. The rationale presented for the use of anti-coagulants 
is that it reduces the occurrence of spontaneous thromboembolism and tumor cell 
dissemination [486, 488]. Some studies have reported the beneficial effects of 
using urokinase in conjunction with chemotherapy [483]. The mechanism for the 
improved response to chemotherapy was not explored.  
In our studies, the benefit of tPA on the anti-cancer activity of paclitaxel 
manifested itself in a particle-size dependent manner. The greatest improvement 
in anti-cancer activity was observed at the largest particle size. This effect may be 
dependent on the tumor model used in our studies. Though highly compressed, 
the blood vessels in B16F10 tumors may be permissive to the entry of paclitaxel 
in solution and Abraxane®. Thus, the distance between functional blood vessels 
for these formulations in this tumor model is not large. A low diffusion distance 
coupled with moderately high diffusivity of the drug in these formulations may 
enable efficient intratumoral distribution. Hence, improving the vascularity of the 
tumor any further does not impact the chemotherapeutic activity of these 
formulations. On the other hand, the blood vessels in B16F10 tumors may not be 
permissive to the entry of large nanoparticles. Additionally, the diffusivity of large 
NPs would be orders of magnitude lower than that of the other formulations. 
Previous work shows that decrease in diffusivity of large NPs in tumor matrices is 
greater than what would be expected by Stokes-Einstein law [489]. Hence, 
144 
 
improving vascular function and decreasing intra-vessel distance in the tumor will 
likely affect the chemotherapeutic activity of larger NPs. Studies in tumors with a 
lower degree of vascularity may help address the mechanism further.  
The time course of change in perfusion area with tumor volume is also 
interesting. Perfusion area in untreated tumors and tPA treated tumors was highest 
after the second dose of treatment. The perfused area in tPA treated tumors was 
found to be ~3-4 fold higher than saline treated tumors at each time point. Previous 
work has shown that blood flow generally decreases with an increase in tumor 
volume [490]. The disparity in results may be due to different techniques used for 
measurement of blood flow. Lack of sensitivity of the ultrasound technique may 
have limited our ability to detect blood vessels in small tumors.  
Studies with anti-angiogenic therapy have shown that there is a time window 
associated with the normalization of blood vessels [402, 491, 492]. In other words, 
the decrease in interstitial fluid pressure is transient. The improvement in drug 
delivery is maximal in this time window. It is conceivable that a similar phenomenon 
may occur with tPA treatment as well. Modeling reports suggest that an increased 
perfusion in leaky blood vessels can result in a rapid increase in interstitial fluid 
pressure [493]. This would quickly neutralize the advantage obtained with 
increased perfusion. Moreover, tPA has a short half-life. If the deposition of fibrin 
in tumors is rapid, the decrease in fibrin content of the tumor will likely be observed 
only for a short period of time. The pharmacokinetics of NP and tPA accumulation 
in the tumor may also be different. Additional studies are needed to determine the 
optimal frequency of tPA dosing and the time window following tPA dosing when 
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the improvement in drug delivery is maximal. Further, we have only considered 
Abraxane and PLGA NPs in this study. The effect of tPA co-delivery on other 
nanoparticulate systems of intermediate sizes would be of interest as well. A 
careful consideration of all these aspects can help maximize benefits obtained 
from this strategy.  
An important difference between collagen or hyaluronic acid and fibrin is the 
mechanism of deposition into the tumor matrix. Both collagen and hyaluronic acid 
are synthesized by the tumor cells. On the other hand, fibrin is deposited into 
tumors due to the leaky tumor blood vessels. This indicates that the leakiness of 
tumor blood vessels is a prerequisite for fibrin occurrence in tumors. As mentioned 
previously, tumors with leaky blood vessels are less likely to benefit from improved 
perfusion due to a rapid increase in interstitial fluid pressure. It might be of interest 
to combine anti-angiogenic therapy with fibrinolytic therapy to improve tumor 
perfusion for prolonged time intervals. 
We successfully conjugated tPA on the surface of NPs and found it to be active 
after the conjugation procedure. We hypothesized that conjugating tPA on the NPs 
may help co-localize the NPs with enzyme, potentially increase its half-life and 
tumor accumulation. All these effects could, in turn, improve the adjuvant activity 
of tPA. Unfortunately, tPA functionalized NPs had comparable activity to non-
functionalized NPs. The current study did not analyze the mechanism for the loss 
of activity. One possible reason could be the decrease in mobility of tPA due to its 
conjugation to the NPs.  
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The results of the lung tumor accumulation study are difficult to explain. Co-
treatment with tPA, either as free enzyme or conjugated on the NP surface, 
decreased the lung accumulation of NPs. One of the major organs that can 
influence the biodistribution of NPs is the liver. The accumulation of the different 
formulations in the liver was comparable. It is however possible that the current 
analysis may not be able to detect a difference in liver accumulation due to the 
rapid metabolism of paclitaxel. Given that there is some evidence in literature of 
tPA-mediated activation of macrophages [474], we measured the macrophage 
uptake of NPs in response to co-incubation with tPA. We did not find any effect of 
tPA on the uptake of NPs. Other evidence suggests that tPA is rapidly taken up by 
the hepatic cells and endothelial cells in the liver [494-497]. Uptake of tPA in the 
endothelial cells occurs through mannose receptors [494]. Alternately, uptake of 
tPA in liver parenchyma occurs via a receptor that binds a complex of tPA and 
plasminogen activator inhibitor, which is abundantly expressed in the liver [495]. 
While these results may partly explain the decreased lung accumulation of tPA 
conjugated NPs, the reason for the decreased lung accumulation of paclitaxel in 
combination therapy is still unclear. A detailed understanding of this phenomenon 
may prove useful for advancing this therapy. 
3.6 Conclusion 
Poor vascular architecture and lack of tumor perfusion limits the overall efficacy 
of chemotherapy. Fibrin deposition within the tumor can be an important cause for 
the compression of tumor blood vessels. Administration of tPA improved blood 
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supply to solid tumors and enhanced chemotherapeutic activity of paclitaxel in 
polymeric NPs.  
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Chapter 4 Reformulating Tylocrebrine in EGFR Targeted 
Polymeric Nanoparticles Improves its Therapeutic 
Index3 
 
                                                           
3 This chapter is published elsewhere [293]. Reproduced with permission.  
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4.1 Summary 
Several promising anti-cancer drug candidates have been sidelined owing to 
their poor physicochemical properties or unfavorable pharmacokinetics, resulting 
in high overall cost of drug discovery and development. Using alternative 
formulation strategies that alleviate these issues can help advance new molecules 
to the clinic at a significantly lower cost. Tylocrebrine is a natural product with 
potent anti-cancer activity. Its clinical trial was discontinued following the discovery 
of severe central nervous system toxicities. To improve the safety and potency of 
tylocrebrine, we formulated the drug in polymeric nanoparticles targeted to the 
epidermal growth factor receptor (EGFR) overexpressed on several types of 
tumors. Through in vitro studies in different cancer cell lines, we found that EGFR 
targeted nanoparticles were significantly more effective in killing tumor cells than 
the free drug. In vivo pharmacokinetic studies revealed that encapsulation in 
nanoparticles resulted in lower brain penetration and enhanced tumor 
accumulation of the drug. Further, targeted nanoparticles were characterized by 
significantly enhanced tumor growth inhibitory activity in a mouse xenograft model 
of epidermoid cancer. These results suggest that the therapeutic index of drugs 
that were previously considered unusable could be significantly improved by 
reformulation. Applying novel formulation strategies to previously abandoned 
drugs provides an opportunity to advance new molecules to the clinic at a lower 
cost. This can significantly increase the repertoire of treatment options available to 
cancer patients. 
 
150 
 
4.2 Introduction 
Much of current cancer research is focused on exploring novel targets and 
discovering new anticancer drugs. While the availability of new molecules certainly 
offers hope to patients who do not respond to existing drugs, development of each 
new molecule is associated with tremendous costs [498, 499]. Many highly active 
drug candidates have been shelved because of poor physicochemical and/or 
pharmacokinetic characteristics [500-502]. Re-formulation of such molecules can 
overcome their unfavorable biological behavior, and would offer a less expensive 
approach to anticancer drug development [501, 503, 504]. 
Tylocrebrine, a phenanthropiperidine alkaloid, is an example of a drug with 
potent anti-cancer activity and whose clinical trial was discontinued following the 
discovery of severe central nervous system (CNS) toxicities. The CNS toxicities of 
the drug were likely caused by its extensive penetration into the brain [505, 506]. 
We hypothesized that encapsulation of tylocrebrine in poly(lactide-co-glycolide) 
(PLGA)-based polymeric NPs will limit the distribution of the drug to the CNS, 
potentially decreasing its neurological toxicities. Additionally, NPs are known to 
passively accumulate in the tumor tissue through the enhanced permeability and 
retention (EPR) effect [507, 508]. The combination of these properties should 
result in significantly improved therapeutic index. To further enhance the tumor cell 
uptake and retention of NPs, we functionalized the NP surface with a peptide 
capable of targeting the epidermal growth factor receptor (EGFR) [227, 228], which 
is over-expressed on the cell membrane of multiple solid tumors [386]. Using in 
vitro and in vivo models of EGFR-overexpressing tumors, we evaluated the 
therapeutic benefit of encapsulating tylocrebrine in NPs. Our studies show that this 
151 
 
reformulation strategy significantly improved the anti-tumor efficacy while reducing 
the brain penetration of tylocrebrine. 
 
4.3 Materials and methods 
4.3.1 Materials 
Amine terminated poly(ethylene glycol) (molecular weight: 3400 Da) was 
purchased from Laysan Bio Inc. (Arab, AL). PLGA (50:50 molar ratio of lactide-
glycolide, molecular weight ~40 kDa) was purchased from Lactel (Birmingham, 
AL). Poly(vinyl alcohol) (molecular weight 30-70 kDa) and lactic acid were obtained 
from Sigma-Aldrich Co. (St. Louis, MO). EGFR targeting peptide 
(YHWYGYTPQNVI) and scrambled peptide (HWPYAHPTHPSW) were obtained 
from Peptide 2.0, Inc. (Chantilly, VA). Radioimmunoprecipiation (RIPA) buffer and 
bicinchoninic acid (BCA) assay kit were obtained from Thermo Scientific 
(Rockford, IL). All other chemicals were obtained from Sigma-Aldrich Co. (St. 
Louis, MO). Tylocrebrine was synthesized as described previously [509].  
4.3.2 Cell culture 
A549 human lung cancer cell line was obtained from ATCC. A431 human 
epidermoid cancer cells were obtained from Dr. Benjamin Hackel (University of 
Minnesota). A549 cells were cultured in Dulbecco’s Minimum Essential Media 
(DMEM) while A431 cells were grown in Roswell Park Memorial Institute media 
(RPMI-1640). Both media were supplemented with 10%v/v fetal bovine serum and 
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1%v/v penicillin-streptomycin. The cells were grown in a humidified environment 
consisting of 5% CO2/95% air and maintained at 37 °C. 
 
4.3.3 Effect of extracellular pH on cell uptake of tylocrebrine 
We determined the effect of extracellular pH on the cell accumulation of 
tylocrebrine. For low pH conditions, serum free RPMI was acidified with 9.1 %v/v 
0.1M HCl. The pH of acidified RPMI was maintained between 6.3-6.7 for 6 h when 
placed under routine cell culture conditions.   
A431 cells were seeded in a 24-well plate (5x104 cells/well) and allowed to 
adhere overnight. Tylocrebrine was first dissolved in 1 M HCl (1:1 molar ratio) and 
then diluted in serum-free RPMI to prepare a stock solution of 1 mg/mL. The stock 
solution was then diluted to 5 μg/mL in neutral or acidic serum-free RPMI and 
added to the cells. Treatments were removed 1 h later, and the cells were washed 
with cold 0.15 mM phosphate buffered saline (pH 7.4, henceforth referred to as 1X 
PBS). Cells were digested with RIPA buffer (0.1 mL) for 15 min and the cell lysate 
was divided into two parts. One part (20 μL) was analyzed by BCA assay to 
determine cell protein concentration (ELx800 absorbance microplate reader, 
Biotek Inc., Winooski, VT). The other part (80 μL) was extracted overnight with 
methanol and tylocrebrine concentration in the methanol extract was analyzed 
using HPLC. HPLC was performed on a Beckman Coulter HPLC system equipped 
with a System Gold 508 autosampler was used. A Beckman Coulter C18 column 
(4.6 mm x 250 mm, 5 μm) was used as the stationary phase. The mobile phase 
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consisted of 80:20 mix of acetonitrile and 87 mM ammonium acetate (pH 4.2), run 
isocratically at a flow rate of 1 mL/min. Tylocrebrine was analyzed by measuring 
absorbance at 265 nm using a System Gold UV detector. 
4.3.4 Synthesis of carboxyl terminated block co-polymer of poly(lactide) 
and poly(ethylene glycol) 
A block co-polymer of poly(lactide) (PLA) and carboxyl terminated 
poly(ethylene glycol) (PEG-COOH) was synthesized in a two-step process. In the 
first step, lactic acid was reacted with amine-terminated PEG to generate an 
amine-terminated block co-polymer (PLA-PEG-NH2) [510]. In the second step, the 
terminal amino group was reacted with succinic anhydride to produce PLA-PEG-
COOH [228].  
All glassware were rinsed with toluene and dried overnight at 100°C prior to 
both reactions. For step 1, amine-terminated PEG (400-500 mg) was dissolved in 
~80 mL dichloromethane and added to a round bottom flask. The mixture was 
stirred in the presence of N2 gas for 10 minutes. Lactic acid (2 g) was added to this 
mixture and stirred for 10 minutes. About 20 μL of 1, 8 diazabicyclo [5,4,0] undec-
7-ene was added as a catalyst and the reaction was allowed to proceed for 1 hour. 
After 1 h, the solvent was reduced to ~20 mL using a rotovap. The solution was 
added drop-wise to chilled diethyl ether to precipitate the amine terminated block 
co-polymer. The suspension was filtered and the solid was dried at 25°C in a 
vacuum oven. The product was dissolved in deuterated chloroform and 
characterized using 1H-NMR (Varian 400 MHz).  
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For step 2, the amine terminated block co-polymer (1 g) was dissolved in 50 
mL tetrahydrofuran and 5 mL triethyl amine in a round bottom flask. The mixture 
was stirred under N2 gas for 10 minutes. Succinic anhydride (molar ratio of succinic 
anhydride to block co-polymer was 1.1:1) was added to this solution. The reaction 
was allowed to proceed at 50°C for 2 h. The reaction mixture was then 
concentrated using a rotavap and added to cold diethyl ether to precipitate the 
polymer. The polymer was filtered and dried in a vacuum oven at 25°C. The 
product was dissolved in deuterated chloroform and characterized by 1H NMR. 
4.3.5 Synthesis, optimization and physicochemical characterization of 
nanoparticles 
PLGA NPs loaded with tylocrebrine and surface functionalized with carboxyl-
terminated PEG were synthesized by the interfacial activity assisted surface 
functionalization (IAASF) technique developed by our lab [33, 210].  
Briefly, PLGA (30-35 mg) and tylocrebrine (5 mg) were dissolved in 1 mL 
chloroform. An aqueous solution of 2%w/v poly(vinyl alcohol) in 1X PBS was 
prepared. The polymer-drug mixture was added to the aqueous surfactant to form 
an o/w emulsion. The emulsion was probe sonicated at an output of 18-21 W for 5 
minutes over an ice bath (Sonicator XL, Misonix, NY) and then stirred at 650 rpm 
on a magnetic stir plate. PLA-PEG-COOH (8 mg) dissolved in 0.2 mL chloroform 
was added drop-wise to the emulsion. The organic solvent was evaporated 
overnight under ambient conditions and then for 2 hours under vacuum. The NP 
dispersion was washed twice with 30 mL 1X PBS by ultracentrifugation (35000 
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rpm, 35 min, 4°C) (Beckman, Palo Alto, CA). After the second wash, NPs were 
dispersed in 1.5 mL 1X PBS. To this dispersion, 0.7 mg N-hydroxysuccinimide 
(NHS), 1.14 mg 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide 
hydrochloride (EDC) and 1.8 mg targeting or control peptide were added, and the 
reaction was allowed to proceed for 3, 5 or 8 hours. Following the conjugation 
reaction, NPs were dispersed in 30 mL deionized water and centrifuged (35000 
rpm, 35 min, 4°C) to remove unconjugated peptide. The NP pellet was redispersed 
in ~10 mL deionized water, frozen below -50°C for 2 h, and lyophilized (Labconco 
FreeZone 4.5, Kansas city, MO). The lyophilized formulation was stored at -20°C.  
To determine particle size and zeta potential, a dispersion of NPs (~1 mg/mL) 
was analyzed by dynamic light scattering (DelsaTM Nano C, Beckman Coulter, 
Fullerton, CA).  
To determine drug loading, NPs were dispersed in a mixture of methanol and 
acetic acid (95:5 v/v). Drug was extracted overnight at room temperature. NPs 
were separated from the extract by centrifugation (14000 rpm, 15 min, 4°C). The 
supernatant was analyzed by HPLC.  
The amount of peptide on the surface of NPs was determined using BCA. NPs 
were dispersed in deionized water and incubated with the BCA reagent for 20 
minutes at 37°C. The NP dispersion and standards were then centrifuged (14000 
rpm, 15 minutes, 25°C), and the absorbance of the supernatant was measured at 
562 nm (ELx800 absorbance microplate reader, Biotek Inc., Winooski, VT). 
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Drug release kinetics was assessed in pH 7.4 and 6.5 buffers. NPs were 
dispersed in a sufficient volume of 1X PBS (pH 7.4 or 6.5) to maintain sink 
conditions. The dispersions were kept on a shaker at 37°C and 100 RPM [C24 
incubator shaker, New Brunswick Scientific (now Eppendorf Inc. Enfield, CT)]. At 
various time points, the released drug was separated from NPs using a MicroKros 
filter module (Spectrum Labs, Rancho Dominguez, CA). The NP concentrate was 
retrieved and redispersed in the buffer. Drug solution was lyophilized, dissolved in 
a mixture of methanol and acetic acid (95:5 v/v), and analyzed by HPLC.  
4.3.6 Cellular uptake of EGFR-targeted and non-targeted nanoparticles 
We first determined whether cellular uptake of EGFR targeted NPs was higher 
than non-targeted NPs, and if their uptake was mediated by EGFR. A549 cells 
were seeded in a 24-well plate at a seeding density of 5 x 104 cells/well and allowed 
to adhere overnight. On the next day, NPs loaded with a fluorescent dye (coumarin 
6), in the presence or absence of excess free targeting peptide, were added to the 
cells. Cells were incubated with the treatments at 4°C for 1 h, washed twice with 
1X PBS, and incubated with fresh media at 37°C. After 1 h, the media was 
aspirated, cells were washed with 1X PBS, and lysed with RIPA buffer. One part 
of the lysed cells was extracted with methanol and coumarin 6 content was 
determined using HPLC [210]. The other part was analyzed by BCA assay to 
determine the amount of cell protein.  
We also compared the cell uptake of targeted and non-targeted NPs loaded 
with tylocrebrine. A431 cells were seeded in a 24-well plate as described above. 
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On the day of the experiment, tylocrebrine loaded NPs, dispersed in serum-free 
media, were added to the cells (100 μg NPs/mL). After 1 h, the media was 
aspirated and the cells were washed thrice with cold 1X PBS. The cells were then 
lysed with 0.1 mL RIPA buffer for 15 minutes. The cell lysate was divided into two 
parts. One part (20 μL) was analyzed by BCA assay to determine the amount of 
cell protein. The other part (80 μL) was extracted with a mixture of methanol and 
acetic acid (95:5 v/v). Tylocrebrine concentration in the methanolic extract was 
determined using HPLC.  
4.3.7 In vitro efficacy of various formulations of tylocrebrine 
We compared the tumor cell kill efficacy of free drug, non-targeted and targeted 
NPs in both neutral and acidic media. A549 cells or A431 cells were seeded in a 
96-well plate (8x103 cells/well) and allowed to attach overnight. NPs or free drug 
were dispersed in serum-free RPMI media to form a stock solution. This stock 
solution was then diluted with either neutral or acidified serum-free media and 
added to the cells at various dilutions. The treatments were removed 6 h later, and 
the cells were washed with cold 1X PBS. The cells were then incubated with serum 
containing media for further 90 h. Cell viability was measured using CellTiter 96® 
AQueous One Solution Cell Proliferation Assay kit (Promega, Madison, WI) 
according to the supplier’s protocol.  
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4.3.8 Pharmacokinetics and biodistribution of various formulations of 
tylocrebrine 
All the animal studies described here were approved by the University of 
Minnesota’s institutional animal care and use committee. 
We determined the pharmacokinetics of tylocrebrine in a mouse tumor model. 
A431 cells (1-2x106) were dispersed in 0.05 mL 1X PBS and injected 
subcutaneously in female athymic nude mice (4-6 weeks old, Taconic Biosciences, 
Hudson, NY). The tumors were allowed to grow to a volume of ~300 mm3. Mice 
were lightly anesthetized using isofluorane and treated with various formulations 
of tylocrebrine (dose: 12 mg/kg; dosing volume: 10 mL/kg) via retroorbital injection.   
The free drug formulation was prepared by dissolving the drug in 1M HCl (1:1 
molar ratio), and diluting the solution with saline. Excess acid was neutralized with 
1M NaOH to obtain a final drug concentration of 1.2 mg/mL. To prepare NP 
treatments, NPs were dispersed in saline and probe sonicated at an output of 18-
21 W thrice for 30 sec each on an ice bath. The NP dispersion was centrifuged 
(1000 rpm, 5 min) to remove any large aggregates and the supernatant was used.  
At various time points, cohorts of mice were sacrificed and blood was collected 
by cardiac stick. Key organs and the tumor were excised. Tissues were 
homogenized in ~1 mL deionized water and lyophilized. The dry organs were then 
extracted overnight with a mixture of methanol and acetic acid (95:5). The extract 
was separated by centrifugation and dried under N2 gas. The dried residue was 
redispersed in a mixture of acetonitrile and acetic acid (95:5). The resulting 
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suspension was centrifuged (14000 rpm, 15 min, 4°C), and the supernatant was 
used for LC-MS/MS analysis. 
LC-MS/MS was performed using an Acquity UPLC system equipped with a 
Waters/Micromass QuattroTM Ultima mass spectrometer. Liquid chromatography 
was performed using Agilent XDB-C18 column (4.6 mm x 50 mm, 1.8 μm) as the 
stationary phase. A mixture of 10 mM ammonium acetate with 0.06%v/v acetic 
acid and acetonitrile (55:45 v/v) was used as the mobile phase. The flow rate was 
0.4 mL/min, and the run time was set to 6 minutes. The mass spectrometer was 
run in the electrospray positive mode. The mass spectrometer conditions were as 
follows: cone voltage, 50 V; collision voltage, 20 V; dwell time, 0.4 seconds. 
Tylocrebrine was detected by monitoring the m/z transition of 394324.9.  
Concentration of tylocrebrine was normalized to tissue weight and injected 
dose, and was represented as % injected dose (ID)/g of organ weight. Drug 
exposure in each tissue was determined by calculating the area under the 
concentration curve (AUC). AUC was calculated using the trapezoidal rule. The 
relative benefit of using the nanoparticulate formulation over the free drug was 
determined using the drug targeting index (DTI) [450]. The DTI was calculated as 
shown below: 
 =  \
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}
 
 
160 
 
4.3.9 Tumor inhibition studies 
The therapeutic efficacy of various formulations of tylocrebrine was determined 
in a mouse model of epidermoid cancer. About 1x106 A431 cells, suspended in 50 
μL 1X PBS, were injected subcutaneously in female nude mice. The dimensions 
of the tumor were measured periodically using a digital caliper. Tumor volume was 
calculated as 0.5 ∗ Ud	ℎ ∗ %	ℎI. When tumor volume reached ~75 mm3, 
animals were treated with saline, free drug, non-targeted NPs or EGFR targeted 
NPs (3 doses, every 96 h, 12 mg/kg). The treatments were prepared and 
administered as described in the biodistribution study.  
At the end of the study, animals were sacrificed and the tumors were excised. 
The tumors were fixed using 5% formalin solution in 1X PBS for 24 hours. After 
the initial fixation, tumors were preserved in 70% ethanol. Microtome sectioning 
was performed on the fixed and mounted tumor samples, and the sections were 
stained for cleaved caspase 3 (to determine apoptosis) and Ki67 (as a marker of 
proliferation). Staining of tumor sections was quantified using ImageJ 1.48v 
software. To determine apoptotic and proliferative indices, the fraction of the total 
cellular area that stained positive for the individual markers was determined and 
presented as apoptotic and proliferative indices.  
4.3.10 Statistical analysis 
All statistical analyses were performed using One-way ANOVA and post-hoc 
Tukey test. For the efficacy study, a linear model was fit to log transformed tumor 
values. Slopes of the tumor growth profile were analyzed at each time point for 
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each animal. One-way ANOVA and post-hoc Tukey test was performed to 
determine if the differences in various treatments were statistically significant. A P 
value < 0.05 was considered statistically significant.  
 
4.4 Results 
4.4.1 Effect of extracellular pH on the cell uptake of tylocrebrine 
Tumors are often characterized by increased production of lactic acid due to 
the Warburg effect [511]. Impaired drainage of the acid from the tumor 
microenvironment leads to low extracellular pH in the tumor [512]. Tylocrebrine is 
a weak base and is ionized under acidic conditions. Ionization of the drug molecule 
can decrease its diffusion across the cell membrane and hence lead to decreased 
intracellular drug availability [513]. We measured the effect of extracellular pH on 
drug accumulation in A431 cells (Figure 4-1). Decreasing the pH of the media from 
7.4 (physiologic) to 6.3-6.7 (to mimic tumor microenvironment) resulted in reduced 
drug uptake (~60% reduction). This is likely due to the protonation of the 
indolizidine nitrogen, leading to a positive charge on the molecule [514]. 
To overcome this unfavorable ionization of tylocrebrine and reduced availability 
inside the cells, we formulated the drug in EGFR-targeted polymeric NPs. NPs 
loaded with tylocrebrine and surface functionalized with PEG-COOH were first 
fabricated using the IAASF technique. These NPs were then conjugated to either 
the EGFR-targeting peptide or a control, non-targeting peptide.  
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Figure 4-1.  Effect of extracellular pH on cellular accumulation of 
tylocrebrine 
Tylocrebrine (as free drug) was incubated with A431 cells at an extracellular 
pH of 7.4 (physiological) or ~6.5 (acidic). Cellular accumulation was measured 
by determining intracellular tylocrebrine concentration using HPLC. 
Tylocrebrine concentration was normalized to cell protein content. Data 
represented as mean ± S.D., n=6, † indicates p<0.005.  
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4.4.2 Synthesis and NMR analysis of block-copolymer 
PLA-PEG-COOH block copolymer was used to incorporate carboxyl groups on 
the surface of PLGA NPs. We synthesized PLA-PEG-COOH through a two-step 
Figure 4-2. 1H-NMR spectra of PLA-PEG block co-polymers 
Block co-polymer of PLA and carboxyl terminated PEG was synthesized by a 
two-step procedure. The starting material (PEG), intermediate product (PLA-
PEG-NH2) and final product (PLA-PEG-COOH) were dissolved in deuterated 
chloroform and analyzed by 1H-NMR. Conjugation of lactide to PEG was 
confirmed by the appearance of peak at 1.6 and 5.2 ppm. Conjugation of 
succinate to the terminal amine group in PEG was confirmed by appearance of 
peak at 2.6 ppm. 
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reaction, involving the generation of PLA-PEG-NH2 from PEG-NH2, followed by the 
reaction of the terminal amino group with succinic anhydride.  The NMR spectra of 
PEG-NH2, PLA-PEG-NH2, and PLA-PEG-COOH are shown in Figure 4-2. 
Conjugation of lactide to PEG was confirmed by the appearance of peaks at δ=5.3 
ppm and δ=1.6 ppm [515]. Conjugation of succinate moiety to PLA-PEG-NH2 was 
confirmed by the appearance of a peak at δ=2.6 ppm [228]. Based on the AUC of 
the peaks, the molecular weight of PLA was estimated to be ~15 kDa.  
4.4.3 Physicochemical characterization of nanoparticles 
We initially determined the effect of reaction time on drug loading in NPs and 
efficiency of targeting peptide conjugation to the surface of NPs. Increasing the 
Figure 4-3. Effect of conjugation time on targeting peptide conjugation 
efficiency and drug loading  
EGFR targeting peptide was conjugated to the surface of nanoparticles using 
NHS-EDC chemistry. The influence of reaction time on (A) conjugation 
efficiency of the peptide and (B) drug loading is shown. Data represented as 
mean ± S.D., n=3.  
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reaction time resulted in an increase in peptide conjugation efficiency but resulted 
in decreased drug loading (Figure 4-3). Particle size and zeta potential were 
unaffected by the duration of the reaction time. In general, the particle size was 
found to be in the range of 300-400 nm and the particles had a net negative zeta 
potential (Table 4-1). We used an intermediate reaction time (5 h) for achieving 
optimum drug loading and conjugation efficiency. The drug and peptide loading for 
NPs used in the rest of the studies are summarized in Table 4-1. 
The drug release profile from NPs at physiological pH is shown in Figure 4-4 A. 
Both targeted and non-targeted NP formulations showed a characteristic initial 
burst release, followed by sustained release over a period of 48 h. Drug release 
profiles were comparable for both targeted and non-targeted NPs. 
Drug release from NPs was also determined at pH 6.5 (Figure 4-4 B). Drug release 
profiles were comparable to those obtained at physiological pH. However, the 
extent of burst release in acidic pH was higher than that at physiologic pH (~25% 
Vs ~50%).  
Table 4-1. Physicochemical characterization of nanoparticles 
Data represented as mean ± S.E.M., n=3-6  
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4.4.4  Cellular uptake of tylocrebrine loaded nanoparticles 
Using fluorescent dye labeled particles, we first determined if cellular uptake of 
targeted NPs was greater than that of non-targeted NPs. We found that targeted 
NPs resulted in ~2-3 fold higher uptake than non-targeted NPs. Additionally, 
uptake of targeted NPs was reduced (not statistically significant) in the presence 
of excess free targeting peptide (Figure 4-5 A). This indicated that the enhanced 
uptake of targeted NPs could be mediated via EGFR. Additional experiments 
investigating uptake in EGFR knockout cells are needed to confirm this finding. 
Figure 4-4. Drug release kinetics from tylocrebrine nanoparticles 
Nanoparticles were dispersed in (A) 1X PBS (pH 7.4) or (B) 1X PBS (pH 6.5) 
and incubated at 37°C and 100 rpm. Drug release from nanoparticles was 
monitored by analyzing tylocrebrine concentration in the release buffer using 
HPLC. Data represented as mean ± S.D., n=3. 
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We determined the uptake of targeted and non-targeted tylocrebrine NPs in 
A431 cells (Figure 4-5 B). We found that encapsulation of tylocrebrine in targeted 
NPs increased the cellular drug uptake by ~3-fold (p<0.05).  
 
 
Figure 4-5. Cell uptake of EGFR-targeted and non-targeted nanoparticles 
(A) A549 cells were incubated with coumarin 6 loaded targeted nanoparticles with 
or without excess peptide, or non-targeted nanoparticles for 1 h at 4°C. Treatments 
were removed and the cells were incubated in fresh media at 37°C for 1h. 
Intracellular levels of coumarin 6 were estimated using HPLC. (B) A431 cells were 
incubated with tylocrebrine loaded nanoparticles.  After 1 h, treatments were 
removed and the cells were washed. Intracellular tylocrebrine concentration was 
measured using HPLC and normalized to cell protein. Data represented as mean 
± S.D., n=6, * indicates p<0.05 
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4.4.5 In vitro efficacy of various formulations of tylocrebrine 
We compared the in vitro efficacy of various formulations of tylocrebrine in both 
A549 and A431 cells. As our previous results showed that acidic pH led to a 
decreased intracellular accumulation of tylocrebrine, we performed these studies 
under both physiologic as well as acidic pH conditions. The free drug was found to 
be potent in both cell lines under neutral conditions, with an IC50 of 210 and 37 
nM (Figure 4-6 A and C). However, there was a dramatic decrease in the efficacy 
of tylocrebrine under acidic conditions (compare Figures 4-6 A and B, and 4-6 C 
and D). The IC50 of tylocrebrine increased from 210 nM and 37 nM to 432 nM and 
361 nM, respectively. At physiological pH the efficacy of non-targeted tylocrebrine 
NPs was comparable to that of the free drug, while targeted tylocrebrine NPs were 
more effective than the free drug. With a decrease in extracellular pH, IC50 of NP 
formulations remained unchanged in A431 cells, while there was a small increase 
in IC50 for the NP formulations in A549 cells. As a result, both non-targeted and 
targeted tylocrebrine NPs showed superior efficacy than the free drug under acidic 
conditions. The IC50 values estimated from the efficacy studies are summarized 
in Table 4-2. 
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Figure 4-6. In vitro cytotoxicity of tylocrebrine 
A431 and A549 cells were treated with different formulations of tylocrebrine at 
physiological and acidic extracellular pH. Cell viability was measured using MTS 
assay and normalized to untreated controls. Data represented as mean ± S.D., 
n=4.   
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4.4.6 Pharmacokinetics of various formulations of tylocrebrine 
Concentration-time profile of the drug in the tumor is shown in Figure 4-7 A. 
Accumulation of the drug and targeted NPs in the tumor was rapid and reached a 
peak at 0.5 hours. When encapsulated in non-targeted NPs, tumor accumulation 
was slower, reaching a peak at ~2 hours. At 0.5, 2, 4 and 6 h post dose, tumor 
tylocrebrine concentrations in targeted NP treated group were 2-4-fold higher than 
free drug group. Tumor concentration of tylocrebrine in animals treated with non-
targeted NPs was 2-fold higher than the free drug-treated animals only at 2 and 4 
hours post-dose; the concentrations were similar to the free drug treatment group 
at later time points. AUCs of the free drug and non-targeted NPs in the tumor were 
comparable. The AUC of targeted NPs was ~3 fold higher than that of the other 
formulations (Table 4-3).  
Table 4-2. IC50 values of various formulations of tylocrebrine in 
A431 and A549 cells 
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The concentration-time profile of the drug in the brain (the major site of toxicity) 
is shown in Figure 4-7 B. Similar to that in the tumor, there was a rapid 
accumulation of the drug in the brain. However, encapsulation in NPs resulted in 
a 5-fold decrease in brain concentration of the drug at the first time point. Drug 
concentrations in the brain declined rapidly. Overall, animals treated with free drug 
had a 2-fold higher drug exposure in the brain as compared to those treated with 
the NP formulations (Table 4-3). Targeted NPs had a DTI of ~5 because of the 
reduced brain exposure and enhanced tumor exposure.  
The concentration time profile of the drug in the blood is shown in Figure 4-7 
C. NPs resulted in higher blood concentration of the drug relative to that achieved 
after the administration of the free drug. Concentration-time profiles of the drug in 
other key organs are summarized in Figure 4-8.  
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Figure 4-7. Pharmacokinetics of tylocrebrine  
A431 tumor bearing mice were treated intravenously with tylocrebrine in solution 
or encapsulated in nanoparticles. At various time points, concentration of 
tylocrebrine in (A) tumor, (B) brain and (C) blood was measured using LC-MS/MS. 
Data represented as mean ± S.E.M, n=3-4, * indicates p<0.05. 
Table 4-3. On-target AUC, off-target AUC, and DTI of tylocrebrine 
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4.4.7 Tumor inhibition studies 
We determined the anti-tumor efficacy of the different formulations of 
tylocrebrine in A431 tumor model (Figure 4-9). There was a reduction in tumor 
growth rate in animals treated with tylocrebrine solution and non-targeted NPs 
relative to that in the saline treated animals. Treatment with non-targeted 
tylocrebrine NPs and tylocrebrine in solution resulted in comparable activities. In 
Figure 4-8. Biodistribution of tylocrebrine in key organs 
A431 tumor bearing mice were treated with various formulations of tylocrebrine. At 
different time points, animals were sacrificed and key organs were excised. 
Tylocrebrine concentration in these organs were determined using LC-MS/MS. 
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agreement with our pharmacokinetic studies, treatment with EGFR targeted 
tylocrebrine NPs resulted in greater tumor growth inhibition than that with the other 
formulations.  
  
Figure 4-9. In vivo tumor inhibition studies 
Anti-tumor efficacy of various formulations of tylocrebrine was determined in 
mouse A431 tumor model. Tumor bearing mice were treated with three doses of 
tylocrebrine (12 mg/kg) administered at 96 h intervals. Tumor volume was 
measured using a digital caliper. Data represented as mean ± S.E.M., n= 3-4. * 
indicates p<0.05 for saline vs. targeted nanoparticles and non-targeted 
nanoparticles vs. targeted nanoparticles  
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Tumor samples were stained for Ki67 and cleaved caspase 3 to determine the 
proliferative and apoptotic indices, respectively. Representative micrographs of 
Ki67 staining are shown in Figure 4-10. Saline treated animals had significantly 
higher Ki67+ cells as compared to the other treatment groups. There was no 
significant difference in the staining profile of free drug and non-targeted NP 
treated tumors. Tumors treated with targeted NPs had the lowest Ki67 staining. An 
opposite profile was observed for cleaved caspase 3 expression (Figure 4-11). 
Cleaved caspase 3 staining was lowest in saline treated animals and highest in 
animals treated with targeted NPs. Taken together, this data suggests that 
treatment with tylocrebrine inhibited tumor cell proliferation and induced apoptosis, 
with targeted NPs resulting in the greatest decrease in tumor cell viability.  
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Figure 4-10. Ki67 staining in tumor sections 
Tumors were excised at the end of the efficacy study and stained for Ki67. 
Representative micrographs of tumor from animals treated with (A) saline (B) free 
drug (C) non-targeted nanoparticles and (D) targeted nanoparticles are shown. 
(E) shows quantification of Ki67 staining. Data represented as mean ± S.E.M, n= 
6 sections x 3 images/ section. * indicates p<0.05.  
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Figure 4-11. Cleaved caspase 3 staining in tumor sections 
Micrographs of cleaved caspase 3 staining in tumors from animals treated with (A) 
saline (B) free drug (C) non-targeted nanoparticles and (D) targeted nanoparticles 
are shown. Quantification of staining is shown in (E). Data represented as mean ± 
S.E.M, n= 6 sections x 3 images/ section. * indicates p<0.05. 
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4.5 Discussion 
Tylocrebrine was originally isolated in 1962 from the North Queensland vine, 
T. crebriflora [516]. With accumulating evidence that this family of 
phenanthropiperidine alkaloids had anti-cancer properties, tylocrebrine was tested 
and found to be effective in several cancer models [506]. Unfortunately, there were 
unforeseen problems with the drug and clinical trials were terminated before 
tylocrebrine’s therapeutic efficacy could be established in the clinic [505]. CNS 
toxicity, as evidenced by ataxia and disorientation, was considered the major 
reason for abandoning clinical trials. In the decades that followed tylocrebrine’s 
failure in the clinic, medical interest in tylocrebrine and other members of its class 
waned. Recently, however, there has been a resurgence of activity with regard to 
these natural products and their analogs. Many of these alkaloids have been found 
to possess potent and broad spectrum cytotoxicity. Several members of this class, 
including tylocrebrine, were found to inhibit tumor cell growth with GI50 values in 
the low nanomolar to sub-nanomolar range across the NCI 60 cell line panel [517].  
A major barrier to the clinical use of tylocrebrine and other members of its class 
is their neurological side effects [518]. In a review [519], Hitchcock and Pennington 
show that the degree of passive diffusion across the blood-brain barrier (BBB) 
correlates with a molecule’s polar surface area (PSA), number of H-bond donors 
(HBD), cLogP, cLogD and molecular weight [519]. A calculation of these properties 
for tylocrebrine reveals that each of these values is well within the suggested 
parameters for CNS penetrant drugs (Table 4-4). Increasing the hydrophilicity of 
tylocrebrine can potentially decrease its diffusion across the blood-brain barrier. 
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To this effect, Lee and colleagues recently reported water-soluble phenanthrene 
based tylophorine derivatives [520-522]. These molecules showed promising anti-
cancer activity in vivo, with minimal gross toxicity [523]. However, brain penetration 
of these molecules needs further investigation.  
 
Tylocrebrine’s anticancer activity is mediated through inhibition of protein 
synthesis. This effect is facilitated through binding of the drug to the 40S and 80S 
ribosomal subunits [524]. Hence, cellular internalization is required for its anti-
cancer activity. Tylocrebrine is a weak base, and is mainly un-ionized at 
physiological pH. Due to its neutral charge and high hydrophobicity, tylocrebrine 
can cross cell membranes efficiently under physiological conditions (for example, 
the blood-brain barrier). However, under acidic conditions (such as those found in 
Table 4-4. Physicochemical characteristics of CNS penetrant drugs and 
tylocrebrine 
Mean values and suggested limits adapted with permission from [519] © 2006 
American Chemical Society 
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the tumor), tylocrebrine is ionized. This is likely to reduce its diffusion across the 
tumor cell membrane and its anti-cancer activity.  
In order to address these twin problems of high CNS penetration and limited 
tumor cell uptake, we encapsulated tylocrebrine in PLGA NPs surface 
functionalized with a peptide targeting the EGFR. PLGA NPs, likely due to their 
colloidal size range, do not cross the intact blood-brain barrier. Additionally, PLGA 
NPs are rapidly taken up by cells through endocytosis [287], a process augmented 
by the presence of targeting ligands [215, 360].  
Our in vitro studies showed that tylocrebrine had potent activity with IC50 
values in the nanomolar range. Encapsulation in EGFR targeted NPs further 
increased its potency. Under acidic conditions, there was a dramatic decrease in 
the potency of the free drug while the activity of the NP formulations showed a 
minor decrease. This suggested that the issue of drug delivery into the tumor cells 
could be addressed through NP-encapsulation. The minor decrease in the efficacy 
of the NP formulations can be attributed to the increase in the burst release 
observed in acidic pH.  
Upon IV administration, we found that there was rapid accumulation of 
tylocrebrine in both the target tissue (tumor) and the site of toxicity (brain). 
Encapsulation of tylocrebrine in non-targeted NPs reduced the brain exposure but 
did not significantly improve the tumor exposure. On the other hand, delivering 
tylocrebrine in targeted NPs resulted in both reduced brain exposure and improved 
tumor exposure. Our studies highlight a few important points. Using a targeting 
moiety on the NP surface merely improves their accumulation at the target site 
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without affecting their accumulation at non-target sites [177]. Usually, the target 
site has negligible influence on the overall pharmacokinetics of the drug or drug 
carrier. There is still some debate in literature regarding whether targeting ligands 
improve the tumor accumulation of NPs or merely increase their tumor cell uptake 
[525]. Bartlett et al. and Choi et al. have shown that transferrin receptor targeted 
NPs have similar tumor accumulation to non-targeted NPs [265, 526]. However, 
owing to improved tumor cell uptake, these NPs resulted in better efficacy. On the 
other hand, studies from our and other labs have shown that NPs targeting folic 
acid receptor, biotin receptor or EGFR improved tumor accumulation of 
encapsulated drug relative to that with non-targeted NPs [215, 216, 224, 227]. 
Differences in tumor models, receptor expression levels, and recycling rates of 
different receptors, and affinities of targeting moieties could contribute to these 
discrepancies. Other variables such as choice of the drug, drug release kinetics 
and mechanisms, and plasma kinetics of drug and drug carrier also make 
comparison between studies difficult. Finally, current characterization techniques 
cannot distinguish between NP-encapsulated and free drug. Additional, in-depth 
characterization studies are needed to draw strong mechanistic conclusions. 
Blood concentrations of NP-encapsulated tylocrebrine were significantly higher 
than the free drug (~6-fold higher). This indicates that the driving force for 
accumulation of tylocrebrine in tumors is much higher when administered in the 
form of NPs. However, the increase in tumor levels of tylocrebrine was less 
dramatic (only ~3-fold with targeted NPs). This may be attributed to the favorable 
partition coefficient of the free drug into the tumor, as illustrated by a high tumor to 
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blood concentration ratio (>10). Thus, the advantage gained by nano-
encapsulation strongly depends on the drug being investigated [450, 527]. 
Additionally, A431 tumors were found to be fluid-filled (not shown), suggesting that 
the interstitial fluid pressure (IFP) in these tumors is high, as previously reported 
[528, 529]. High IFP is likely to affect the intratumoral transport of NPs more 
significantly than that of free drug molecules [460, 493]. The relatively large 
hydrodynamic particle size of the NPs used in our studies may also decrease their 
tumor penetration. Decreasing the particle size can potentially increase the 
delivery of NPs into the tumor [424, 527]. Alternately, tumors with a low IFP may 
prove to be better candidates for treatment with these formulations. 
The in vivo tumor growth inhibition studies show that free drug inhibited tumor 
growth even at the low dose used. While treatment efficacy did not improve with 
non-targeted NPs, targeted NPs resulted in a considerably greater tumor growth 
inhibition than other treatments. This effect may be a manifestation of both the 
higher tumor tissue accumulation and higher cytotoxicity of targeted NPs.  
The dose of tylocrebrine used in our studies was relatively low (12 mg/kg). This 
dose was effective only if the treatment was started before the tumors reached a 
volume of ~75 mm3. Larger tumors did not respond to this dose of tylocrebrine in 
any formulation (data not shown). The overall dose of tylocrebrine that could be 
administered was limited by its loading in NPs. Additionally, burst release of drug 
from NPs may limit the overall efficiency of targeting and chemotherapeutic 
efficacy of NPs. Strategies that enable higher drug loading and prolonged drug 
release will allow for larger doses to be administered and this could further 
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enhance the anti-tumor efficacy of the drug. Using polymers that have greater 
interaction with the drug can help achieve this goal. To this end, micelles formed 
from polymers consisting of aromatic rings have been shown to improve drug 
loading and stability as compared to micelles formed from aliphatic polymers [530, 
531]. This has been attributed to the formation of π-π stacks between the drug and 
polymer. Future studies could investigate the use of such polymers for improving 
the therapeutic index of tylocrebrine.  
4.6 Conclusion 
Tylocrebrine is a potent anti-cancer agent but significant penetration into the 
brain and low tumor cell uptake limits its use. Encapsulation of the drug in PLGA 
NPs significantly limited its CNS penetration. Moreover, surface functionalizing 
NPs with an EGFR targeting peptide led to enhanced tumor cell uptake, tumor 
tissue accumulation and in vivo anti-tumor efficacy. We expect that the re-
formulation approach presented here will enable further clinical testing of a number 
of previously abandoned drug candidates while potentially minimizing drug 
development costs. 
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Chapter 5 Summary 
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There is tremendous interest in the targeted delivery of drugs to solid tumors. 
This can be achieved by delivering drugs in nano-sized drug carriers. 
Consequently, in the past two decades, there has been an exponential growth in 
the amount of pre-clinical research involving nano-drug delivery systems. In spite 
of the progress made in this field, these systems deliver only a small fraction of the 
dose to the tumor. Poor drug delivery to the tumor and extensive distribution to 
normal tissues compromises the overall efficacy of chemotherapy. In an effort to 
improve the chemotherapeutic efficacy of nano-sized drug carriers, we studied 
their transport from the site of administration to the site of action. We particularly 
examined three processes: systemic distribution, intratumoral distribution, and cell 
uptake. In this chapter, we summarize our major findings. We also critically review 
the techniques and results presented in this thesis. This could provide future 
directions to further improve the state of nanomedicine.   
In Chapter 2, we analyzed the systemic distribution and transvascular transport 
of nanoparticles (NPs). A semi-physiologically based pharmacokinetic model was 
constructed to describe the systemic distribution of drug delivered in NPs. Since 
NPs and drug have distinct pharmacokinetics, the model consisted of separate 
compartments for NP-encapsulated drug and the released drug. The distributional 
clearance of NPs across compartments was modeled using equations describing 
convection and diffusion. The performance of NP formulations was characterized 
using a metric called the drug targeting index (DTI). DTI compares drug exposure 
of two different formulations (NP and free drug) in the target and toxicity 
compartments.  
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We analyzed the influence of particle size and tumor vascular pore size on the 
DTI of NPs. Using our model, we found that the maximal targeting efficiency was 
observed in a limited particle size range. The ideal particle size range for drug 
targeting was dictated by the vascular pore size of the toxicity and target 
compartments. Prolonging the duration of drug release also improved the 
efficiency of drug targeting. However, this effect was also observed in a limited 
particle size range. Some important conclusions can be drawn from these 
modeling efforts. First, though distributional clearance provides strong mechanistic 
information about the deposition of NPs in the target compartment, whole body 
pharmacokinetics are a better indicator of formulation performance. Second, the 
enhanced permeability and retention (EPR) effect is likely a special occurrence. 
The magnitude of the EPR effect strongly depends on the physicochemical 
properties of the NP platform and drug as well as on the physiological properties 
of the tumor blood vessels.  
There are several limitations to the current model. First, we considered the 
tumor to be a well-stirred compartment with homogeneous vascular pore size. The 
intratumoral distribution of NPs, differences in transvascular pressure gradients 
and vascular pore size in tumors are known to be highly heterogeneous. Hence, 
describing NP or drug transport in tumors using singular values for these 
parameters is not accurate. Moreover the effects of particle shape, charge, degree 
of aggregation etc. were not considered in this model. The performance of NPs 
was measured in terms of pharmacokinetic parameters such as AUC. This can 
prove erroneous especially when dealing with controlled release systems such as 
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NPs. Applying a pharmacodynamic model that uses concentration of drug to 
determine cell kill may prove to be more useful. Several parameters affecting cell 
uptake, such as effect of NP size and expression of efflux transporters, were not 
considered. These processes can have a significant impact on the efficacy of 
chemotherapy. Finally, the model only determined the effect of NP properties on 
drug targeting. Drugs with different pharmacokinetic behaviors will benefit to 
different extents with nano-encapsulation.  
In Chapter 3, we studied the influence of fibrinolytic enzymes on the 
intratumoral distribution and chemotherapeutic efficacy of NPs. Poor intratumoral 
distribution of NPs and inadequate delivery to certain tumor cell niches is an 
important yet overlooked cause of drug resistance. Fibrinogen, a soluble blood 
protein, deposits in the tumor ECM due to leaky blood vessels. It is converted to 
cross-linked fibrin due to the prothrombogenic activity of tumor cells. Presence of 
fibrin in the tumor matrix can be an important cause of solid stress in tumors and 
result in the compression of blood vessels. Degrading fibrin in the tumor matrix can 
lead to decompression of blood vessels and improvement in drug delivery to 
tumors.  
We used a fibrinolytic enzyme, tissue plasminogen activator (tPA), to degrade 
fibrin inside tumors. We found that co-administration of tPA resulted in an 
enhanced anti-cancer activity of paclitaxel NPs in an orthotopic lung cancer model 
and a syngeneic mouse model of melanoma. Interestingly, co-administration of 
tPA with paclitaxel solution did not have any significant impact on its efficacy in the 
syngeneic model. We then analyzed the mechanism for the favorable activity of 
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tPA. Using immunohistochemistry, we determined that treatment with tPA led to 
an increase in the mean vascular diameter of angiogenic blood vessels. This result 
was further corroborated with ultrasound imaging. tPA treated tumors showed a 
higher perfusion area as compared to saline treated tumors.  
There are several mechanistic and translational questions that have not been 
addressed in this study. tPA mediates several pharmacological effects other than 
fibrin degradation. It is not clear if the improved chemotherapeutic efficacy of NPs 
or improved perfusion is mediated solely through fibrin degradation. Conducting 
these studies in transgenic fibrinogen deficient mice may provide insight into this 
question. It will also be interesting to determine if co-administration of tPA enables 
the NPs to access hypoxic regions within the tumor. We are currently probing into 
this question using confocal microscopy to analyze the intratumoral distribution of 
Doxil®. Our studies also showed that fibrin expression in tumors is highly variable. 
Pre-selecting tumors with high fibrin expression may help maximize chances of 
success with this therapy (if the effect of tPA is fibrin-mediated). Due to its short 
half-life, using tPA in its current form is not ideal. Conjugating tPA to hydrophilic 
polymers such as poly(ethylene glycol) may improve its circulation half-life, and 
tumor accumulation. We attempted to achieve this goal by conjugating tPA to the 
surface of NPs. This approach was not successful, likely due to the liver 
accumulation of NPs and the reduced mobility of tPA. Encapsulating tPA in fast 
releasing NPs may help overcome both these issues.  
The goal of our studies in Chapter 4 was to improve the therapeutic index of an 
abandoned chemotherapeutic drug, tylocrebrine. Due to significant central 
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nervous system (CNS) side-effects, such as ataxia, its clinical development was 
discontinued. Additionally, we found that the cell uptake of tylocrebrine is reduced 
under the acidic tumor microenvironment. We hypothesized that encapsulating the 
drug in polymeric NPs may address both issues of enhanced CNS penetration and 
reduced tumor cell uptake. To improve their tumor cell uptake, we surface 
functionalized the NPs with a peptide that binds the epidermal growth factor 
receptor (EGFR).  
We first compared the cytotoxicity of the free drug, non-targeted NPs and 
targeted NPs in vitro. Under acidic conditions, both NP formulations were more 
potent than the drug. However, targeted NPs had a higher cell uptake and potency 
than non-targeted NPs. Through pharmacokinetic studies, we found that treatment 
with targeted NPs resulted in higher drug exposure in the tumor and lower drug 
exposure in the brain as compared to the free drug. We then determined the 
chemotherapeutic efficacy of various formulations of tylocrebrine in a mouse model 
of xenografted human epidermoid cancer. Treatment with tylocrebrine solution or 
non-targeted NPs resulted in comparable tumor inhibition. Treatment with targeted 
NPs led to the greatest inhibition of tumor growth.  
The studies presented here show great promise for the future development of 
tylocrebrine. However some limitations still remain. Drug loading in poly(latide-co-
glycolide) (PLGA) NPs was moderate, and drug release was rapid. Altering the 
molecular weight of PLGA and the lactide: glycolide ratio did not have any 
influence on the loading of the drug. Low drug loading limited the dose of drug. 
Drug release was also rather rapid, which may be responsible for some of the drug 
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accumulation in the brain. It may be valuable to investigate a different polymer to 
enhance drug loading of tylocrebrine. It is currently not known if tylocrebrine is a 
substrate for efflux transporters. However, previous clinical reports of CNS toxicity, 
and our pharmacokinetic studies suggest that the drug accumulates in the brain. 
This may suggest that it is not a substrate to efflux transporters. If this is indeed 
true, tylocrebrine holds great promise for treating multidrug resistant tumors. 
Investigating the activity of tylocrebrine in multidrug resistant tumors will be 
valuable.  
In summary, this thesis analyzed the various steps of NP transport from the site 
of administration to its uptake by tumor cells. Loss of NPs at various steps of the 
transport decreases the overall efficacy of chemotherapy. Approaches described 
here may help to further improve the delivery of NPs to solid tumors.  
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